kkdalgdcieqcqccausqeheaedccixiiavgwkyelg length 6 261623 page 261623 <!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<HEAD><!--ccm   -->
				<script id="cookieConsentScript" async src="https://img.lb.wbmdstatic.com/webmd_static_vue/file-explorer/webmd/consumer_assets/site_images/webmd-ccm/ccm_oo.min.js"></script>
<meta charset="UTF-8">
<script>
    // Flag set to know we are using the newest Global Ads coded
    var globalAsyncAdsCode = false;
</script>
<link rel="preconnect" href="https://securepubads.g.doubleclick.net" crossorigin>
<link rel="preconnect" href="https://assets.adobedtm.com" crossorigin>
<link rel="preconnect" href="https://img.webmd.com" crossorigin>

<link rel="shortcut icon" href="https://www.rxlist.com/images/fav/rx.ico" />
<link rel="apple-touch-icon" href="https://www.rxlist.com/images/mobile/rxlist-icon.png" />

<link rel="preconnect" href="https://images.rxlist.com">
<link rel="preload" href="https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-regular.woff2" as="font" type="font/woff2" crossorigin>
<link rel="preload" href="https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-600.woff2" as="font" type="font/woff2" crossorigin>
<link rel="preload" href="//assets.adobedtm.com/2c8c1e17b98c/bd8b7ed95b8d/launch-a2e2197ecad5.min.js" as="script" />
<link rel="preload" href="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_head.min.js" as="script">
<link rel="preload" href="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_body.min.js" as="script">
<link rel="preload" href="https://img.webmd.com/bi_common/bi_oocommon.js" as="script">
<style>/*** Icomoon ***/@font-face {font-family: 'icomoon';src: url(data:application/x-font-ttf;charset=utf-8;base64,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)format('truetype');font-weight: normal;font-style: normal;font-display: block}[class^="icon-"],[class*=" icon-"] {font-family: 'icomoon' !important;speak: never;font-style: normal;font-weight: normal;font-variant: normal;text-transform: none;line-height: 1;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: grayscale}.icon-facebook:before {content: "\e608"}.icon-twitter:before {content: "\e607"}.icon-shield:before {content: "\e906"}.icon-search:before {content: "\e612"}.icon-menu:before {content: "\e613"}.icon-close:before {content: "\e624"}.icon-arrow-right2:before {content: "\e605"}.icon-slide:before,.icon-slideshow:before,#artPromoCunk .slide:before {content: "\e604"}.icon-image:before,#artPromoCunk .image:before {content: "\e623"}.icon-quiz:before,#artPromoCunk .quiz:before {content: "\e602"}.icon-right:before {content: "\e628"}.icon-wrong:before {content: "\e629"}.icon-start-over:before {content: "\e630"}.icon-pro:before {content: "\e901"}.icon-consumer:before {content: "\e902"}.icon-side-effect:before {content: "\e903"}.icon-drug-interaction:before {content: "\e905"}.icon-pill-id:before {content: "\e907"}.icon-drug-class:before {content: "\e908"}.icon-drug-cf:before {content: "\e900"}.icon-vit:before {content: "\e904"}.icon-map:before {content: "\e600"}.icon-toc-arrow:before {content: "\e909"}/*** Font ***/@font-face {font-family: 'Open Sans';font-style: normal;font-display: swap;font-weight: 400;src: local(''), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-regular.woff2') format('woff2'), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-regular.woff') format('woff')}@font-face {font-family: 'Open Sans';font-style: normal;font-display: swap;font-weight: 600;src: local(''), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-600.woff2') format('woff2'), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-600.woff') format('woff')}/*** Normalize ***/html {line-height: 1.15;-webkit-text-size-adjust: 100%}body {margin: 0}main {display: block;max-width:1250px;width: calc(100vw - 80px);margin: 0 auto;}h1 {font-size: 2em;margin: 0.67em 0}hr {box-sizing: content-box;height: 0;overflow: visible}pre {font-size: 1em}a {background-color: transparent}abbr[title] {border-bottom: none;text-decoration: underline;text-decoration: underline dotted}b,strong {font-weight: bolder}code,kbd,samp {font-size: 1em}small {font-size: 80%}sub,sup {font-size: 75%;line-height: 0;position: relative;vertical-align: baseline}sub {bottom: -0.25em}sup {top: -0.5em}img {border-style: none}button,input,optgroup,select,textarea {font-size: 100%;line-height: 1.15;margin: 0}button,input {overflow: visible}button,select {text-transform: none}button,[type="button"],[type="reset"],[type="submit"] {-webkit-appearance: button}button::-moz-focus-inner,[type="button"]::-moz-focus-inner,[type="reset"]::-moz-focus-inner,[type="submit"]::-moz-focus-inner {border-style: none;padding: 0}button:-moz-focusring,[type="button"]:-moz-focusring,[type="reset"]:-moz-focusring,[type="submit"]:-moz-focusring {outline: 1px dotted ButtonText}fieldset {padding: 0.35em 0.75em 0.625em}legend {box-sizing: border-box;color: inherit;display: table;max-width: 100%;padding: 0;white-space: normal}progress {vertical-align: baseline}textarea {overflow: auto}[type="checkbox"],[type="radio"] {box-sizing: border-box;padding: 0}[type="number"]::-webkit-inner-spin-button,[type="number"]::-webkit-outer-spin-button {height: auto}[type="search"] {-webkit-appearance: textfield;outline-offset: -2px}[type="search"]::-webkit-search-decoration {-webkit-appearance: none}::-webkit-file-upload-button {-webkit-appearance: button;font: inherit}details {display: block}summary {display: list-item}template {display: none}[hidden] {display: none}/*** Owl Carousel (core) ***/.owl-carousel {display: none;width: 100%;-webkit-tap-highlight-color: transparent;position: relative;z-index: 1}.owl-carousel .owl-stage {position: relative;-ms-touch-action: pan-Y;touch-action: manipulation;-moz-backface-visibility: hidden}.owl-carousel .owl-stage:after {content: ".";display: block;clear: both;visibility: hidden;line-height: 0;height: 0}.owl-carousel .owl-stage-outer {position: relative;overflow: hidden;-webkit-transform: translate3d(0px, 0px, 0px)}.owl-carousel .owl-wrapper,.owl-carousel .owl-item {-webkit-backface-visibility: hidden;-moz-backface-visibility: hidden;-ms-backface-visibility: hidden;-webkit-transform: translate3d(0, 0, 0);-moz-transform: translate3d(0, 0, 0);-ms-transform: translate3d(0, 0, 0)}.owl-carousel .owl-item {position: relative;min-height: 1px;float: left;-webkit-backface-visibility: hidden;-webkit-tap-highlight-color: transparent;-webkit-touch-callout: none}.owl-carousel .owl-item img {display: block;width: 100%}.owl-carousel .owl-nav.disabled,.owl-carousel .owl-dots.disabled {display: none}.owl-carousel .owl-nav .owl-prev,.owl-carousel .owl-nav .owl-next,.owl-carousel .owl-dot {cursor: pointer;-webkit-user-select: none;-khtml-user-select: none;-moz-user-select: none;-ms-user-select: none;user-select: none}.owl-carousel .owl-nav button.owl-prev,.owl-carousel .owl-nav button.owl-next,.owl-carousel button.owl-dot {background: none;color: inherit;border: none;padding: 0 !important;font: inherit}.owl-carousel.owl-loaded {display: block}.owl-carousel.owl-loading {opacity: 0;display: block}.owl-carousel.owl-hidden {opacity: 0}.owl-carousel.owl-refresh .owl-item {visibility: hidden}.owl-carousel.owl-drag .owl-item {-ms-touch-action: none;touch-action: none;-webkit-user-select: none;-moz-user-select: none;-ms-user-select: none;user-select: none}.owl-carousel.owl-grab {cursor: move;cursor: grab}.owl-carousel.owl-rtl {direction: rtl}.owl-carousel.owl-rtl .owl-item {float: right}.no-js .owl-carousel {display: block}.owl-carousel .owl-item .owl-lazy {opacity: 0;transition: opacity 400ms ease}.owl-carousel .owl-item img.owl-lazy {transform-style: preserve-3d}/*** Common ***/html {font-family: 'Open Sans', sans-serif;font-size: 17px;font-weight: 400;color:#232323;}b,strong,optgroup,h1,h2,h3,h4,h5,h6 {font-weight: 600;}h1{font-size:55px;line-height:57px;}h2{font-size:26px;line-height:30px;}h3{font-size:20px;line-height:30px;}h4{font-size:20px;line-height:30px;margin:5px 0px;}p{line-height:25.5px;font-size:17px;margin:5px 0px;}a {color: #2196f3;text-decoration: none;cursor: pointer}a:hover {text-decoration: underline}::-moz-selection {background: #000;text-shadow: none;color: #fff}::selection {background: #000;text-shadow: none;color: #fff}a[data-title]:hover:before {content: attr(data-title);padding: 4px 8px;color: #fff;position: absolute;z-index: 9999;border-radius: 3px;background: #333;font-size: 12px;margin: 35px 15px 0 0;line-height: normal}.apPage h2, #apPage h2 {border-left: 5px solid #2196f3;padding: 5px 10px;}#backTop {display: none;position: fixed;right: 20px;top: calc(100vh - 60px);z-index: 49}#backTop .icon-arrow-right2:before{background: #2196F3;    border-radius: 50px;    box-shadow: 0px 4px 4px rgb(0 0 0 / 25%);color:#fafafa;padding:7px;} #backTop span {color: #232323;font-size: 36px;padding: 3px;transform: rotate(-90deg);display: block;transition: all 250ms}#backTop span:hover {cursor: pointer;color: #fff;}main ::-webkit-scrollbar-track {-webkit-box-shadow: inset 0 0 5px rgba(0, 0, 0, 0.3);background: #f4f4f4}main ::-webkit-scrollbar {width: 5px;background: #f4f4f4}main ::-webkit-scrollbar-thumb {background: #000}.sc-modal button {color: #fff;font-size: 14px;font-weight: normal;line-height: normal;text-decoration: none;text-transform: uppercase;text-align: center;padding: 17px;margin: 15px 0;background: #2196f3;width: 250px;border: none;outline: none;display: inline-block;position: relative;z-index: 1;overflow: hidden}.sc-modal button:hover {text-decoration: none;cursor: pointer}.sc-modal button:after {content: "";background: #000;position: absolute;z-index: -1;left: 0;right: 0;top: -100%;bottom: 100%;transition: all 250ms}.sc-modal button:hover:after {left: 0;right: 0;top: 0;bottom: 0}.stickyColLeft {display: none}.icon-arrow-left2:before {content: "\e605";display: inline-block;transform: rotate(180deg)}.w-full {width: 100%}/*** AD ***/body>header.fixed {margin-top: 100px}.adTopWrapper {border-bottom: #e2e2e2 solid 1px;width: 100%;min-height: 100px;z-index: 1;position: relative;background-color: #fff;position: sticky;top: 68px;}.adTopWrapper #bannerAd_rdr,.ad-slot.content-ads {background: url(https://images.rxlist.com/images/ads/1atopbannerside.gif) no-repeat 0 center;margin: 0 auto;padding: 5px 10px;position: relative;display: table}.adTopWrapper #bannerAd_fmt {padding: 4px;border: 1px solid #ccc;min-width: 738px;min-height: 90px}#rightAd_rdr:after,#leftAd_rdr:after {content: '';background: url(https://images.medicinenet.com/images/ads/rightad_toptransparent.gif) no-repeat center 0;height: 10px;display: block}.rightAd_BG_fmt {width: 300px;min-height: 250px;padding: 0px;border: 1px solid #ddd}.leftAd_BG_fmt {width: 160px;min-height: 600px;padding: 4px;border: 1px solid #ddd}.leaderboard_fmt {background: url(https://images.medicinenet.com/images/ads/1atopbannerside.gif) no-repeat 0 20px;width: 738px;margin: 30px auto;padding: 16px 10px;clear: both}.leaderboard_fmt>div {padding: 4px;border: 1px solid #ddd;width: 728px;height: 90px}.ad-slot.content-ads {min-height: 90px;min-width: 748px;}/*** Modal ***/.innerBox iframe {position: absolute;top: 0;left: 0;padding: 0;margin: 0;border: 0}.modalBox .logo {text-indent: -9999px;margin-top: -33px;background: url(https://images.rxlist.com/images/mobile/rxlist/logo-rxl-reverse.png) no-repeat 0 2px/130px 24px}.modalClose:after {content: "\e624";font-family: 'icomoon';font-size: 28px;right: 0;top: -38px;z-index: 1;position: absolute;color: #FFF;padding: 4px 6px;line-height: 30px}.modalClose:hover:after {color: #47638D}.modalBox {border-top: 38px solid #6896DA;box-shadow: 0 0 15px #000;background: #fff;z-index: 99999999;position: absolute}.modalBox>a {text-decoration: none}.blockPage {position: absolute;top: 0;left: 0;background: rgba(0, 0, 0, 0.6);z-index: 99999998}.innerBox a {background: #47638D !important}.innerBox a:hover {background: #000 !important}.sc-modal {text-align: center;position: fixed;top: 0;right: 0;bottom: 0;left: 0;background: rgba(0, 0, 0, .8);overflow: auto;overscroll-behavior: contain;z-index: 1000000}.sc-modal-dialog {max-height: 80vh;max-width: 80vw;min-width: 300px;background: #fff;padding: 30px;position: absolute;top: 50%;left: 50%;transform: translate(-50%, -50%)}.sc-modal-title {display: none}.sc-modal .close {color: #232323;font-size: 26px;line-height: 20px;text-decoration: none;padding: 5px;border: 1px solid #ccc;background: rgba(255, 255, 255, .9);right: 10px;top: 10px;position: absolute;transition: all 250ms}.sc-modal .close:hover {cursor: pointer;color: #fff;background: #000;border-color: #000;text-decoration: none}.sc-modal h3 {font-size: 17px;font-weight: 400;line-height: 24px}/*** Module ***/.extra .from_webmd {width: 65%}.from_webmd {margin: 40px auto;border-collapse: separate;border-spacing: 5px;border-radius: 10px;background: #E4F3FA;padding: 20px;}.from_webmd h2, .from_webmd h3 {letter-spacing: 1px;margin: 0;text-decoration: none !important;font-size: 26px;padding-bottom: 10px;border-bottom: 1px solid #000;}.from_webmd .logoTitle {height: 18px;margin-top: -5px}.from_webmd .content {display: flex}.from_webmd .wrapper {padding-right: 24px;flex-grow: 1;}.from_webmd h5 {font-size: 18px;color: #000;line-height: 16px;margin: 10px 0;}.from_webmd .content ul {padding: 0;margin: 0;list-style: none}.from_webmd ul li {padding: 10px 0;line-height: 15px}.from_webmd ul li a {font-size: 15px}.webmdrx a {background: #1D72A8;border-radius: 3px;padding: 5px 15px;text-align: center;display:inline-block;transition: background 250ms}.webmdrx p {font-size: 14px;color: #fff;margin: 0}.webmdrx_img {background: url(https://images.rxlist.com/images/rxlist/webmdrx-btn.png) 0 0 no-repeat;width: 91px;height: 15px;float: right;margin: 5px 0 0 6px}.webmdrx a:hover {background: #000;text-decoration: none}/*** Header ***/body.freeze {position: fixed;overflow-y: scroll;width: 100%}body>header:after {content: '';background: rgba(0, 0, 0, 0);width: 100%;height: 100vh;position: fixed;top: 50px;z-index: -1;transition: all 400ms}body.freeze>header:after,body>header.miniMenu:after {background: rgba(0, 0, 0, .7);z-index: 9999}.masterhead {height: 65px;background: #fff;border-bottom: 1px solid #ddd;z-index: 999999;position: relative;margin: 0}.masterhead .wrapper {position: relative}.masterhead .menu>span {padding: 18px;font-size: 29px;display: inline-block;cursor: pointer;transition: color 250ms}.masterhead .menu>span:hover,.masterhead .search button:hover {color: #2196f3}.masterhead .logo {top: 18px;left: 55px;position: absolute}.masterhead .search {top: 0;right: 90px;position: absolute}.masterhead .search button {border: none;background: transparent;outline: none;font-size: 19px;color: #232323;padding: 24px 8px 18px;transition: color 250ms;cursor: pointer}.masterhead .search button .icon-close {font-size: 26px;margin: -4px;display: block}.masterSub,.searchBar {background: #fff;width: 100%;top: -100vh;z-index: 99999;position: fixed;transition: .4s top ease}.masterSub {overflow-x: hidden}.masterSub.on,.searchBar.on {top: 175px}.masterSub nav {max-width: 1645px;min-width: 843px;height: 45vh;padding: 18px 0 55px;}.masterSub nav .wrapper {width: 35%;margin: 0 20px;float: left}.masterSub nav .wrapper h3 {border-bottom: 1px solid #ddd;padding: 5px 8px}.masterSub nav a {color: #232323;font-size: 16px;text-decoration: none;padding: 10px;display: block;transition: all 250ms}.masterSub nav .trustBadge {position: static;border: none}.masterSub nav .trustBadge .icon-shield {display: none}.masterSub nav a:hover {background: #000;color: #fff}.masterSub .stack .icon-arrow-right2 {vertical-align: middle}.masterSub .stack .sideBar {background: #6896DA;width: calc(100vw - 350px);height: 45vh;top: 0;left: 100vw;padding: 30px;z-index: 99999;position: absolute;transition: .3s left ease}.masterSub .stack.on {background: #6896DA;transition: all 250ms}.masterSub .stack.on a {color: #fff}.masterSub .stack.on a:hover {background: none}.masterSub .stack.on .sideBar {left: calc(100vw - 40%)}.masterSub .stack .sideBar a {color: #fff;width: 300px}.masterSub .stack .sideBar a:hover {background: #fff;color: #000}.socialWrapper {top: 22px;right: 20px;position: absolute}.socialWrapper li {list-style: none;float: left}.socialWrapper li a {color: #232323;font-size: 20px;padding: 20px 8px 19px;transition: all 250ms;cursor: pointer}.socialWrapper li a:hover {color: #2196f3;text-decoration: none}.socialWrapper a[data-title]:hover:before {right: -15px}.sc-searchbox {position: relative}.sc-searchbox .sc-searchbox-input-wrapper {display: flex}.sc-searchbox .sc-searchbox-input {flex-grow: 1}.sc-searchbox .sc-searchbox-list {position: absolute;width: 100%;z-index: 50;background: #fff;box-sizing: border-box}.sc-searchbox .sc-searchbox-list .sc-searchbox-list-item.sc-searchbox-item-active {background: #f5f5f5}.nav-search.sc-searchbox .sc-searchbox-form {padding: 125px 20%}.nav-search.sc-searchbox .sc-searchbox-input {font-size: 18px;padding: 12px 20px;border: none;outline: none;background: #f5f5f5}.nav-search.sc-searchbox .sc-searchbox-input:focus {background: #000;color: #fff}.nav-search.sc-searchbox .icon-search:before {display: none}.nav-search.sc-searchbox .sc-searchbox-button {padding: 7px 25px;font-weight: 600;background: #6896DA;color: #fff;outline: none;border: none;transition: all 250ms}.nav-search.sc-searchbox .sc-searchbox-button:hover {background: #000 !important}.nav-search.sc-searchbox .sc-searchbox-list {background: #fff;padding: 6px;border: 1px solid #ddd;border-top: none;color: #232323;width: 60%;z-index: 1000}.nav-search.sc-searchbox .sc-searchbox-list .sc-searchbox-list-item.sc-searchbox-item-active {background: #000;color: #fff;cursor: pointer}.nav-search.sc-searchbox .sc-searchbox-list-item {padding: 5px 8px;border-radius: 3px}/*** Footer ***/#sponsors {margin: 40px auto;padding: 20px;clear: both;max-width: 1250px;width: calc(100vw - 80px);}.hstitle {font-size: 26px;font-weight: 600;margin: 0 0 15px 0}.hstitle span {font-size: 14px;font-weight: 400}#sponsors .wrapper ul {list-style: none;padding: 0;margin: 0;column-count: 3;column-gap: 50px}#sponsors .wrapper li {font-size: 13px;line-height: 15px;padding: 5px 0;break-inside: avoid}#sponsors .wrapper li a {color: #2196f3;text-decoration: none;cursor: pointer;word-break: break-word}#sponsors .wrapper li a:hover {text-decoration: underline}footer {max-width: 1250px;margin: 130px auto 50px;padding: 0 20px;position: relative;width: calc(100vw - 80px);}footer .social-section {list-style: none;margin: 0;padding: 0;top: -40px;right: 30px;position: absolute}footer .social-section li {float: left}footer .social-section li a {color: #232323;font-size: 20px;padding: 8px;cursor: pointer;transition: all 250ms}footer .social-section li a:hover {color: #2196f3;text-decoration: none}footer .social-section a[data-title]:hover:before {right: 0}footer nav {padding: 20px 0 40px;border-top: 2px solid #ddd;border-bottom: 2px solid #ddd;display: flex;justify-content: space-between}footer .col {width: 26%}footer .col ul {list-style: none;margin: 0;padding: 0}footer .col li a {color: #666;font-size: 13px;line-height: 14px;text-decoration: none;padding: 6px 0;display: block}footer .col li a:hover {text-decoration: underline}footer .footerCopy {display: flex;justify-content: space-between}footer .badge {padding: 10px 0}footer .copyright {text-align: right;margin: 10px 0}footer .ccpaFtrLnk {font-size: 12px;color: #2196f3}footer .copyright p {font-size: 12px;line-height: 15px;width: 430px;margin: 5px 0}footer .copyright p a {color: #232323;text-decoration: underline}/*** HP ***/.promoSearch:after,.news_hp:after,.topRx:after {content: "";position: absolute;width: 20px;height: 40px;left: 0;bottom: -40px;border-radius: 10px 0 0 0;box-shadow: 0 -20px 0 0 #d5edfc;background: transparent}.promoSearch:after {box-shadow: 0 -20px 0 0 #0171bb}.news_hp:before,.topRx:before {content: "";position: absolute;width: 20px;height: 40px;left: 0;top: -40px;border-radius: 0 0 0 10px;box-shadow: 0 20px 0 0 #d5edfc;background: transparent}.promoSearch,.shortcut,.news_hp,.AdWrapper,.topRx,.media {padding: 40px 5vw;text-align: center;position: relative}.news_hp h2,.topDrug h2,.topRx h2,.media h2 {font-size: 30px;padding-bottom: 15px;text-transform: uppercase}.shortcut a,.news_hp a,.topDrug a,.topRx a,.media a {color: #232323;transition: 250ms all}.promoSearch {background: #0171bb;border-radius: 0 0 10px 0}.promoSearch img {width: 300px;height: 200px;margin-bottom: 20px}.promoSearch .sc-searchbox .sc-searchbox-input-wrapper {position: relative;z-index: 51}.promoSearch .sc-searchbox input {font-size: 15px;padding: 0 45px 0 20px;border-radius: 10px;border: 0;outline: 0;height: 50px}.promoSearch .sc-searchbox button {font-size: 18px;color: #0171bb;background: transparent;border: 0;outline: 0;position: absolute;right: 15px;top: 16px}.promoSearch .sc-searchbox .sc-searchbox-list {position: absolute;top:45px;padding: 70px 10px 15px 10px;z-index: 50;background: #000;text-align: left;border-radius: 10px;border-top-left-radius: 0px;border-top-right-radius: 0px;}.promoSearch .sc-searchbox .sc-searchbox-list-item {color: #fff;padding: 10px}.promoSearch .sc-searchbox .sc-searchbox-list .sc-searchbox-list-item.sc-searchbox-item-active {background: #fff;color: #232323;cursor: pointer}.promoSearch p {color: #fff;font-size: 14px}.promoSearch p a {color: #adf;font-size: 14px;text-decoration: underline;transition: 250ms all}.promoSearch p a:after {content: ',';display: inline-block}.promoSearch p a:last-child:after {display: none}.promoSearch p a:hover {color: #fff}.shortcut {display: flex;flex-wrap: wrap;justify-content: center}.shortcut a {font-size: 16px;font-weight: 600;background: #d5edfc;border-radius: 10px;padding: 20px 15px 20px 50px;margin: 5px;width: 100px;height: 40px;text-align: left;position: relative;display: flex;align-items: center}.shortcut span {color: #2196f3;font-size: 25px;top: 28px;left: 14px;position: absolute;transition: 250ms all}.shortcut a:hover,.news_hp .wrapper a:hover,.topDrug .az li a:hover,.media .wrapper a:hover,#A_Z li a:hover {background: #000;color: #fff;text-decoration: none}.shortcut a:hover *,.news_hp .wrapper a:hover *,.media .wrapper a:hover * {color: #fff}.news_hp,.topRx {background: #d5edfc;border-radius: 0 10px 10px 0}.news_hp .wrapper a {text-align: left;border-radius: 10px;height: 85px;padding: 20px;margin-bottom: 14px;background: #fff;display: block}.news_hp .wrapper span {color: #2196f3;font-size: 12px;font-weight: bold;line-height: 12px;text-transform: uppercase;display: block;transition: 250ms all}.news_hp .wrapper h3 {font-size: 16px;line-height: 20px;margin: 10px 0}.news_hp .wrapper .timestamp {color: #999;font-size: 12px;transition: 250ms all}main#HP .AdWrapper #rightAd_rdr {position: absolute;right: 5vw;top: auto;bottom: 90px}.topDrug .az ul,#A_Z ul {list-style: none;padding: 0;display: flex;flex-wrap: wrap;justify-content: center}.topDrug .az li,#A_Z li {margin: 6px;padding: 0 !important}.topDrug .az li a,#A_Z li a {color: #fff;font-size: 24px;font-weight: 600;line-height: 40px;border-radius: 100%;padding: 5px;width: 40px;height: 40px;background: #e5e5e5;display: inline-block;transition: all 250ms}.topDrug .az li a.active,#A_Z li a.active {background: #2196f3}.topDrug .azList {height: 300px;width: calc(100% - 340px);margin: 40px 0;overflow-y: auto;position: relative}.topDrug .azList ul {display: none;list-style: none;margin: 20px;padding: 0;column-count: 2;column-gap: 30px;text-align: left;width: calc(100% - 40px);position: absolute}.topDrug .azList #list-azA {display: block}.topDrug .azList li {border-bottom: 1px dotted #ddd;padding: 0 !important;width: 100%;display: inline-block}.topDrug .azList li a {color: #2196f3;font-size: 16px;padding: 8px 0;display: block}.topRx ul {list-style: none;margin: 0;padding: 0;text-align: left;column-count: 2;column-gap: 50px}.topRx li {padding: 0 !important;border-bottom: 1px solid #f1f6f9;display: flex;align-items: center}.topRx li:before {content: "\e605";font-family: 'icomoon';color: #fff;font-size: 14px;line-height: 16px;width: 15px;height: 15px;background: #2196f3;border-radius: 100%}.topRx li a {font-size: 16px;padding: 8px;width: 100%;min-height: 38px;display: flex;align-items: center}.media #leftAd_rdr {position: absolute}.media .container {margin-left: 200px}.media .wrapper a {text-align: left;background: #d5edfc;border-radius: 10px;margin-bottom: 14px;display: block;height: 70px;padding: 10px}.media .wrapper img {border-radius: 10px;width: 70px;height: 70px;position: absolute}.media .wrapper h3 {font-size: 16px;line-height: 18px;margin: 10px 0 10px 80px}/*** Article ***/.rxArt main {display: flex;}.rxArt main#HP,.rxArt.imgcol main {display: table;width: 100%}.story {margin: 0;max-width: 950px;}.story .share {float: right;margin-top: -32px}.story article {font-size: 16px;padding: 5px 0}.story article a:hover {text-decoration: underline}.story article .alert {background: #ed1c24;font-size: 12px;color: #fff;padding: 5px 10px;border-radius: 30px;font-weight: 600;text-transform: uppercase;display: inline-block}.story article h3 {text-decoration: underline;text-transform: uppercase}.monograph_sum{width:auto;border: 2px solid #59A3DD;    border-radius: 6px;margin-bottom: 25px;}.monograph_header{background: #F1F8FC;    border-radius: 3px 3px 0px 0px;padding:1px 10px;font-size:17px;line-height:26px;}.monograph_header h2.monograph_source{line-height: 20px;}.monograph_date{float:right;}.monograph_cont{padding:15px;}.drug_fda{  padding-top: 15px;  padding-bottom:10px;  background-image: linear-gradient(to right, #232323 40%, rgba(255, 255, 255, 0) 20%);  background-position:bottom;  background-size: 17px 1px;  background-repeat: repeat-x;}.drug_review_btn{background: #0171BB;border-radius: 3px;}.story article ul {margin: 30px 0}.story article ul li,.story article ol li, .monograph_cont ul li {padding: 8px 0;line-height: 22px;break-inside: avoid}.story .pageSection {margin: 60px 0}.story .pageSection:first-child {margin-top: 20px}.story .pageSection .clear {clear: none}#apPage h5 {font-size: 15px}.bookmark {display: block;position: relative;top: -230px}#apPgNum {font-size: 18px;font-weight: 600;text-align: left;color: #333333;padding: 5px 10px;margin-bottom: 25px;border-left:5px solid #2196f3;}#apPgNum span{font-size:26px;line-height:30px;}.rxArt.pgcon #apPgNum {background: #92A74E}.rxArt.pgsideeffect #apPgNum {background: #F3614D}.slide-viewpoert {margin-bottom: 25px}.monomodmsg {font-size: 14px;text-align: right;margin: 10px 0}/**.rxArt .stickyColLeft,.rxArt .stickyColRight{padding:0px 20px}**/.rxArt #rxlistAD160,.rxArt #rightAd_rdr {position: sticky;position: -webkit-sticky;top: 182px}.story .driver {display: inline-block;font-size: 18px;font-weight: 600}.story .btn_driver a {display: inline-block;color: #fff;padding: 6px 40px;border-radius: 3px;background: #2196f3;transition: background 250ms}.story .btn_driver a:hover {text-decoration: none;background: #000}.story .Red,.story .final {color: #f00;text-transform: uppercase;font-size: 16px;font-weight: 600}#Disc_Warning {border-radius: 12px;padding: 15px 20px;margin: 20px 0 -40px 0;line-height: 17px;font-size: 16px;font-weight: 600;text-transform: uppercase;color: #fff;background: #da1b23}.pgContent .blackBorderBox_fmt {    border-radius: 6px;    padding: 25px;    background: #F9F4F4;margin:20px 0;}.blackBorderBox_fmt b{font-weight:400;line-height:26px;}.blackBorderBox_fmt p:nth-child(2)>b{color: #DB5757;    font-size: 20px;    font-weight: 600;    line-height: 30px;    text-align: center;}.mnvit_copy {margin: 20px 0;width: 100%;max-width: 470px}.pgContent center {overflow-x: auto}.pgContent .artTable,.pgContent .blacktbl,.pgContent .blackpic {width: 100%;margin-bottom: 10px;border-spacing: 0;text-align: center;table-layout: fixed}.pgContent .artTable tr td:nth-child(odd),.pgContent .blacktbl tr td:nth-child(odd) {background: #eee}.pgContent .artTable tr td:first-child,.pgContent .blacktbl tr td.EmphTd {border-left: 1px solid #989898;text-align: center;background: #555;color: #fff;font-weight: 600}.pgContent .artTable tr td,.pgContent .blacktbl tr td {font-size: 12px;padding: 5px;border-bottom: 1px solid #e0e0e0;border-top: none}.pgContent .blackpic img {width: auto;height: auto;max-width: 100%}#forPatients {margin: 20px 0}#forPatients .forPatientsHdr {margin: 0;padding: 5px;text-align: center;border-radius: 3px 3px 0 0;background: #92A74E;color: #fff;font-size: 18px}#forPatients .forPatientContent {padding: 0 25px 25px 25px;border: 1px solid #92a74e}#fdaWrapper {background: #003152;color: #fff;margin: 30px auto;max-width: 715px}#fdaWrapper img {padding: 25px;position: absolute}#fdaWrapper h3 {padding: 15px;margin: 0 0 0 190px;font-size: 19px;line-height: 24px;border-left: 1px solid #4d6f86;text-decoration: none}#fdaWrapper p {padding: 11px 15px;font-size: 12px;margin: 0 0 0 190px;border-left: 1px solid #4d6f86}#fdaWrapper p a {color: #fff;text-decoration: underline}.medianet {margin: 50px auto}.story .fdbTerms {border-radius: 5px;padding: 15px 20px;margin: 20px 0;background: #000}.story .fdbTerms a {font-size: 14px;display: inline-block;color: #fff}.consumerHeading {font-weight: 600;display: block;margin: 30px 0 5px}.continue_reading {font-weight: 600;color: #6cc2ff;margin: 50px auto;text-align: center;display: table}.continue_reading:before,.continue_reading:after {content: '.............';font-size: 15px;color: #ccc;top: -5px;letter-spacing: 2px;position: relative;display: table-cell}.story #sponsors .wrapper ul {column-count: 2}.apPageBottom {border-top: 1px solid #ccc;margin: 40px 0}.apPageBottom #refs {font-size: 14px;font-style: italic;margin: 10px 0;color: #2196f3}.apPageBottom #refs .icon-search {font-size: 12px;color: #F26522;padding: 0 4px;vertical-align: middle;display: inline-block}.apPageBottom #refs:hover {cursor: pointer;text-decoration: underline}.apPageBottom #refStash {display: none;background: #eee;padding: 20px;margin-bottom: 20px;font-size: 12px}.lastreviewed {margin: 10px 0;font-size: 14px;color: #777}.story .source,.story .credit,.story .disclaimer,.story .Sizeminus {font-size: 12px}.otherNames p {font-size: 14px}/*** Article (hero) ***/.wrapper-hero {padding: 30px 2% 10px;position: relative;margin: 0;}.wrapper-hero .hero h1,.pageWrapper h1 {text-transform: uppercase;margin: 45px 0 15px}.story .slideshow h1 {font-size: 42px}.wrapper-hero .hero ul {margin: 0;padding: 0}.wrapper-hero .hero ul li {list-style: none;line-height: 26px;padding: 2px 0;}.wrapper-hero .hero ul li[itemprop="name"] span {font-weight: 400}.wrapper-hero .hero ul li[itemprop="name"] a {color: #2196f3}.wrapper-hero .hero .drug_name {margin: 5px 0 10px -22px}.wrapper-hero .hero .drug_name [class^="drug"] {padding: 8px 12px;margin: 0 10px;display: inline-block;position: relative}.wrapper-hero .hero .drug_name [class^="drug"]:after {content: " | ";color: #aaa;position: absolute;right: -13px}.wrapper-hero .hero .drug_name span:last-of-type:after {display: none}.wrapper-hero .hero .drug_name [class^="drug"] a {color: #2196f3;font-size: 18px;line-height: 22px;text-decoration: none;display: inline-block}.wrapper-hero .hero .drug_name [class^="drug"] a:hover {text-decoration: underline}.wrapper-hero .monolastreviewed,.wrapper-hero .reviewer,.wrapper-hero .reviewdate {    line-height: 26px;padding: 5px 0 10px;}.wrapper-hero .monolastreviewed a {color: #232323;margin-right: 10px}.wrapper-hero .monolastreviewed i {font-style: normal}.wrapper-hero .hero ul+p {color: #fff;font-size: 14px;background: #333;text-align: center;padding: 5px 0;width: 150px}.author a {color: #2196f3;text-decoration: none}.author a:hover {text-decoration: underline}.breadcrumbs {color: #777777;font-size: 14px;line-height: 16px;width: 95%;top: 20px;position: absolute;text-transform: uppercase}.breadcrumbs a {color: #2196f3;font-size:14px;line-height:16px;}.breadcrumbs a:after {font-family: 'icomoon';content: "\e605";padding-left: 4px;display: inline-block;vertical-align: middle;color: #232323;}.trustBadge {color: #4CAF50;font-size: 14px;padding: 6px 10px 5px 35px;margin: 10px 0;border: 1px solid #4CAF50;position: relative;display: inline-block;transition: all 250ms;display:none;}.trustBadge .icon-shield {font-size: 19px;color: #4CAF50;position: absolute;left: 8px;top: 5px;transition: all 700ms}.trustBadge:hover {text-decoration: none;background: #000;color: #fff;border-color: #fff;cursor: pointer}.trustBadge:hover .icon-shield {color: #fff}.trustBadgeContent {text-align: center;padding: 30px}.trustBadgeContent ul {padding: 0;margin: 0;display: inline-block}.trustBadgeContent li {float: left;list-style: none}.trustBadgeContent .trustLink {margin: 20px 0}.trustBadgeContent .trustLink li:before {content: "|";padding: 0 10px}.trustBadgeContent .trustLink li:first-child:before {display: none}.trustBadgeContent .trustLink a {color: #2196f3;font-size: 16px;text-decoration: none}.trustBadgeContent .trustLink a:hover {text-decoration: underline}.trustBadgeContent .badge {display: block;margin: 15px auto;width: 340px;height: 60px}.trustBadgeContent p {font-size: 12px;margin: 5px 0}.trustBadgeContent p a {color: #2196f3}.drugDropdown {height: 30px;list-style: none;margin: 10px 0 16px;padding: 0}.drugDropdown li {float: left;}.drugDropdown li>a {text-decoration: none;background: #F1F5F7;margin-right: 15px;padding: 7px 10px;display: inline-block;position: relative;border-radius: 3px;    width: 160px;    color: #2196F3;white-space: nowrap;font-size: 15px;}.drug_review_btn a{background: none !important;color:#ffffff !important;}.drugDropdown .drugSelect {padding: 6px 25px 6px 10px;}.drugDropdown .drugSelect:after {font-family: 'icomoon';    content: "\e605";    font-size: 27px;    position: absolute;    top: -1px;    right: 1px;    transform: rotate(90deg);    background: #DBEBF8;    color: #2196F3;    width: 29px;    height: 31px;    text-align: center;}.drugDropdown a.prof:hover,.drugDropdown a.sideEffect:hover{background: #555;color: #fff}.drugDropdown .drugOption {display: none;position: absolute;border-radius: 0px 3px 3px 3px;    margin:0;background: #EAF4FC;z-index: 9;max-height: 40vh;width: 194px;overflow-y: auto;box-shadow: 0 6px 4px -4px #ccc;font-size: 15px;}.drugDropdown li:hover .drugSelect {background: #EAF4FC;border-radius: 3px 3px 0px 0px;}.drugDropdown li:hover .drugSelect:after{background: #2196F3;transform: rotate(270deg);color:#ffffff;line-height:35px;border-radius: 0px 0px 3px 3px;}.drugDropdown li:hover .drugOption {display: block;}.drugDropdown .drugOption a {display: block;line-height: 30px;text-decoration: none;padding: 8px 10px}.drugDropdown a.sideEffect {background: #F3614D;color: #fff;display:none;}.drugDropdown a.prof {background: #47638D;color: #fff;}.drugOption::-webkit-scrollbar-track {box-shadow: inset 0 0 6px rgba(0, 0, 0, 0.3);background: #fafafa}.drugOption::-webkit-scrollbar {width: 3px;background: #fafafa}.drugOption::-webkit-scrollbar-thumb {background: #000}.drugOption::-webkit-scrollbar-thumb:hover {background: #2196f3}/*** Article (submenu) ***/.submenu .icon-menu {display: none}.submenu .tab {border-bottom: 5px solid #eee}.submenu .tab a {color: #47638D;font-size: 18px;font-weight: 600;padding: 10px 12px;margin-bottom: -7px;text-decoration: none;height: 32px;border-bottom: 5px solid #eee;display: inline-block;opacity: .3;transition: all 250ms}.submenu .tab a.con {color: #92A74E}.submenu .tab a.sideEffect {color: #F3614D}.submenu .tab a.active {cursor: default}.submenu .tab a.prof.active,.submenu .tab a.prof:hover {border-bottom: 5px solid #47638D;opacity: 1}.submenu .tab a.con.active,.submenu .tab a.con:hover {border-bottom: 5px solid #92A74E;opacity: 1}.submenu .tab a.sideEffect.active,.submenu .tab a.sideEffect:hover {border-bottom: 5px solid #F3614D;opacity: 1}.submenu .tab a span {font-size: 32px;margin-right: 8px;vertical-align: -32%}.submenu .tab a .icon-pro {font-size: 26px}.submenu .toc.link {    background: #F1F8FC;    border-radius: 6px 6px 0px 0px;    padding: 0px 16px 0px 16px;}.submenu .icon-menu:before {margin-right:20px;}.submenu .icon-menu:after{content: url("https://images.rxlist.com/images/mobile/rxlist/logo-rxl.png");background-repeat: no-repeat;margin-left:20px;}.submenu .toc.link ul {padding: 0;margin: 5px 0 0px -6px;list-style: none;display: inline-block}.submenu .toc.link ul li {padding: 0;float: left;}/* .submenu .toc.link li.active a {    background: #2196F3;    color: #ffffff;    border-radius: 3px;} */.submenu .toc.link a {color: black;line-height: 25.5px;text-decoration: none;padding: 6px 6px;margin: 0 6px;display: inline-block;position: relative;}.submenu .toc.link a:hover {color: #2196f3;}.submenu .toc.link a:after {content: " | ";color: #aaa;position: absolute;right: -13px}.submenu .toc.link li:last-child a:after {display: none}.submenu .toc.link a:hover {text-decoration: underline}.miniMenu .masterSub {top: 50px}/*.miniTitle .hero h1 {position: fixed;top: -33px;left: 70px;font-size: 24px !important;line-height: 26px;width: calc(100% - 650px);white-space: nowrap;overflow: hidden;text-overflow: ellipsis;z-index: 9999999;transition: all 250ms}*/.submenu.stuck h2.drug_fda {    display: none;}/* .submenu.stuck {position: fixed;top: -150px;left: 0;right: 0;background: #fff;box-shadow: 0 1px 5px 0 #ccc;height: 50px;z-index: 999999}.submenu.stuck>span[class*="icon-"] {color: #2196f3;display: block;padding: 0 20px;font-size: 30px;cursor: pointer;line-height: 50px;position: absolute} */.submenu.stuck>span[class*="icon-"]:hover {color: #232323;}.submenu.stuck .tab {border: none;right: 10px;position: absolute}.submenu.stuck .tab a {display: none;font-size: 16px;line-height: 18px;height: auto;margin: 0;padding: 15px 35px 15px 20px;border-bottom: none !important;white-space: nowrap}.submenu.stuck .tab a span {font-size: 20px;vertical-align: text-bottom}.submenu.stuck .tab a.active {display: block;cursor: pointer;top: 0;right: 0;position: absolute}.submenu.stuck .tab a.active:after {font-family: 'icomoon';content: "\e605";color: #232323;font-size: 22px;position: absolute;right: 8px;z-index: -1;transform: rotate(90deg)}/* .submenu.stuck .tab.select:before {content: '';width: 100%;height: 50px;display: block;border-bottom: 2px solid #eee} */.submenu.stuck .tab a.option {display: block;background: #fff;box-shadow: inset 0px -1px 3px -1px #ccc;opacity: 1}.submenu.stuck .tab a.option:hover {color: #232323}.submenu.stuck .toc.link ul {bottom: 18px;  right: 100px;margin: 0;position: fixed;}.submenu.stuck .toc.link li {float: none;/* background:white; */}.submenu.stuck .toc.link a {font-size: 17px !important;line-height: 19px !important;margin: 0;padding: 10px 30px;white-space: nowrap}.submenu.stuck .toc.link a:after {display: none}.submenu.stuck .toc.link a:hover {text-decoration: none}/* .submenu.stuck .toc.link li.active a {display: block;color: #232323;top: 0;right: 0;position: absolute;background: none;} *//* .submenu.stuck .toc.link li.active:after {font-family: 'icomoon';content: "\e605";font-size: 22px;position: absolute;right: 0;top: 14px;z-index: -1;transform: rotate(90deg)} */.submenu.stuck li.active {display: block;background: #2196f3;border-radius: 10px;}.submenu.stuck li.active a {color: white;}.submenu.stuck li {display: none;}.submenu.stuck ul:hover li {display: block;}/* .submenu.stuck .toc.link .select:before {content: '';width: 100%;height: 50px;display: block;border-bottom: 2px solid #eee} *//* .submenu.stuck .toc.link a.option {display: block;padding: 15px 20px;background: #fff;box-shadow: inset 0px -1px 3px -1px #ccc;transition: all 250ms}.submenu.stuck .toc.link a.option:hover {color: #232323;} *//*** Article (right column) ***/aside {width: 310px}aside .sideBox {padding: 20px 0;z-index: 0;position: relative}aside .sideBox.promo {padding-top: 0}aside .dialog-activator:after{content:'Tools';font-weight: 700;    font-size:24px;line-height: 140%;color: #333333;text-align: center;display: flex;justify-content: center;}aside .sideBox.promo a {text-decoration: none;}aside .sideBox.promo .rrpromo:hover{background:#000;border-radius:3px;}aside .sideBox.promo .rrpromo {border-bottom: 1px solid #E3E6E8;}aside .sideBox.promo .rrpromo .icon-arrow-right2{   display: none;}aside .sideBox.promo .rrpromo p {font-size: 14px;line-height: 21px;font-weight: 700;margin: 16px 0 14px 5px;color: #2196F3;}aside .sideBox.promo .rrpromo span[class^="icon-"] {font-size: 25px;color: #2196F3;padding: 8px;margin: 1px 5px 1px 0;float: right;transition: all 250ms}aside .sideBox.promo .rrpromo span[class^="icon-arrow"] {background: none !important;color: #232323;font-size: 35px;float: right;margin: 0;padding: 0}aside .sideBox.promo .rrpromo span {font-size: 12px;color: #777777;display: inline-block;font-weight:400;line-height:18px;}aside .sideBox.slide h2,aside .featured_slideshow h3 {background: #777777;color: #fff;font-size: 16px;padding: 6px;margin: 0;text-align: center;text-decoration: none !important}aside .sideBox.slide .owl-carousel {width: 310px;min-height: 250px;display: inline-block;margin: 0 auto}aside .sideBox.slide .wrapper {text-align: center;background: #000;background: rgba(0, 0, 0, .3);position: absolute;top: 166px;height: 40px;display: table;width: 100%;transition: all 250ms;z-index: 1}aside .sideBox.slide .wrapper span {vertical-align: middle;padding: 11px 45px;color: #fff;width: 190px;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;display: inline-block;font-size: 14px}aside .sideBox.slide .item img {height: 210px}aside .sideBox.slide .item p {font-size: 14px;font-style: italic;line-height: 17px;margin: 6px}aside .sideBox.slide .owl-nav [class*='owl-'] {color: #fff;font-size: 45px;opacity: 0.5;position: absolute;top: 158px}aside .sideBox.slide .owl-nav [class*='owl-']:hover {opacity: 1}aside .sideBox.slide .owl-nav .owl-prev {left: 0}aside .sideBox.slide .owl-nav .owl-next {right: 0}aside .sideBox.reviews {border-left: 5px solid #568a10;background: #e8f7b8;margin: 20px 0;padding: 0}aside .sideBox.reviews a {text-decoration: none;color: #568a10;font-weight: 600;font-size: 18px;text-transform: uppercase;padding: 16px 10px;width: calc(100% - 20px);display: inline-block;transition: all 250ms}aside .sideBox.reviews a:hover {color: #e8f7b8;background: #568a10}aside #rightAd_rdr {width: 310px;margin: 20px auto}aside .featured_slideshow {padding: 20px 0}aside .featured_slideshow .content {padding: 0;list-style: none}aside .featured_slideshow .content li {border-top: 1px solid #ccc;padding: 10px 0}aside .featured_slideshow .content li:first-child {border: none;padding-top: 0}aside .featured_slideshow .content img {width: 79px;height: 79px;float: left;transition: opacity 400ms}aside .featured_slideshow .content p {color: #777777;display: inline-block;width: calc(100% - 90px);height: 73px;margin: 6px 0 0 10px;font-size: 16px;line-height: 18px}aside .featured_slideshow .content p span {display: block;font-size: 13px;line-height: 15px;color: #777777;padding-top: 8px}aside .featured_slideshow .content li:hover * {color: #2196f3;cursor: pointer}aside #rightAd_rdr.sidebox:after {display: none}aside .sideBox ul {padding: 0;list-style-type: none;display: inline;}aside .sideBox ul li {display: inline;}aside .sideBox ul li a:after {content: ", ";}aside .sideBox ul li a:last-child:after {content: ""}/*** Article (lite TOC $ vitTOC) ***/.apPage .toc_lite, .vitTOC{background-color: #F1F8FC;padding:10px;}.apPage .toc_lite .owl-carousel,.vitTOC {margin: 0px !important;list-style: none;display: inline-block;column-count: 1 !important;padding:0px;}.apPage .toc_lite .owl-carousel>li,.vitTOC>li {padding: 0 !important;float: left}.apPage .toc_lite .owl-carousel>li>a,.vitTOC>li>a {font-size: 18px;line-height: 22px;padding: 8px 12px;margin: 0 10px;border-radius: 5px;display: inline-block;position: relative}.apPage .toc_lite .owl-carousel>li>a:hover,.apPage .toc_lite .owl-carousel .open,.vitTOC>li>a:hover {background: #2196f3;color: #fff;text-decoration: none}.apPage .toc_lite .owl-carousel>li>a:after,.vitTOC>li>a:after {content: " | ";color: #aaa;position: absolute;right: -13px}.apPage .toc_lite .owl-carousel>li:last-child a:after,.vitTOC>li:last-child a:after {display: none}.apPage .toc_lite .sub {display: none;border: 2px solid #2196f3;border-radius: 0 0 5px 5px;list-style: none;margin: -5px 0 0 10px;padding: 3px;width: auto;max-width: 26vw;background: #fff;position: absolute;z-index: 1}.apPage .toc_lite .sub li {padding: 0 !important;line-height: 22px !important}.apPage .toc_lite .sub li a {color: #232323;font-weight: 400;padding: 4px 0;display: block}.apPage .toc_lite .sub li span[class^="icon-"] {color: #f7941d;background: #fff;position: absolute;left: 10px;margin-top: 12px}/*** Article (interval) ***/.mediaPrmo {border-radius: 10px;height: 300px;max-width: 800px;margin: 50px auto;display: block;position: relative;clear: both;background: #999;transition: all 250ms;}.mediaPrmo {border-radius: 10px;height: 300px;max-width: 800px;margin: 50px auto;display: block;position: relative;clear: both;background: #999;transition: all 250ms}.mediaPrmo img {border-radius: 10px;object-fit: cover;width: 45%;height: 300px;position: absolute;transition: all 250ms}.mediaPrmo .skew {position: absolute;left: 38%;width: 150px;height: 300px;background: #999;transform: skew(-10deg);transition: all 250ms}.mediaPrmo [class^="icon-"] {position: absolute;right: 10px;top: 10px;color: #fff;opacity: .8;transition: all 250ms}.mediaPrmo .label,.mediaPrmo .caption,.mediaPrmo .desc,.mediaPrmo .btn {display: block;color: #fff;margin: 25px 20px 25px 45%;text-align: center;position: relative;transition: all 250ms}.mediaPrmo .label {font-size: 15px;padding-top: 30px}.mediaPrmo .label:before,.mediaPrmo .label:after {content: "";border: .5px solid #fff;width: 20px;margin: 5px 10px;display: inline-block}.mediaPrmo .caption {font-size: 20px;font-weight: 600;line-height: 24px}.mediaPrmo .desc {font-size: 14px}.mediaPrmo .btn {color: #777777;padding: 10px;font-weight: 600;border-radius: 5px;background: #fff;transition: all 250ms}.mediaPrmo:hover {text-decoration: none !important;background: #eee}.mediaPrmo:hover img {width: 33%;filter: grayscale(100%)}.mediaPrmo:hover .skew {background: #eee;left: 25%}.mediaPrmo:hover [class^="icon-"] {color: #232323;}.mediaPrmo:hover .label,.mediaPrmo:hover .caption,.mediaPrmo:hover .desc,.mediaPrmo:hover .btn {margin-left: 30%;color: #232323;}.mediaPrmo:hover .label:before,.mediaPrmo:hover .label:after {border-color: #000}.mediaPrmo:hover .btn {background: #000;color: #fff}.article-promo {margin: 50px 0;padding: 20px 0;border: 0 solid #f2f2f2;border-width: 5px 0;text-align: center}.article-promo .item {padding: 0 15px;width: calc(33% - 30px);max-width: 150px;height: 230px;display: inline-table}.article-promo a img {width: 100%;max-width: 150px;transition: opacity 250ms}.article-promo a span {font-size: 14px;font-weight: 600;color: #232323;margin: 20px 0;text-align: left;width: 100%;display: inline-block}.article-promo .icon-slideshow:before {content: 'SLIDESHOW'}.article-promo .icon-quiz:before {content: 'QUIZ'}.article-promo .icon-image:before {content: 'IMAGE'}.article-promo a p {font-size: 14px;margin-top: -10px;line-height: 16px !important;text-align: left}.article-promo a:hover img {opacity: .6}.pgContent .learn_more_zomig {background: #f7941d;color: #fff;font-size: 16px;padding: 5px 55px 5px 15px;border-radius: 3px;margin-top: 15px;display: inline-block;position: relative;transition: background 250ms}.pgContent .learn_more_zomig span {font-weight: 600;font-size: 18px}.pgContent .learn_more_zomig .icon-arrow-right2 {position: absolute;right: 0;top: 0;border-left: 1px solid rgba(255, 255, 255, 0.30)}.pgContent .learn_more_zomig .icon-arrow-right2:before {border-left: 1px solid rgba(0, 0, 0, 0.15);font-size: 38px}.pgContent .learn_more_zomig:hover {text-decoration: none;background: #000}#crsprm-2081-assmnt {max-width: 748px;border-color: #eee;border-style: solid;border-width: 5px 0;clear: both;margin: 50px auto;overflow: hidden;padding: 18px 0}#crsprm-2081-assmnt .cross-promo__hero {float: left;margin-right: 40px}#crsprm-2081-assmnt .cross-promo__content {padding-top: 10px}#crsprm-2081-assmnt .cross-promo__subheading {color: #3a6d69;font-size: 12px;font-weight: 600;text-transform: uppercase}#crsprm-2081-assmnt .cross-promo__subheading img.logoTitle {margin: 6px 0 10px 5px}#crsprm-2081-assmnt a:hover {text-decoration: none}#crsprm-2081-assmnt .cross-promo__heading {color: #232323;font-size: 30px;font-weight: 600;line-height: 32px;margin-bottom: 20px}#crsprm-2081-assmnt .cross-promo__cta {color:#232323;font-size: 17px}#crsprm-2081-assmnt .cross-promo__cta::after {content: '';display: inline-block;width: 30px;height: 30px;margin: 0 0 -5px 8px;vertical-align: bottom;background-image: url(https://images.medicinenet.com/images/ads/btn-blue-arrow.png)}.webmd_lab_ad {margin: 40px 0}.webmd_lab_testing {border: 1px solid #eee;margin: 0 auto;background: #fafeff;padding: 0 40px;max-width: 550px}.webmd_lab_testing h4 {font-size: 26px;color: #232323;line-height: 28px;margin: 30px 0 -5px 0}.webmd_lab_testing p {color: #777777;line-height: 18px !important}.webmd_lab_testing .webmd_lab_testing_btn {background: #f26522;width: 300px;border-radius: 3px;padding: 6px;color: #fff;text-align: center;font-size: 18px}.webmd_lab_testing a:hover {text-decoration: none !important}.webmd_lab_testing span.icon-arrow-right2:before {position: absolute;font-size: 29px}.webmd_lab_testing .webmd_lab_logo {font-size: 10px;color: #aaa;margin: 25px 0}.webmd_lab_ad:after {content: '';background: url(https://images.medicinenet.com/images/ads/rightad_toptransparent.gif) no-repeat center 0;height: 10px;display: block}.webmdrx_coup .webmdrx p {text-align: left;padding-right: 100px;width: 140px;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;position: relative}.webmdrx_coup .webmdrx .webmdrx_img {position: absolute;right: 0}.webmdrx_coup h3 {margin: 5px 0;font-size: 14px;line-height: 16px;text-decoration: none !important}.webmdrx_coup .wrapper {margin: 10px 0;padding: 10px 10px 20px;box-shadow: 0 0 4px 0 #ddd;max-width: 600px;position: relative}.webmdrx_coup .wrapper img {width: 40px;padding: 0 20px 2px}.webmdrx_coup .wrapper .pharmName {position: absolute;font-size: 10px;text-align: center;width: 80px;white-space: nowrap;overflow: hidden;text-overflow: ellipsis}.webmdrx_coup .wrapper .reg {position: absolute;top: 20px;left: 20%;color: #777777;font-size: 13px}.webmdrx_coup .wrapper .reg span {text-decoration: line-through}.webmdrx_coup .wrapper .reg p {margin: 0}.webmdrx_coup .wrapper .cou {position: absolute;top: 17px;left: 45%}.webmdrx_coup .wrapper .cou span {font-size: 15px;font-weight: 600}.webmdrx_coup .wrapper .cou p {margin: -3px 0;font-size: 13px;color: #777777;}.webmdrx_coup .wrapper a {position: absolute;top: 18px;right: 5%;color: #fff !important;font-size: 14px;font-weight: 600;background: #02c96a;padding: 8px 25px;transition: all 250ms}.webmdrx_coup .wrapper a:hover {text-decoration: none !important;background: #000}/*** Article (landing) ***/#Drugs_AZlist ul,.quizAtoZ,.sc_az ul {padding: 0;display: inline-block}#Drugs_AZlist ul li,.quizAtoZ li,.sc_az li {list-style: none;padding: 0;margin: 6px;float: left}#Drugs_AZlist li a,.quizAtoZ li a,.sc_az li a {text-decoration: none;display: inline-block;padding: 10px;color: #6896da;font-size: 24px;font-weight: 600;line-height: 30px;border-radius: 3px;width: 30px;height: 30px;text-align: center;background: #f5f5f5;transition: all 250ms}#Drugs_AZlist li a:hover,.quizAtoZ li a:hover,.sc_az li a:hover {background: #000;color: #fff;text-decoration: none}.Rxl_landing_DC,.Rxl_landing_feat,.sc_common_ss {margin: 50px 0;clear: both}.Rxl_landing_DC ul,.sc_common_ss ul,.sc_popular_sym ul {margin: 0;font-size: 18px}.Rxl_landing_feat img {margin-right: 20px}.Rxl_landing_feat .feat_quiz {text-decoration: underline}#Drugs_AZlist .roundtop {padding: 20px 0;text-transform: uppercase;font-size: 19px;font-weight: 600;text-decoration: underline}.contentstyle h4,.AZ_results h4 {font-size: 20px;margin: 20px 0}.contentstyle h4 a,.AZ_results h4 a {margin: 4px 2px;padding: 5px 15px;border-radius: 20px;background: #f5f5f5;display: inline-block;transition: all 250ms}.contentstyle h4 a:hover,.AZ_results h4 a:hover {background: #000;color: #fff;text-decoration: none}.contentstyle h5,.AZ_results h5 {background: #6896DA;margin: 30px 0 0 0;padding: 5px 10px;color: #6896DA}.contentstyle h5 a,.AZ_results h5 a {color: #fff;font-size: 24px;cursor: default;pointer-events: none}.contentstyle ul,.AZ_results ul {list-style-type: none;margin: 0;padding: 0;display: block !important}.contentstyle li,.AZ_results li,.drugChecker_Page .drug_A-Z_list li {padding: 0 !important;position: relative}.contentstyle li a,.AZ_results li a,.drugChecker_Page .drug_A-Z_list li a {padding: 10px !important;font-size: 16px;display: block;transition: all 250ms}.contentstyle li:nth-child(even) *,.AZ_results li:nth-child(even) *,.drugChecker_Page .drug_A-Z_list li:nth-child(even) * {background: #f5f5f5}.contentstyle li:hover *,.AZ_results li:hover *,.drugChecker_Page .drug_A-Z_list li:hover * {background: #000 !important;color: #fff;text-decoration: none !important}.contentstyle li span,.AZ_results li span {position: absolute;right: 10px;top: 13px;font-size: 14px;background: #fff;transition: all 250ms}#imageCategories:first-child a {border: none}#imageCategories a {text-decoration: none;padding: 20px 0;min-height: 180px;display: inline-block;border-top: 1px solid #eee}#imageCategories img {width: auto;position: absolute;transition: all 250ms}#imageCategories h4 {color: #232323;margin: 10px 0 10px 200px;font-size: 20px;line-height: 22px;transition: color 250ms}#imageCategories p {font-size: 16px;line-height: 22px;color: #777777;margin: 10px 0 10px 200px;display: inline-block;transition: color 250ms}#imageCategories a:hover * {color: #2196f3}#imageCategories a:hover img {filter: grayscale(100%)}.quizLinks_fmt {margin: 30px 0}.quizLinks_fmt .alpha {color: #fff;font-weight: 600;background: #6896da;font-size: 24px;padding: 8px 20px;margin-top: 30px;position: relative}.quizLinks_fmt .alpha .top {visibility: hidden}.quizLinks_fmt .alpha .top:after {content: "\e605";font-family: 'icomoon' !important;font-size: 40px;color: #fff;padding: 0 10px;position: absolute;right: 0;top: -6px;visibility: visible;transform: rotate(-90deg)}.quizLinks_fmt .alpha .top:hover:after {color: #aac7f3}.quizLinks_fmt .quizLink_fmt {padding: 20px;min-height: 79px;width: calc(100% - 40px);display: inline-block;transition: all 250ms}.quizLinks_fmt .quizLink_fmt:nth-child(odd) {background: #f5f5f5}.quizLinks_fmt .quizLink_fmt img {border-radius: 3px;position: absolute}.quizLinks_fmt .quizLink_fmt h3 {margin: 0 0 0 90px;color: #2196f3;line-height: 20px;text-decoration: none;text-transform: capitalize;transition: all 250ms}.quizLinks_fmt .quizLink_fmt p {color: #232323;margin: 10px 0 0 90px;font-size: 14px;line-height: 18px;transition: all 250ms}.quizLinks_fmt .quizLink_fmt:hover {background: #000;text-decoration: none}.quizLinks_fmt .quizLink_fmt:hover * {color: #fff}#accordion h3 {margin: 5px 0;text-decoration: none}#accordion h3 a {color: #fff;background: #6896da;font-size: 20px;line-height: 26px;padding: 10px 60px 10px 15px;text-transform: capitalize;display: block;text-decoration: none;position: relative;transition: all 250ms}#accordion h3 a:after {content: "\e605";font-family: 'icomoon' !important;font-size: 40px;padding: 0 10px;position: absolute;top: 50%;right: 0;transform: translateY(-50%) rotate(90deg)}#accordion h3 a:hover {background: #000}#accordion .fold {display: none;position: relative}#accordion h3:first-child+.fold {display: block}#accordion .fold ul {list-style: none;padding: 0;display: block;column-count: 2}#accordion .fold ul li {padding: 0}#accordion .fold a {padding: 20px;height: 260px;width: calc(100% - 40px);max-width: 200px;text-align: center;display: inline-block;transition: background 250ms}#accordion .fold a img {border-radius: 3px}#accordion .fold a h4 {color: #232323;font-size: 20px;line-height: 22px;text-align: left;margin: 20px 0 10px;transition: color 250ms}#accordion .fold a p {color: #232323;font-size: 16px;line-height: 20px;text-align: left;margin: 0;transition: color 250ms}#accordion .fold a:hover {text-decoration: none;background: #000 !important}#accordion .fold a:hover * {color: #fff}#centering_area .breadcrumb {margin: 30px auto 0;font-size: 14px;width: 1100px}#centering_area .breadcrumb a:after {font-family: 'icomoon';content: "\e605";padding-left: 4px;display: inline-block;vertical-align: middle;color: #232323;}#symptom_checker {width: 1100px;margin: 0 auto}#symptom_checker .sc_content_well {margin: 50px 0}#symptom_checker .sc_content_well h3 {text-decoration: underline;text-transform: uppercase}#symptom_checker .sc_common_ss ul li,#symptom_checker .sc_popular_sym ul li {padding: 5px 0}#symptom_checker .sc_common_ss ul li a,#symptom_checker .sc_popular_sym ul li a {color: #2196f3;text-decoration: none;cursor: pointer}#symptom_checker .sc_common_ss ul li a:hover,#symptom_checker .sc_popular_sym ul li a:hover {text-decoration: underline}#centering_area .medianet,#centering_area .from_webmd {width: 1100px}#search {max-width: 1265px;margin: 0 auto;padding: 0 20px;grid-template-columns: 0 auto 350px}#search .story {margin: 0;padding: 0 20px 30px 20px;width:100%;max-width: 1400px;}#search .breadcrumbs {display: none}#search .story article {padding: 25px 0}#search .searchresults {width: auto;padding: 0;text-align: left;position: relative;margin: 70px 0}#search .searchresults.main {margin-top: 30px}#search .searchresults h3 {color: #fff;font-size: 20px;background: #6896da;text-decoration: none !important;padding: 5px 10px;margin: 10px 0}#search .searchresults ul {padding: 0;margin: 0;list-style: none;overflow: hidden;display: block !important}#search .searchresults li {padding: 0 !important;border-top: 1px solid #eee}#search .searchresults li:first-child {border: none}#search .searchresults li a {font-weight: 600;font-size: 18px;line-height: 22px;padding: 15px;display: block;transition: all 250ms}#search .searchresults li img {margin-right: 15px;float: left}#search .searchresults li .brand {font-size: 18px;color: #2196f3;font-weight: 600;line-height: 22px}#search .searchresults li .generic {color: #232323;font-size: 15px;font-weight: 400;line-height: 19px}#search .searchresults li span {font-size: 12px;color: #777777;line-height: 14px;display: block;transition: all 250ms}#search .searchresults li p {font-size: 14px;color: #232323;line-height: 18px;font-style: italic;transition: all 250ms}#search .searchresults li a:hover {background: #000;color: #fff;text-decoration: none}#search .searchresults li a:hover * {color: #fff}#search .searchresults .gradient,#ForumCenter_fmt .sideBox[class$=List] .gradient {width: 100%;height: 30px;position: absolute;bottom: 0;background: -moz-linear-gradient(top, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0) 1%, rgba(255, 255, 255, 1) 100%);background: -webkit-linear-gradient(top, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0) 1%, rgba(255, 255, 255, 1) 100%);background: linear-gradient(to bottom, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0) 1%, rgba(255, 255, 255, 1) 100%);filter: progid:DXImageTransform.Microsoft.gradient(startColorstr='#00ffffff', endColorstr='#ffffff', GradientType=0)}#search .searchresults .more,#ForumCenter_fmt .sideBox[class$=List] .more {border-top: 1px solid #DCDCDC;position: relative}#search .searchresults .more span,#ForumCenter_fmt .sideBox[class$=List] .more span {border: 1px solid #dcdcdc;border-radius: 3px;border-top: 1px solid #fff;padding: 3px 20px;margin-top: -1px;position: absolute;top: 50%;left: calc(50% - 42px);cursor: pointer;font-size: 40px;line-height: 20px;color: #2196f3;-webkit-transition: color 200ms;transition: color 200ms}#search .searchresults .more span:before,#ForumCenter_fmt .sideBox[class$=List] .more span:before {transform: rotate(90deg);display: block}#search .searchresults .more span:hover,#ForumCenter_fmt .sideBox[class$=List] .more span:hover {color: #ccc;background: #fff;background: -moz-linear-gradient(top, #fff 0%, #eee 100%);background: -webkit-linear-gradient(top, #fff 0%, #eee 100%);background: linear-gradient(to bottom, #fff 0%, #eee 100%);filter: progid:DXImageTransform.Microsoft.gradient(startColorstr='#fff', endColorstr='#eee', GradientType=0)}#search .searchresults .more span.active:before,#ForumCenter_fmt .sideBox[class$=List] .more span.active:before {transform: rotate(-90deg)}#search #noresult {margin: 50px 0}/*** Article (user reviews) ***/.pgContent .related .relMono {font-size: 22px}#patientComments_fmt {padding: 30px;margin: 30px 0;background: #f5f5f5;border: 1px solid #d9d9d9;border-radius: 5px;position: relative}#patientComments_fmt:before,#patientComments_fmt:after {content: "";position: absolute;width: 0;height: 0;border-style: solid;border-color: transparent;border-top: 0}#patientComments_fmt:before {top: -8px;left: 25px;border-bottom-color: #D9D9D9;border-width: 8px}#patientComments_fmt:after {top: -7px;left: 26px;border-bottom-color: #f5f5f5;border-width: 7px}#patientComments_fmt .commentTop {font-style: italic}#patientComments_fmt .patComment {padding: 40px 20px;position: relative}#patientComments_fmt .patComment:before {content: open-quote;font-size: 100px;position: absolute;color: #e4e4e4;margin: -55px 0 0 -35px}#patientComments_fmt .patComment:after {content: close-quote;font-size: 100px;position: absolute;color: #e4e4e4;margin: -55px -15px 0 0;right: 0}#patientComments_fmt .suggReading a {text-transform: capitalize}/*** Article (FAQ) ***/#faqContent #faq-top,#faqContent h2 {display: none}#faqContent .faq-reviewed p {font-size: 14px;line-height: 16px}#faqContent #faqPromo {margin: 20px 0;padding: 20px;border: 1px solid #dedede;border-radius: 10px}#faqContent #faqPromo .faqContImg img {margin-right: 8px;float: left}#faqContent #faqPromo .faqContTitle {font-size: 16px;font-weight: 600;display: block}#faqContent #faqPromo .faqContTag {font-size: 13px;margin: 10px 0;display: block}#faqContent .faqAnswers img {width: 100%;height: auto;border-radius: 5px;max-width: 800px;margin: 10px auto;display: block}#faqContent .faqAnswers img.spec {max-width: 180px}#faqContent .faqAnswers .q,#faqContent .faqAnswers .a {font-size: 22px;font-weight: 600;color: #6896DA;padding-right: 5px}#faqContent .faqAnswers .ques {font-size: 22px;font-style: italic;line-height: 24px}#faqContent .faqAnswers .faqHead+p {padding: 20px;margin: 15px 0;background: #f5f5f5;border: 1px solid #d9d9d9;border-radius: 3px;position: relative}#faqContent .faqAnswers .faqHead+p:before,#faqContent .faqAnswers .faqHead+p:after {content: "";position: absolute;width: 0;height: 0;border-style: solid;border-color: transparent;border-top: 0}#faqContent .faqAnswers .faqHead+p:before {top: -8px;left: 25px;border-bottom-color: #D9D9D9;border-width: 8px}#faqContent .faqAnswers .faqHead+p:after {top: -7px;left: 26px;border-bottom-color: #f5f5f5;border-width: 7px}#faqContent .faqAnswers .backToTop {font-size: 15px;text-align: right;margin: -10px 0 40px 0;display: block}#faqContent .faq-source {border-top: 1px solid #ccc;font-size: 14px;font-style: italic;line-height: 16px;margin: 40px 0;padding: 10px 0;display: block}#faqContent .starCont .faqHead {font-size: 18px;text-decoration: underline;text-transform: uppercase}/*** Article (secondary) ***/.rxlsecondary .toc,.RXLSyndicated .toc {position: relative;border-bottom: 1px solid #ccc;margin: 20px 0}.rxlsecondary .toc ul li,.RXLSyndicated .toc ul li {list-style: none}.rxlsecondary .toc ul li:before,.RXLSyndicated .toc ul li:before {font-family: 'icomoon';content: "\e909";font-size: 15px;vertical-align: text-bottom;position: absolute;left: 12px;transition: transform 250ms}.rxlsecondary .toc ul li a,.RXLSyndicated .toc ul li a {color: #2196f3;text-decoration: none}.rxlsecondary .toc ul li:hover,.RXLSyndicated .toc ul li:hover {cursor: pointer}.rxlsecondary .toc ul li:hover a,.RXLSyndicated .toc ul li:hover a {text-decoration: underline}.rxlsecondary .toc ul li:hover:before,.RXLSyndicated .toc ul li:hover:before {transform: rotate(90deg)}.authEditorWrap {padding: 10px 15%;max-width: 1100px}.authEditorWrap .authEditorCont {list-style: none;font-size: 16px;color: #e0f0ff;line-height: 18px;text-align: center;padding: 4px 0}.authEditorWrap .authEditorCont * {display: inline}.authEditorWrap .authEditorCont a {color: #fff}.authEditorWrap .authEditorCont .magOnOff,.authEditorWrap .authEditorCont .authEditorPopOut {display: none}/*** Article (syndicated) ***/.RXLSyndicated .wrapper h3 {font-size: 26px;line-height: 30px;text-decoration: none}.RXLSyndicated .apPage {clear: both}.RXLSyndicated .wrapper p {line-height: 32px}.RXLSyndicated .wrapper ul {display: block}.RXLSyndicated .wrapper ul li,.RXLSyndicated .wrapper ol li {padding: 8px 0;line-height: 26px}.RXLSyndicated .AP-wrapper {width: 340px;margin: 0 40px 30px 0;float: left}#lrgArtImg {margin: 20px auto;max-width: 650px}#lrgArtImg img {width: 100% !important}#lrgArtImg .lrgArtImgCap {font-size: 13px;color: #777777;line-height: 15px;display: inline-block;padding: 5px 0}.RXLSyndicated .AP-wrapper .slide span {font-size: 12px}.forum_symptom_checker {margin: 50px auto;max-width: 600px}.forum_symptom_checker a {background: #fafafa;border: 5px solid #eee;border-radius: 10px;height: 223px;display: block;transition: all 250ms}.forum_symptom_checker a:hover {border-color: #ddd;background: #fff;text-decoration: none !important}.forum_symptom_checker .sym_image {float: left}.forum_symptom_checker .sym_text {margin: 0 20px 0 165px}.forum_symptom_checker .sym_h3 {font-size: 30px;font-weight: 600;text-decoration: none}.forum_symptom_checker .sym_h3 .green {color: #588527}.forum_symptom_checker .sym_h3 .blue {color: #2196f3}.RXLSyndicated .aia_rdr {width: 420px;float: right;border: 1px solid #ddd;margin: 0 0 20px 20px;clear: both}.RXLSyndicated .aia_title_bar_fmt {background: #5385b5;padding: 8px;text-align: center;color: #fff}.RXLSyndicated .aia_rdr h4 {margin: 0;font-size: 18px}.RXLSyndicated .aia_content_fmt {font-size: 15px;padding: 0 15px}.RXLSyndicated .aia_rdr li {padding: 10px 0;line-height: 17px}.separator {display: none}.article-extra .thumbnails h3,#ForumCenter_fmt .sideBox h3 {font-size: 24px}.article-extra .thumbnails ul {padding: 0;margin: 0;display: block}.article-extra .thumbnails .relCondImageQuizContent li,.article-extra .thumbnails .mainart li {padding: 0 !important;list-style: none}.article-extra .thumbnails .relCondImageQuizContent li:nth-child(even),.article-extra .thumbnails .mainart li:nth-child(even) {background: #f5f5f5}.article-extra .thumbnails .relCondImageQuizContent li a,.article-extra .thumbnails .mainart li a {padding: 14px;min-height: 79px;width: calc(100% - 28px);transition: all 250ms;display: inline-block;color: #777777;}.article-extra .thumbnails .relCondImageQuizContent li img,.article-extra .thumbnails .mainart li img {border-radius: 3px;float: left;margin-right: 15px}.article-extra .thumbnails .relCondImageQuizContent li h2,.article-extra .thumbnails .mainart li h2 {margin: 0 0 0 90px;font-size: 18px;line-height: 20px;color: #2196f3}.article-extra .thumbnails .relCondImageQuizContent li p,.article-extra .thumbnails .mainart li p {margin: 10px 0 0 90px;font-size: 16px;line-height: 18px !important}.article-extra .thumbnails .relCondImageQuizContent li a:hover,.article-extra .thumbnails .mainart li a:hover {color: #fff;background: #2196f3;text-decoration: none}.article-extra .thumbnails .relCondImageQuizContent li a:hover h2,.article-extra .thumbnails .mainart li a:hover h2 {color: #fff}.article-extra .thumbnails .Tab_Items ul {padding-left: 30px}#A_Z ul {justify-content: left;text-align: center}/*** Article (ForumCenter) ***/#ForumCenter_fmt .sideBox[class$=List] {margin-bottom: 50px}#ForumCenter_fmt .sideBox[class$=List] .wrapper {margin: 0;position: relative;overflow: hidden}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul {margin: 0;padding: 0;list-style: none;display: block}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li {padding: 0}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li:nth-child(even) {background: #f5f5f5}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li:last-child {margin-bottom: 20px}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a {padding: 20px;min-height: 79px;width: calc(100% - 40px);display: inline-block;transition: all 250ms}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a:hover {color: #fff;background: #2196f3;text-decoration: none}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a:hover p {color: #fff}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a img {border-radius: 3px;position: absolute}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a h2 {margin: 0 0 0 100px;font-size: 18px;line-height: 18px}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a p {color: #232323;margin: 10px 0 0 100px;font-size: 15px;line-height: 18px;transition: all 250ms}#ForumCenter_fmt .sideBox[class$=List] .more span:before {content: "\e605"}/*** Slideshows ***/.slideshow #apPage:before {content: "";border-top: 4px dotted #ddd;margin: 10% auto;padding-bottom: 25px;display: block;text-align: center;width: 150px}.slideshow #apPage:first-child:before {display: none}.slideshow .apPage {text-align: center}.slideshow .apPage h3 {font-size: 26px;text-decoration: none}.slideshow .apPage img {width: 100%;max-width: 493px;border-radius: 5px}.slideshow .apPage .content {text-align: justify;margin: 25px auto 80px;max-width: 493px}#slideshow_resources {margin: 60px 5%}#slideshow_resources .resources_left {border-top: 1px solid #ccc;border-bottom: 1px solid #ccc;padding: 10px 0}#slideshow_resources .copyright p {float: right;font-size: 13px;line-height: 16px;text-align: right}#slideshow_resources p {margin: 5px 0}#slideshow_resources p a {font-style: italic}#slideshow_resources p a:hover {text-decoration: underline}#slideshow_resources p a:after {font-family: 'icomoon' !important;content: "\e612";font-size: 12px;color: #F26522;padding: 0 4px;vertical-align: middle;font-style: normal;display: inline-block}#slideshow_resources h4,#slideshow_resources p a img {display: none}#slideshow_resources #sources_fmt,#slideshow_resources #disclaimer_fmt {background: #eee;padding: 10px 20px 20px 20px;margin-bottom: 20px;font-size: 13px}#slideshow_resources #sources_fmt .heading {font-weight: 600;margin: 15px 0}#slideshow_resources #sources_fmt p,#slideshow_resources #disclaimer_fmt p {margin: 10px 0}.pageWrapper #headline .author {list-style: none;padding: 0;margin: -10px 0 0 0;font-size: 14px}.pageWrapper #headline .author a {color: #000}.pageWrapper #headline .reviewdate {font-size: 14px}/*** Images ***/.imgcath{    font-size: 50px;    line-height: 54px;    margin:32px 0 0 0;    font-weight: 600;    font-style: normal;    display: inline-block;    font-family: 'Raleway', sans-serif;}.imagecol.content {display: flex;justify-content: space-between}.imagecol .pageWrapper {padding: 40px 0}.imagecol .apPage {text-align: center}.imagecol .apPage h1 {line-height: 28px;margin: 40px auto;font-size: 18px;color: #fff;padding: 5px 10px;background: #000;text-decoration: none;text-transform: none}.imagecol .apPage img {max-width: 493px;width: 100%;margin-bottom: 20px}.imagecol .apPage .content {text-align: justify}.imagecol .apPage .source {text-align: left;font-style: italic}body.imgcol footer,body.imgcol #sponsors {display: none}/*** Quizzes ***/.wrapper-hero.quiz .reviewer {margin: 10px 0}.wrapper-hero.quiz .reviewer a {text-decoration: none;color: #2196f3}.wrapper-hero.quiz .reviewer a:hover {text-decoration: underline}article#quizWrapper {max-width: 800px !important;margin: 0 auto;padding: 0}#quiz-wrapper .instream-ad {text-align: center}#quizWrapper .question {background: #6896DA;margin: 30px 0;width: 100%;border-radius: 5px;display: table}#quizWrapper .question-header {position: absolute}#quizWrapper .question-number {color: #fff;font-size: 16px;font-weight: 600;position: absolute;z-index: 0;padding: 10px}#quizWrapper .question-number i {width: 0;height: 0;border-style: solid;border-width: 70px 70px 0 0;border-color: #000 transparent transparent transparent;position: absolute;left: 0;top: 0;z-index: -1}#quizWrapper .question-message.show {color: #fff;font-size: 20px;font-weight: 600;text-transform: uppercase;background: #ed1c24;width: calc(100vw - 431px);max-width: 736px;padding: 19px 0;border-radius: 0 5px 0 0;text-align: center}#quizWrapper .question img {width: 100%;border-radius: 5px 5px 0 0}#quizWrapper .question-content {padding: 50px 30px 30px 30px;min-height: 380px}#quizWrapper .question-content h2 {font-size: 26px;line-height: 34px;color: #fff;margin: 20px 0 30px 0}#quizWrapper .question-content .answer {margin: 6px 0;background: #fff;cursor: pointer;width: 100%;min-height: 55px;display: table;transition: all 250ms}#quizWrapper .question-content .answer:hover {background: #f26522;color: #fff}#quizWrapper .question-content .answer-letter {background: #000;color: #fff;font-size: 20px;font-weight: 600;padding: 0 20px;vertical-align: middle;width: 15px;display: table-cell}#quizWrapper .question-content .answer-text {font-size: 17px;padding: 10px 15px;vertical-align: middle;display: table-cell}#quizWrapper .question-content .image-type {border: 5px solid #000;background: #000;color: #fff;width: calc(100% - 10px)}#quizWrapper .question-content .image-type img {border-radius: 0}#quizWrapper .question-content .image-type .answer-text {text-align: center;padding: 10px 15px;display: block}#quizWrapper .question-content .image-type:hover {border: 5px solid #f26522}#quizWrapper .question-content .correct,#quizWrapper .question-content .correct:hover {background: #dff0d8;color: #598527;cursor: auto}#quizWrapper .question-content .correct .answer-letter {background: #598527}#quizWrapper .question-content .correct:after {font-family: 'icomoon' !important;content: "\e628";font-size: 20px;color: #63bf71;vertical-align: middle;text-align: center;width: 55px;display: table-cell}#quizWrapper .question-content .incorrect,#quizWrapper .question-content .incorrect:hover {background: #f2dede;color: #a94442;cursor: auto}#quizWrapper .question-content .incorrect .answer-letter {background: #9e0b0f}#quizWrapper .question-content .incorrect:after {font-family: 'icomoon' !important;content: "\e629";font-size: 20px;color: #ff6363;vertical-align: middle;text-align: center;width: 55px;display: table-cell}#quizWrapper .question-content .image-type.correct {border-color: #598527;background: #598527;color: #fff}#quizWrapper .question-content .image-type.incorrect {border-color: #9e0b0f;background: #9e0b0f;color: #fff}#quizWrapper .question-content .explanation.hide {visibility: hidden;display: block}#quizWrapper .question-content .explanation.show {visibility: visible;background: #fff;margin-top: -6px}#quizWrapper .question-content .explanation-heading {font-weight: 600;padding: 20px}#quizWrapper .question-content .explanation-correct-answer {display: block;color: #598527;font-size: 150%}#quizWrapper .question-content .explanation-content {padding: 20px;border-top: 1px solid #ddd}#quizWrapper .question-content .explanation-content>span {font-weight: 600}#quizWrapper .question-content .notselected,#quizWrapper .question-content .image-type.correct:after,#quizWrapper .question-content .image-type.incorrect:after {display: none}#quizWrapper .question .question-next-button {visibility: hidden;color: #fff;border: 1px solid rgba(255, 255, 255, 0.5);padding: 10px 0;margin: 0 40% 30px 40%;font-size: 16px;text-transform: capitalize;text-align: center;display: block;border-radius: 5px;cursor: pointer;transition: background 250ms}#quizWrapper .question.answered .question-next-button.show {visibility: visible}#quizWrapper .question.answered .question-next-button:hover {background: rgba(255, 255, 255, 0.2)}#quizWrapper .quiz-check-button {background: #f26522;color: #fff;font-size: 24px;text-transform: uppercase;text-align: right;border-radius: 5px;padding: 20px 60px;position: relative;cursor: pointer;transition: background 250ms}#quizWrapper .quiz-check-button:after {font-family: 'icomoon' !important;content: "\e605";font-size: 50px;position: absolute;top: 0}#quizWrapper .quiz-check-button:hover {background: #000}#quizWrapper #quizResources {border-top: 1px solid #ccc;margin: 40px 0;padding: 10px 0;font-size: 14px}#quizWrapper #quizResources p {margin: 5px 0}#quizWrapper #quizResources p a {font-style: italic}#quizWrapper #quizResources p a:hover {text-decoration: underline}#quizWrapper #quizResources p a:after {font-family: 'icomoon' !important;content: "\e612";font-size: 12px;color: #F26522;padding: 0 4px;vertical-align: middle;font-style: normal;display: inline-block}#quizWrapper #quizResources p a img {display: none}#quizWrapper #sources_fmt,#quizWrapper #disclaimer_fmt {background: #eee;padding: 10px 20px 20px 20px;margin-bottom: 20px;font-size: 13px}#quizWrapper #sources_fmt .heading {font-weight: 600;margin: 15px 0}#quizWrapper #sources_fmt p,#quizWrapper #disclaimer_fmt p {margin: 10px 0}#quizWrapper .quiz-status {position: fixed;top: 0;right: 0;left: 0;z-index: 999999;background: rgba(80, 114, 165, 0.95);padding: 12px 20px;height: 26px;display: none}#quizWrapper .quiz-status h1 {color: #fff;font-size: 20px !important;line-height: 24px;margin: 0;max-width: calc(100% - 125px);white-space: nowrap;overflow: hidden;text-overflow: ellipsis}#quizWrapper .quiz-status .quiz-progressbar {background: #fbc98e;margin: 14px -20px 0 -20px}#quizWrapper .quiz-status .quiz-progress-indicator {background: #f26522;height: 6px;transition: width 1s}#quizWrapper .quiz-status .quiz-status-right {position: absolute;right: 20px;top: 11px;font-size: 20px;color: #fff;line-height: 25px}#quizWrapper .quiz-status .quiz-correct-num {float: left;margin-right: 10px}#quizWrapper .quiz-status .quiz-incorrect-num {float: right}#quizWrapper .quiz-status .quiz-correct-num:before {font-family: 'icomoon' !important;content: "\e628";font-size: 20px;color: #63bf71;margin: 0 5px;vertical-align: text-bottom}#quizWrapper .quiz-status .quiz-incorrect-num:before {font-family: 'icomoon' !important;content: "\e629";font-size: 20px;color: #ff6363;margin: 0 5px;vertical-align: text-bottom}#quizWrapper .quiz-modal-overlay {background: rgba(0, 0, 0, 0.8);position: fixed;top: 0;left: 0;right: 0;height: 100%;z-index: 999999}#quizWrapper .quiz-modal {background: #fff;width: 60%;border-radius: 3px 3px 0 0;position: absolute;top: 50%;left: 50%;transform: translate(-50%, -50%)}#quizWrapper .quiz-modal-header {background: #f26522;color: #fff;font-size: 20px;font-weight: 600;padding: 13px 20px;border-radius: 3px 3px 0 0;text-align: center;position: relative}#quizWrapper .quiz-modal-header .facebook-like {background: #4267b2;border: 1px solid #4267b2;color: #fff;font-size: 14px;text-decoration: none;border-radius: 5px;padding: 4px 7px 3px 1px;position: absolute;right: 12px;top: 12px}#quizWrapper .quiz-modal-header .facebook-like:before {font-family: 'icomoon' !important;content: "\e608";font-size: 14px;color: #fff;margin: 0 6px;vertical-align: text-bottom}#quizWrapper .quiz-modal-header .facebook-like:hover {background: #000;border: 1px solid #000}#quizWrapper .quiz-modal-content {padding: 40px}#quizWrapper .quiz-modal-content .quiz-modal-message {font-size: 18px}#quizWrapper .quiz-modal-content .quiz-result {border-top: 1px solid #ddd;border-bottom: 1px solid #ddd;margin: 50px 0;padding: 15px 0}#quizWrapper .quiz-modal-content .quiz-result-text {font-size: 18px;font-weight: 600;line-height: 26px}#quizWrapper .quiz-modal-content .quiz-result-text:before {font-family: 'icomoon' !important;content: "\e605";font-size: 20px;font-weight: bold;margin-right: 4px;vertical-align: text-bottom}#quizWrapper .quiz-modal-content .quiz-result-text-bold {color: #f26522}#quizWrapper .quiz-modal-content .quiz-related-text {font-size: 18px;font-weight: 600;padding-bottom: 8px}#quizWrapper .quiz-modal-content .quiz-related a {display: block;line-height: 26px;font-size: 18px}#quizWrapper .quiz-modal-content .quiz-button {background: #4e6d9f;color: #fff;font-size: 18px;font-weight: 600;line-height: 21px;padding: 15px 50px;border-radius: 3px;width: 140px;text-align: center;margin: 50px auto 0 auto;transition: background 250ms}#quizWrapper .quiz-modal-content .quiz-button.startover:before {font-family: 'icomoon' !important;content: "\e630";font-size: 20px;color: #fff;margin-right: 10px;vertical-align: text-bottom}#quizWrapper .quiz-modal-bottom:after {font-family: 'icomoon' !important;content: "\e605";font-size: 40px;color: #fff;position: absolute;right: 10px;bottom: -55px}#quizWrapper .quiz-modal-bottom a {color: #fff;font-size: 18px;background: #6896da;padding: 15px 70px 15px 15px;position: absolute;bottom: -51px;right: 0;left: 0;border-radius: 0 0 3px 3px;text-align: right;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;transition: background 250ms}#quizWrapper .quiz-modal-bottom .next-quiz-bold {font-weight: 600;padding: 0 10px}#quizWrapper .quiz-modal-content .quiz-button:hover,#quizWrapper .quiz-modal-bottom a:hover {text-decoration: none;background: #000;cursor: pointer}@media screen and (-ms-high-contrast: active),screen and (-ms-high-contrast: none) {article#quizWrapper {width: 100%;padding: 0 10%}}/*** Pill Identifier ***/#srch-drug-pillid,.PillId_fmt,#imageSlider,#PillID_fmt .sc-searchbox,.nav-search.sc-searchbox.drug-search {width: calc(100% - 52px);max-width: 600px;margin: 50px auto;border: 1px solid #ccc;padding: 25px;background: #fafafa}#pill_identifier_fmt .frmPillIdentifier-field-fmt {padding: 10px;position: relative}#srch-drug-pillid label,.PillId_fmt .HighlightedMsg {float: left;color: #888;font-size: 16px;font-weight: 600;line-height: 30px}#pill_identifier_fmt .frmPillIdentifier-field-fmt img {float: left;margin: 9px 10px 0 7px}#simprint,#scolor,#sshape {border: 1px solid #ccc;padding: 5px 10px;outline: none;border-radius: 3px}form#frmPillIdentifier #drug-pill-imprints-wrap {position: absolute;left: 177px;top: 39px;z-index: 1}#drug-pill-imprints-suggest {border: 1px solid #ccc;background: #fff;padding: 5px;border-radius: 3px;margin-top: -1px}#drug-pill-imprints-suggest p {margin: 0;padding: 5px 10px}#drug-pill-imprints-suggest .selected p {background: #000;color: #fff;cursor: pointer;border-radius: 3px}#pill_identifier_fmt .overlay,#pill_identifier_fmt .radio-color,#pill_identifier_fmt .jawsonly,#pill_identifier_fmt .shim {display: none}#pill_identifier_fmt #colorSwatch,#pill_identifier_fmt #shapeSwatch {border: 1px solid #ccc;background: #fff;width: 460px;padding: 15px;border-radius: 5px;margin-top: -1px;position: absolute;z-index: 10000}#pill_identifier_fmt .colorContent ul,#pill_identifier_fmt .shapeContent ul {display: block;margin: 0;padding: 0}#pill_identifier_fmt .colorContent li {float: left;background: url(https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/miscellaneous/pill_identifier/pill_id_color_solid_sprite.gif) no-repeat top left;height: 78px;width: 92px;padding: 0;list-style: none}#pill_identifier_fmt li.pc-solid-white {background-position: -1px -2px}#pill_identifier_fmt li.pc-solid-offwhite {background-position: -87px -2px}#pill_identifier_fmt li.pc-solid-clear {background-position: -174px -2px}#pill_identifier_fmt li.pc-solid-black {background-position: -1px -76px}#pill_identifier_fmt li.pc-solid-gray {background-position: -87px -76px}#pill_identifier_fmt li.pc-solid-brown {background-position: -174px -76px}#pill_identifier_fmt li.pc-solid-tan {background-position: -1px -149px}#pill_identifier_fmt li.pc-solid-red {background-position: -87px -149px}#pill_identifier_fmt li.pc-solid-pink {background-position: -174px -149px}#pill_identifier_fmt li.pc-solid-orange {background-position: -1px -220px}#pill_identifier_fmt li.pc-solid-peach {background-position: -87px -220px}#pill_identifier_fmt li.pc-solid-yellow {background-position: -173px -220px}#pill_identifier_fmt li.pc-solid-green {background-position: 0px -293px}#pill_identifier_fmt li.pc-solid-blue {background-position: -87px -293px}#pill_identifier_fmt li.pc-solid-purple {background-position: -173px -293px}#pill_identifier_fmt .pillcolor-solid a {display: block;height: 76px}#pill_identifier_fmt .pillcolor-solid a:hover,#pill_identifier_fmt .pillshape a:hover {background: rgba(0, 114, 188, 0.2);border-radius: 5px}#pill_identifier_fmt .shapeContent li {float: left;background: url(https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/miscellaneous/pill_identifier/pill_id_shape_sprite.gif) no-repeat top left;height: 70px;width: 75px;padding: 0;list-style: none}#pill_identifier_fmt li.ps-circle {background-position: 0px 0px}#pill_identifier_fmt li.ps-oblong {background-position: -78px 0px}#pill_identifier_fmt li.ps-oval {background-position: -155px 0px}#pill_identifier_fmt li.ps-square {background-position: -227px 0px}#pill_identifier_fmt li.ps-rectangle {background-position: -1px -63px}#pill_identifier_fmt li.ps-diamond {background-position: -78px -63px}#pill_identifier_fmt li.ps-triangle {background-position: -153px -63px}#pill_identifier_fmt li.ps-pentagon {background-position: -226px -63px}#pill_identifier_fmt li.ps-hexagon {background-position: -1px -130px}#pill_identifier_fmt li.ps-heptagon {background-position: -80px -130px}#pill_identifier_fmt li.ps-octagon {background-position: -152px -130px}#pill_identifier_fmt li.ps-other {background-position: -226px -130px}#pill_identifier_fmt .pillshape a {display: block;height: 68px}#PillID_fmt .submit_button {background: #6896da;border: 0;outline: 0;color: #fff;text-transform: uppercase;border-radius: 3px;padding: 10px;margin: 30px;width: calc(100% - 60px);transition: all 250ms}#PillID_fmt .submit_button:hover {background: #000}#PillID_fmt .sc-searchbox-input,.nav-search.sc-searchbox.drug-search .sc-searchbox-input {border: 1px solid #ccc;border-right: none;outline: none;border-radius: 3px 0 0 3px}#PillID_fmt .sc-searchbox-input:focus,.nav-search.sc-searchbox.drug-search .sc-searchbox-input:focus {border-color: #000}#PillID_fmt .sc-searchbox-button,.nav-search.sc-searchbox.drug-search .sc-searchbox-button {background: #6896da}#PillID_fmt .sc-searchbox-list {max-width: calc(100% - 50px)}.PillId_fmt .search {border: 1px solid #ccc;padding: 5px 10px;margin-left: 10px;outline: none}#PillID_fmt .PillId_fmt .submit_button {margin-bottom: 10px}#imageSlider {text-align: center;z-index: 0;position: relative}#imageSlider .sliderwrapper {min-height: 355px;position: relative}#imageSlider .contentdiv {position: absolute;top: 50%;left: 50%;transform: translate(-50%, -50%)}#imageSlider .contentdiv h1 {font-size: 20px;line-height: 22px}#imageSlider .contentdiv img {border-radius: 5px}#imageSlider .contentdiv p {font-size: 16px;line-height: 20px}.pagination2 a {background: #ccc;font-size: 18px;color: #fff !important;border-radius: 5px;border: none !important;padding: 5px 14px;margin: 4px 2px !important;display: inline-block;transition: all 250ms}.pagination2 a.selected {background: #6896da}.pagination2 a:hover {text-decoration: none !important;background: #000}.drugSearchResult {padding: 0;margin: 0;list-style: none;width: calc(100vw - 407px)}.drugSearchResult li {padding: 25px !important;margin: 10px 0;background: #fafafa;border: 1px solid #ccc;display: inline-block;width: calc(100% - 50px)}.drugSearchResult .drug_img img {width: auto;height: 125px;border-radius: 5px;transition: 250ms all}.drugSearchResult .drug_img a:hover img {opacity: .8}.drugSearchResult .drug_info .drug_name {margin: 15px 0}.drugSearchResult .drug_info .drug a:hover {text-decoration: underline}.drugSearchResult.fdbdrug {overflow-x: auto;display: inline-flex;min-height: 300px}.drugSearchResult.fdbdrug::-webkit-scrollbar-track {box-shadow: inset 0 0 3px rgba(0, 0, 0, 0.2);background-color: #F5F5F5}.drugSearchResult.fdbdrug::-webkit-scrollbar {height: 15px;background-color: #F5F5F5}.drugSearchResult.fdbdrug::-webkit-scrollbar-thumb {background-color: #000}.drugSearchResult.fdbdrug::-webkit-scrollbar-thumb:hover {background: #2196f3}.drugSearchResult.fdbdrug li {width: 167px;margin: 10px 5px;padding: 15px !important}.drugSearchResult.fdbdrug .drug_info .drug_name {font-size: 12px}h3.drugheader {font-size: 18px;text-align: center;color: #333;text-decoration: none !important;text-transform: capitalize;padding: 5px 10px;margin: 60px 0 25px 0;background: #ddd}/*** Drug Checker ***/.drugChecker_Page ul {margin: 0 0 -3px !important;padding: 0;list-style-type: none}.drugChecker_Page .drug_header img.pillimage {float: right;width: 276px;height: 228px}.drugChecker_Page .drug_header .drugresults.p2 li {position: relative;list-style: none;padding: 10px 0}.drugChecker_Page .drug_header .drugresults.p2 li:before {top: 2px !important}.drugChecker_Page .drug_header .drugresults.p2 li a {margin-left: 40px}.drugChecker_Page .drug_A-Z_list {border-bottom: 1px solid #ccc;padding-bottom: 20px}.drugChecker_Page .drug_A-Z_list h4 {color: #fff;border-bottom: 1px solid #ccc;padding: 40px 0;margin: 0 0 20px}.drugChecker_Page .drug_A-Z_list h4 a {display: inline-block;padding: 10px;margin: 5px 0;color: #6896DA;font-size: 24px;font-weight: 600;line-height: 30px;border-radius: 3px;width: 30px;height: 30px;text-align: center;background: #f5f5f5;transition: all 250ms}.drugChecker_Page .drug_A-Z_list h4 a:hover {background: #000;color: #fff;text-decoration: none}.drugChecker_Page .drug_A-Z_list h4 a.disabled {color: #ddd;pointer-events: none}.drugChecker_Page .drug_A-Z_list h4 a:last-child {font-size: 17px;vertical-align: bottom}.drugChecker_Page #drugNameInput {padding: 30px 0}.drugChecker_Page #drugNameInput h3 {float: left;color: #888;font-size: 16px;margin: 5px 10px 5px 0;text-decoration: none;text-transform: capitalize}.drugChecker_Page #txtAutoComplete {width: 395px;height: 30px}.drugChecker_Page #drugNameOutput {margin: 20px 0;display: none}.drugChecker_Page #drugNameOutput .listresult {border: 1px solid #ccc;border-radius: 10px;padding: 20px}.drugChecker_Page #drugNameOutput .listresult li {font-size: 14px;background: #000;color: #fff;margin: 5px 0;padding: 5px 35px 5px 10px;position: relative}.drugChecker_Page #drugNameOutput .listresult li .remove:before {font-family: 'icomoon';content: "\e624";font-size: 15px;color: #fff;position: absolute;right: 6px;top: 5px}.drugChecker_Page #drugNameOutput .listresult .buttons input {background: #6896da;border: 0;outline: 0;color: #fff;text-transform: uppercase;border-radius: 3px;padding: 10px;margin-right: 5px;transition: all 250ms}.drugChecker_Page #drugNameOutput .listresult .buttons input:hover {background: #000}.drugChecker_Page #foundCount {font-weight: 600;color: #f00;margin: 20px 0;display: block}.drugChecker_Page #resultSevUrl li {margin: 10px 0;line-height: 16px;font-size: 13px}.drugChecker_Page .tabWrap {margin: 20px 0}.drugChecker_Page .tabList li {display: inline-block;margin-right: 3px;padding: 9px 0;z-index: 1;position: relative}.drugChecker_Page .tabList li a {color: #fff;padding: 10px 25px;background: #6896DA;border: 1px solid #6896DA;border-radius: 3px 3px 0 0;transition: all 250ms}.drugChecker_Page .tabList li a:hover {text-decoration: none;background: #000;border-color: #000}.drugChecker_Page .tabList li.active a {color: #232323;background: #fff;border-color: #ccc;border-bottom-color: #fff}.drugChecker_Page .tabContent {border: 1px solid #ccc;margin: -2px 0 40px;padding: 20px;position: relative}.drugChecker_Page .tabContent .sevdesctitle {font-size: 19px;font-weight: 600;margin-left: 40px}.drugChecker_Page .tabContent .sevdesc {display: inline-block;font-size: 15px;line-height: 17px;margin-left: 40px}.drugChecker_Page .tabContent .intsource,.drugChecker_Page .tabContent .intcopyright,.drugChecker_Page .drug_disclaimer {font-size: 13px}.drugChecker_Page .divider {border-top: 1px dotted #ddd;margin: 30px 0}.drugChecker_Page .pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li:before {font-family: 'icomoon';content: "\e905";font-size: 26px;position: absolute;top: 15px}.drugChecker_Page .serious.pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li.serious:before {color: #cc0000}.drugChecker_Page .significant.pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li.significant:before {color: #ff6600}.drugChecker_Page .minor.pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li.minor:before {color: #ffaf00}.drugChecker_Page .drugexplained {border: 1px solid #ccc;padding: 20px}.drugChecker_Page .drugexplained h3 {margin: 0}.drugChecker_Page .drugexplaindetail {padding: 5px 0;position: relative}.drugChecker_Page .drugexplaindetail h3 {font-size: 16px;margin: 16px 0 2px 40px;text-decoration: none}.drugChecker_Page .drugexplaindetail p {line-height: 20px;margin: 0 0 0 40px}.drugChecker_Page .drug_content {margin: 30px 0}.drugChecker_Page .intChkDriverText {text-align: center;margin: 40px 0 0 0}.drugChecker_Page .intChkDriverBtn {text-align: center;margin: 20px 0 40px}.drugChecker_Page .intChkDriverBtn a {background: #6896da;color: #fff;text-transform: uppercase;border-radius: 3px;padding: 10px 30px;transition: all 250ms}.drugChecker_Page .intChkDriverBtn a:hover {background: #000;color: #fff;text-decoration: none}/*** Pharmacy Locater ***/.cityAlphaDiv h3 {color: #6896da;font-size: 24px;background: #6896DA;margin: 0;padding: 5px 10px;text-decoration: none !important;position: relative}.cityAlphaDiv h3 span {position: absolute;left: 16px;color: #fff}.cityAlphaDiv ul {list-style-type: none;margin: 0;padding: 0;display: block !important}.cityAlphaDiv li {padding: 0 !important}.cityAlphaDiv li a {padding: 10px !important;font-size: 16px;display: block;transition: all 250ms}.cityAlphaDiv li:nth-child(even) a {background: #f5f5f5}.cityAlphaDiv li a:hover {background: #000;color: #fff;text-decoration: none}.cityAlphaDiv .noCityLetter {color: #ec4747;font-size: 18px}#divCityAZ table {width: 100% !important;table-layout: fixed}#divCityAZ table ul {list-style-type: none;margin: 0 5px;padding: 0;display: block}#divCityAZ table li {padding: 0;border-bottom: 1px solid #ddd}#divCityAZ table li a {padding: 10px 15px;font-size: 16px;display: block;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;transition: all 250ms}#divCityAZ table li a:hover {background: #000;color: #fff;text-decoration: none}#divCityAZ table img {margin-right: 10px}#localTopicsPharm .legend,#tabcontentcontainer .tabcontent {display: none}#map_canvas_pharmacy,#map_canvas_hospital {width: 100% !important;margin: 15px 0}#localTopicsPharmTabs {margin: 20px 0;position: relative}#localTopicsPharmTabs #tablist {margin: 0;padding: 0;width: 100%}#localTopicsPharmTabs #tablist li {float: left;list-style: none;padding: 0;margin-right: 10px}#localTopicsPharmTabs #tablist li a {color: #fff;font-weight: 600;text-transform: uppercase;text-decoration: none;padding: 10px 20px;background: #ec4747 !important;display: inline-block;border-radius: 3px 3px 0 0;transition: all 250ms}#localTopicsPharmTabs #tablist li a.current {background: #2196f3 !important}#localTopicsPharmTabs #tablist li a:hover {background: #000 !important}#localTopicsPharmTabs #tabcontentcontainer,#localTopicsHospitalsContent {background: #fff !important;height: 400px;overflow-y: auto;clear: both}#tabcontentcontainer .tabcontent:before {content: "";width: 100%;position: absolute;border-top: 3px solid #2196f3;margin-top: -3px}#tabcontentcontainer .tabcontent:last-child:before {border-color: #ec4747}#localTopicsPharmDiv,#localTopicsHospitalsDiv {padding: 15px;margin-right: 15px;position: relative}#localTopicsPharmDiv:nth-child(even),#localTopicsHospitalsDiv:nth-child(even) {background: #f2f2f2}#localTopicsPharmDiv img,#localTopicsHospitalsDiv img {position: absolute}#localTopicsPharmDiv p,#localTopicsHospitalsDiv p {margin: -3px 90px 0 26px}#localTopicsPharmDiv .pharmacy a,#localTopicsHospitalsDiv .hospital a {font-weight: 600;text-decoration: underline}#localTopicsPharmDiv h2 {position: absolute;font-size: 12px;color: #ec4747;right: 10px;top: 3px}#hospitalTerms {font-size: 11px;padding: 30px 0}#hospitalTerms span {font-weight: 600}#pharm,#emerg,#hospitals {margin-top: 70px}/*** Responsive ***/@media (min-width:768px) {.story {width: calc(100% - 352px);padding: 0 50px 0 0;}.masterhead,.rxArt .adTopWrapper.hide,.wrapper-hero,.submenu.stuck {max-width: calc(100vw - 80px);margin: 0 auto;}.masterSub.on,.masterSub {max-width: calc(100vw - 80px);margin: 0 auto;left: 0;right: 0;}.miniTitle .hero h1 {left: 150px;}}@media (max-width:1023px) {.topDrug .azList ul {column-count: 1}}@media (min-width:1024px) and (max-width:1199px) {.submenu .tab a {font-size: 13px;padding: 10px;height: 22px}.submenu .tab a span,.submenu .tab a .icon-pro {font-size: 20px}.submenu .toc.link a {font-size: 16px;line-height: 18px;padding: 6px 10px}.webmdrx_coup .wrapper .reg {display: none}.webmdrx_coup .wrapper .cou {left: 26%}}@media (min-width:1024px) {.stickyColLeft {display: block}#quiz-wrapper .story {width: 100%;padding: 0 20px 30px 20px}.article-promo .item {padding: 0 2px;width: calc(33% - 6px)}.drugChecker_Page .drug_A-Z_list li a {width: calc(100vw - 645px)}.drugSearchResult {width: calc(100vw - 597px)}}@media (min-width:1200px) {.wrapper-sponsors {padding: 40px 5%}.wrapper-sponsors h2 {font-size: 30px}.wrapper-sponsors .sponsors ul li a {font-size: 18px}.wrapper-sponsors .sponsors ul {margin: 16px 0}footer nav a {padding: 0 15px}footer nav .network a:after {padding: 0 20px}footer nav .network a {font-size: 16px}main section>.wrapper {max-width: 1100px}.story header h2 {font-size: 30px;margin: 20px 190px 10px 0;line-height: 30px}.story article .alert {font-size: 16px;padding: 8px 16px}.share a {font-size: 22px;width: 40px;height: 40px;margin: 0 2px}.share span {padding: 9px;line-height: 39px}#accordion .fold ul {column-count: 3}.article-promo .item {padding: 0 20px}#quizWrapper .question-message.show {min-width: 758px}}@media (min-width:1300px) {main#HP .container {column-count: 2;column-gap: 14px}.masterhead .wrapper {}.breadcrumbs {width: calc(95% - 375px)}#quiz-wrapper .story {padding: 0 20px 30px 0}#quizWrapper .question-message.show {width: calc(100vw - 557px)}.Rxl_landing_DC ul,.sc_common_ss ul,.sc_popular_sym ul,.drugCentRelatedDrugs ul {column-count: 2;column-gap: 50px;list-style-position: inside;display: block !important}.Rxl_landing_DC ul li,.sc_common_ss ul li,.sc_popular_sym ul li,.drugCentRelatedDrugs ul li {break-inside: avoid}.drugSearchResult {width: 100%}.drugSearchResult .drug_img {float: left;margin: 0 30px 5px 0}.drugSearchResult .drug_info .drug_name {margin: 0 0 15px 0}}@media (min-width:1350px) {.masterhead,.rxArt .adTopWrapper.hide,.wrapper-hero,.submenu.stuck {max-width: 1250px;}.masterSub.on,.masterSub {width: 1250px;left: 0;right: 0;}}@media (min-width:1400px) {main section>.wrapper {max-width: 1200px}.submenu.stuck .tab {width: 190px}.submenu.stuck .tab a {font-size: 16px}.submenu.stuck .toc.link a {font-size: 15px}.story header h2 {font-size: 42px;line-height: 42px}.story article {font-size: 17px}.pgContent #artPromoCunk .artPCLinks {width: 72%}#accordion .fold ul {column-count: 4}.slideshow .apPage h3 {font-size: 30px}.slideshow .apPage .content {font-size: 18px;max-width: 800px}/**.mediaPrmo img{width:60%}**/.mediaPrmo .skew {left: 55%}.mediaPrmo .label,.mediaPrmo .caption,.mediaPrmo .desc,.mediaPrmo .btn {margin-left: 60%}.miniTitle .hero h1 {left: 200px;}}@media (min-width:1500px) {main#HP .promoSearch {display: flex;align-items: center}.promoSearch{padding:40px 12vw;}main#HP .promoSearch img {margin: 0 80px 0;}main#HP .sc-searchbox {width: 100%}main#HP .promoSearch .sc-searchbox .sc-searchbox-list {width: calc(60vw - 350px)}.article-promo .item {padding: 0 10px;height: 125px;width: calc(33% - 20px);max-width: 350px}.article-promo a img {position: absolute}.article-promo a span,.article-promo a p {margin-left: 160px;font-size: 15px}.story #sponsors .wrapper ul {column-count: 3}#lrgArtImg {float: right;clear: both;margin: 20px 0 20px 20px !important;width: 500px !important}.miniTitle .hero h1 {left: 250px;}/**.story{margin:0 6%;width: calc(76% - 240px)}**//**.masterhead .wrapper{margin:0 4%}**//**.wrapper-hero{margin:0 4%}**//**.masterSub nav{margin:0 3%}**/}@media (min-width:1600px) {.miniTitle .hero h1 {left: 300px;}/**.wrapper-hero{margin:0 4%}.story{margin:0 6%;width: calc(86% - 400px)}**//**.masterhead .wrapper{margin:0 5%}**//**.masterSub nav{margin:0 5%}**/}@media (min-width:1800px) {.miniTitle .hero h1 {left: 400px;}}/*** Print ***/@media print {*,*:before,*:after {background: transparent !important;color: #000 !important;box-shadow: none !important;text-shadow: none !important}a,a:visited {text-decoration: underline}abbr[title]:after {content: " (" attr(title) ")"}a[href^="#"]:after,a[href^="javascript:"]:after {content: ""}pre,blockquote {border: 1px solid #999;page-break-inside: avoid;padding: 20px}thead {display: table-header-group}tr,img {page-break-inside: avoid}img {max-width: 100% !important}p,h2,h3 {orphans: 3;widows: 3}h2,h3 {page-break-after: avoid}#backTop,.adTopWrapper,header,.sticky-wrapper,.stickyColLeft,.stickyColRight,.toc,.webmdrx,.driver,.btn_driver,.medianet,.article-promo,#crsprm-2081-assmnt,#fdaWrapper,.from_webmd,.aia_rdr,.forum_symptom_checker,.article-extra,#footerAd_rdr,#sponsors,footer {display: none !important}.wrapper-hero {padding: 0 !important}}</style>
<style>.moduleSpacer_rdr{background:url(https://images.medicinenet.com/images/sponsorbox/spacer.gif) 0 0;clear:both;font-size:1%;height:4px}.sponsorBox_right_rdr{width:470px;background-color:#fff;padding-right:4px;clear:both}.sponsorBox_right_rdr a:link,.sponsorBox_right_rdr a:visited{color:#069!important;text-decoration:none}.sponsorBox_right_rdr a:hover,.sponsorBox_right_rdr a:active{color:#24a2dd!important;text-decoration:underline}.sponsorBox_right_rdr.sponsorBoxCenterArea{padding-right:0}.sponsorBox_header_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBorderTop.gif) repeat-x;height:33px;padding:1px 0 0}.sponsorBox_topLeft_fmt{float:left;margin:-1px 0 0 0;padding:0}.sponsorBox_topRight_fmt{float:right;margin:-1px 0 0 0}.sponsorBox_mainLinks_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBorderRight.gif) repeat-y 100% 0;clear:both}.sponsorBox_mainLinksContent_fmt{padding:0;background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBorderLeft.gif) repeat-y}* html .sponsorBox_mainLinksContent_fmt{height:0}.sponsorBox_sponsorText_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/SponsorBoxText.gif) no-repeat;float:left;width:13px;margin:0}.sponsorBox_links_fmt{float:left;width:350px}.sponsorBox_links_wide_fmt{float:left;width:350px}.sponsorBox_links_fmt ul,.sponsorBox_links_wide_fmt ul,.sponsorBox_linksRightAligned_fmt ul,.sponsorBox_center_links_fmt ul,.sponsorBox_center_linksRightAligned_fmt ul{clear:left;list-style:none;margin:0;padding:0 0 0 9px}.sponsorBox_links_fmt li,.sponsorBox_links_wide_fmt li,.sponsorBox_linksRightAligned_fmt li,.sponsorBox_center_links_fmt li,.sponsorBox_center_linksRightAligned_fmt li{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxListBullet.gif) no-repeat 0 3px;font-size:90%;list-style-image:none!important;margin:4px 0 0;padding:0 0 0 15px}* html .sponsorBox_links_fmt li,* html .sponsorBox_links_wide_fmt li,* html .sponsorBox_linksRightAligned_fmt li,* html .sponsorBox_center_links_fmt li,* html .sponsorBox_center_linksRightAligned_fmt li{background-position:0 5px;margin:2px 0 0}#middleContent_fmt .sponsorBox_links_fmt li,#middleContent_fmt .sponsorBox_links_wide_fmt li,#middleContent_fmt .sponsorBox_linksRightAligned_fmt li,#middleContent_fmt .sponsorBox_center_links_fmt li,#middleContent_fmt .sponsorBox_center_linksRightAligned_fmt li{font-size:90%}*+html .sponsorBox_mainLinksContent_fmt{min-height:0}*+html .sponsorBox_links_fmt li,*+html .sponsorBox_links_wide_fmt li,*+html .sponsorBox_linksRightAligned_fmt li,*+html .sponsorBox_center_links_fmt li,*+html .sponsorBox_center_linksRightAligned_fmt li{background-position:0 5px;margin:2px 0 0}*+html .sponsorBox_links_fmt{font-size:100%}.sponsorBox_photo_fmt{float:right;padding:7px 8px 6px 0}.sponsorBox_linksRightAligned_fmt{float:right;width:210px}.sponsorBox_photoLeftAligned_fmt{float:left;padding:7px 0 0 8px}.sponsorBox_bottom_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBkg.gif) no-repeat 100% 100%}.sponsorBox_bottomBorder_fmt{background:#fff url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBkg.gif) no-repeat 0 100%;font-size:1%;height:10px;width:20px}* html .sponsorBox_bottomBorder_fmt{height:7px}.sponsorBox_clear_fmt{clear:both}.sponsorBox_header_fmt .sponsorBox_headerTbl_fmt{float:left;width:93%}.sponsorBoxCenterArea .sponsorBox_headerTbl_fmt{float:left;width:95%}.sponsorBox_header_fmt .dottedLineSP{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxDottedLine.gif) no-repeat right top;padding-left:5px;padding-right:8px}.sponsorBox_header_fmt .topLogoSP{padding-left:8px;padding-top:1px}.sponsorBox_bottomLinks_fmt{clear:both;font-size:80%;padding:3px 0 0 20px}.sponsorBox_bottomLinks_fmt a{padding-right:8px}.sponsorBox_right_rdr.sponsorBoxCenterArea .sponsorBox_bottomLinks_fmt a{padding-right:15px}.sponsorBox_header_fmt h1{color:#6C340A!important;font-size:90%;line-height:1em;margin:0;padding:0}.sponsorBox_header_fmt h1 a:link,.sponsorBox_header_fmt h1 a:visited{color:#6C340A!important}.sponsorBox_clearingDiv_fmt{clear:both;font-size:0;height:0}#mainContent_ctr .sponsorBox_right_rdr{padding-right:0}#mainContent_ctr .sponsorBox_headerTbl_fmt{width:93%}#mainContent_ctr .sponsorBox_links_fmt{float:left;width:350px}#mainContent_ctr .sponsorBox_bottomLinks_fmt a{padding-right:15px}#mainContent_ctr .sponsorBox_header_fmt h1{font-size:90%}#mainContent_ctr .sponsorBox_links_fmt li,#mainContent_ctr .sponsorBox_links_wide_fmt li,#mainContent_ctr .sponsorBox_linksRightAligned_fmt li,#mainContent_ctr .sponsorBox_center_links_fmt li,#mainContent_ctr .sponsorBox_center_linksRightAligned_fmt li{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxListBullet.gif) no-repeat 0 5px}#thirdCol_area .sponsorBox_header_fmt h1{font-size:80%}#thirdCol_area .sponsorBox_links_fmt li,#thirdCol_area .sponsorBox_links_wide_fmt li,#thirdCol_area .sponsorBox_linksRightAligned_fmt li,#thirdCol_area .sponsorBox_center_links_fmt li,#thirdCol_area .sponsorBox_center_linksRightAligned_fmt li{font-size:85%}#MiddleCol .sponsorBox_links_fmt{float:left;font-size:90%;width:350px}#MiddleCol .sponsorBox_links_fmt li,#MiddleCol .sponsorBox_links_wide_fmt li,#MiddleCol .sponsorBox_linksRightAligned_fmt li,#MiddleCol .sponsorBox_center_links_fmt li,#MiddleCol .sponsorBox_center_linksRightAligned_fmt li{font-size:110%}#MiddleCol .sponsorBox_header_fmt h1{font-size:100%}td.topPad .sponsorBox_links_fmt{float:left;font-size:90%;width:350px}td.topPad .sponsorBox_links_fmt li,td.topPad.sponsorBox_links_wide_fmt li,td.topPad .sponsorBox_linksRightAligned_fmt li,td.topPad .sponsorBox_center_links_fmt li,td.topPad .sponsorBox_center_linksRightAligned_fmt li{font-size:12px}#sponsorBox_frame_fmt{border:1px solid #000;clear:both;margin:0 0 0 25px;overflow:auto;padding:3px}#sponsorBox_frame_fmt a{color:#069}#sponsorBox_frame_fmt a:hover{text-decoration:underline}#sponsorBox_frame_fmt h1{font-size:11px;margin:1px 0 2px;padding:0}#sponsorBox_frame_fmt h2{color:#00539F;font-size:130%;line-height:1.1em;margin:1px 0 2px}#sponsorBox_frame_fmt h3{color:#00539F;font-size:90%;line-height:1.1em;margin:1px 0 2px}#sponsorBox_frame_fmt p{color:#000;font-size:11px;margin:0 0 5px;padding:0}#sponsorBox_frame_fmt ul{color:#000;margin:10px 0 0 20px;padding:0}#sponsorBox_frame_fmt li{background:#fff;color:#000;font-size:11px;list-style-type:dot;margin:0 0 5px;padding:0}#sponsorBox_frame_fmt{background-color:#fff;border:1px solid #999;height:85px;margin:0 5px 0 17px;overflow:auto;position:relative}#sponsorBox_frame_fmt sup{font-size:90%;vertical-align:text-top}#sponsorBox_bottomLinks_fmt{clear:left;font-size:11px;padding:3px 0 0 20px}.sponsorBox494_rdr{background:#fff;font-family:Arial,Verdana,Helvetica,sans-serif;font-size:10pt;padding-right:4px;position:relative;width:100%}.sponsorBox_bottomLinks_fmt{clear:both;font-size:80%;padding:0 0 0 1px}.sponsorBox_bottomLinks_fmt a.infolnk{padding:0 0 0 15px}.sponsorBox_popupHidden{display:none!important}.sponsorBox494_rdr .sponsorBox_popupVisible{background:#fff;border:2px solid #000;left:16px;display:block!important;position:absolute;top:37px;width:454px}.sponsorBox494_rdr .sponsorBox_PopupContent{background:#fff;height:67px;overflow:auto;padding:2px 5px 0 2px;width:447px}.sponsorBox494_rdr .sponsorBox_PopupClose{font-size:80%;text-align:right;width:454px}.sponsorBox_PopupContent h1,.sponsorBox_PopupContent h2,.sponsorBox_PopupContent h3,.sponsorBox_PopupContent h4,.sponsorBox_PopupContent h5{font-size:90%;line-height:12px;margin:0;padding:0 0 2px}.sponsorBox_PopupContent p{font-size:90%;line-height:12px;margin:0;padding:0 0 2px}.sponsorBox_PopupContent strong{font-size:110%;font-weight:700}.sponsorBox_PopupContent ol,.sponsorBox_PopupContent ul{font-size:90%;line-height:12px;margin:0;padding:0 0 2px}.sponsorBox_PopupContent li{margin:0;padding:0}.sponsorBox494_rdr .sponsorBox_PopupClose a,.sponsorBox494_rdr .sponsorBox_PopupClose a:link,.sponsorBox494_rdr .sponsorBox_PopupClose a:hover,.sponsorBox494_rdr .sponsorBox_PopupClose a:visited{color:#069}.sponsorBox494_rdr .sponsorBox_PopupClose a,.sponsorBox494_rdr .sponsorBox_PopupClose a:link{text-decoration:none}.sponsorBox494_rdr .sponsorBox_PopupClose a:hover,.sponsorBox494_rdr .sponsorBox_PopupClose a:visited{text-decoration:underline}.sponsorBox_bottomLinks_fmt{clear:both;font-size:80%;padding:3px 0 0;margin-left:20px}.sponsorBox_title_fmt{padding:0 0 0 5px;float:left}* html .sponsorBox_title_fmt{float:left;margin-left:8px;padding-left:0}.sponsorBox_attribution_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/SponsorBoxDottedLine.gif) no-repeat;float:right;height:32px;margin:0 0 0 4px;padding:0 3px 0 27px}.sponsorBox_title_fmt a:link,.sponsorBox_title_fmt a:visited{color:#6C340A!important;text-decoration:none}.sponsorBox_title_fmt a:hover,.sponsorBox_title_fmt a:active{text-decoration:underline}.sponsorBox_links_fmt a:link,.sponsorBox_links_fmt a:visited{color:#069!important;text-decoration:none}.sponsorBox_links_fmt a:hover,.sponsorBox_links_fmt a:active{color:#24a2dd!important;text-decoration:underline}.video_container{width:300px;border:1px #ddd solid;background-color:#fff;border-radius:5px;-webkit-border-radius:5px;-moz-border-radius:5px}.video_container .video_header{background-color:#f0f0ee;padding:5px 0 5px 6px}.video_container .video_container_links{border-top:1px #ddd solid}.video_container .video_container_links h3{margin:7px 0 0 6px;padding:0;font-size:100%;font-weight:700}.video_container .video_container_links ul{list-style:none;margin:3px 0 17px 12px;padding:0}.video_container .video_container_links ul li{background:url(https://images.medicinenet.com/images/webmd/li_purple.gif) no-repeat 0 9px;line-height:18px;padding-left:8px;font-size:13px!important}</style>
<style>.cookie-consent-ctr .close,.cookie-consent-ctr .legal{box-sizing:border-box;position:relative;vertical-align:middle}.cookie-consent-ctr{background-color:#EDEFEF;box-sizing:border-box;color:#666;font:14px/1.4 Lato,Arial,sans-serif;min-width:1052px;overflow:hidden;padding:1em;position:relative;text-align:center;z-index:1000}.cookie-consent-ctr .close{background:url(data:image/png;base64,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) no-repeat #EDEFEF;cursor:pointer;display:block;float:right;height:28px;width:28px}.cookie-consent-ctr .legal{display:inline-block;max-width:90%}#colorbox,#webmdHoverClose{position:absolute;z-index:999}.thin .cookie-consent-ctr{min-width:790px}.thin.harmony .cookie-consent-ctr{min-width:768px}.ua_type_mobile .cookie-consent-ctr{min-width:100%}.ua_type_mobile .cookie-consent-ctr .legal{float:left;max-width:80%;text-align:left}#webmdHoverOverlay{background:#fefefe;height:100%;position:fixed;width:100%;z-index:999}#colorbox{background:#fff;-moz-box-shadow:0 0 15px 2px #7f7f7f;-webkit-box-shadow:0 0 15px 2px #7f7f7f;box-shadow:0 0 15px 2px #7f7f7f;-moz-border-radius:10px;border-radius:10px;width:550px;overflow:visible!important;padding:0!important}.browserIE #colorbox{border:1px solid #7f7f7f}#webmdHoverContent{background:#fff;-moz-border-radius:12px;border-radius:12px}.browserIE #webmdHoverContent{border:1px solid #999}.browserIE_7 #colorbox,.browserIE_8 #colorbox{border-color:#DADADA;padding-bottom:2px!important;padding-right:2px!important}.browserIE_7 #webmdHoverContent,.browserIE_8 #webmdHoverContent{border-color:#B9B9B9}#webmdHoverClose{background:url(https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/modules/webmd_overlay_close_x.png) no-repeat;cursor:pointer;display:block;height:34px;text-indent:-5000px;width:34px;top:-15px;right:-15px}#webmdHoverTitle,.app_view #adLabel,.app_view .logo_AdChoices{display:none}#webmd_confirm{text-align:center;padding:28px}#webmd_confirm .webmd_confirm_content{text-align:left}#webmd_confirm .webmd_confirm_buttons{margin-top:10px}#webmd_confirm_false_button{margin-left:12px}</style>

<link href="https://images.rxlist.com/oocommon/css/oo-ui.css" rel="stylesheet">

<script type="text/javascript">
var s_account="webmdcom";
var s_pagename="rxlist.com/selarsdi-drug.htm";
var s_bu="cns";
var s_siteclass="od";
var s_site="rxlist";
var s_server_type="MN";
var s_channel_health="rxlist";
var s_refpath="rxlist";
var s_server_number="MA1-NET";
var s_asset="295205rdesc";
var s_template_name="RXL_Drug";
var s_channel="4223";
var s_asset_class="rx-mono";
var s_asset_type="content";
var s_articletype="rx-mono";
var s_pagenum="1";
var s_pub="rxlist";
var s_user_group="unregistered";
</script>
<script type="text/javascript" src="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_head.min.js"></script>
<script async src="https://preferences.trustarc.com/webservices/js?domain=webmd&amp;type=webmd_popnew&amp;js=responsive"></script>
<script src="//assets.adobedtm.com/2c8c1e17b98c/bd8b7ed95b8d/launch-a2e2197ecad5.min.js"></script>

<title>Selarsdi (Ustekinumab-aekn Injection): Side Effects, Uses, Dosage, Interactions, Warnings</title>
<meta NAME="Description" CONTENT="Selarsdi (Ustekinumab-aekn Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources." />
<meta NAME="KeyWords" CONTENT="Selarsdi Ustekinumab-aekn Injection drug description chemical structure black box warning medications drugs generic fda approved patient labeling reviews professionals clinicians clinical" />



        
<script async src="https://images.rxlist.com/rxlist/js/all.min.js"></script>
<meta name="y_key" content="11fe84c14ab87627" /> 

<meta http-equiv="X-UA-Compatible" content="IE=Edge">
<meta http-equiv="content-type" content="text/html; charset=iso-8859-1" />
<link rel="alternate" type="application/rss+xml" title="RxList - Updated and New Drug Monographs" href="https://www.rxlist.com/rss/rxlist_drugs.xml"/>
<link rel="alternate" type="application/rss+xml" title="RxList - News and Features" href="https://www.rxlist.com/rss/rxlist_news.xml"/>
<link rel="alternate" type="application/rss+xml" title="RxList - Health and Medical Slideshows" href="https://www.rxlist.com/rss/rxlist_slideshows.xml" />

<link rel="canonical" href="https://www.rxlist.com/selarsdi-drug.htm" />
<meta property="og:title" content="Selarsdi (Ustekinumab-aekn Injection): Side Effects, Uses, Dosage, Interactions, Warnings" />
<meta property="og:description" content="Selarsdi (Ustekinumab-aekn Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources." />
<meta property="og:site_name" content="RxList" />
<meta property="og:image" content="https://images.rxlist.com/images/facebook/rxlist/fb-rxlist-default-2.jpg" /><meta property="fb:page_id" content="131322716913673" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://www.rxlist.com/selarsdi-drug.htm" />
<meta property="topicid" content="4223" />
<script type="application/ld+json">
[
{
"@context":"https://schema.org",
"@type":"Drug",
"mainEntityOfPage":"https://www.rxlist.com/selarsdi-drug.htm",
"lastReviewed":"4/30/2024",

"warning":"https://www.rxlist.com/selarsdi-drug.htm#warnings",
"name":"selarsdi",
"drugClass":"Antipsoriatics, Systemic",
"isAvailableGenerically":"true",
"relatedDrug":"Ustekinumab",
"reviewedBy":{"@type":"Person","name":"John P. Cunha, DO, FACOEP"},
"about":"Selarsdi (Ustekinumab-aekn Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.",
"datePublished":"4/30/2024",
"headline":"Selarsdi (Ustekinumab-aekn Injection): Side Effects, Uses, Dosage, Interactions, Warnings",
"publisher":{
    "@type":"Organization",
    "name":"RxList",
    "logo": {
        "@type":"ImageObject",
        "url":"https://images.rxlist.com/images/oologos/rxlist-logo.jpg"
        }
    }
}
]
</script></head>
<body class="rxArt pgprof">
<div id="backTop">
    <span class="icon-arrow-right2"></span>
</div>    <script type="module" async src="https://images.rxlist.com/oocommon/js/oo-ui.js"></script>
<svg hidden width="240.12" height="37.437" viewBox="0 0 63.533 9.9052"
  xmlns="https://www.w3.org/2000/svg">
  <symbol id="mni-logo-svg">
  <g transform="translate(-32.677 -80.098)">
    <path d="m34.663 81.236 2.6238 6.5484 2.6238-6.5484h1.3725v8.0257h-1.0583v-3.1254l0.09922-3.3734-2.6348 6.4988h-0.81029l-2.6293-6.4823 0.10473 3.3569v3.1254h-1.0583v-8.0257zm10.804 8.1359q-1.2127 0-1.9734-0.79375-0.76068-0.79926-0.76068-2.1332v-0.18741q0-0.88746 0.33624-1.582 0.34175-0.70004 0.94809-1.0914 0.61185-0.39688 1.3229-0.39688 1.1631 0 1.808 0.76619 0.64492 0.76619 0.64492 2.1938v0.42444h-4.0404q0.02205 0.88194 0.51263 1.4276 0.49609 0.54019 1.2568 0.54019 0.54019 0 0.91502-0.22049 0.37483-0.22049 0.65595-0.58429l0.62287 0.48507q-0.74965 1.152-2.249 1.152zm-0.12678-5.3468q-0.61736 0-1.0363 0.452-0.41892 0.44648-0.51814 1.2568h2.9876v-0.07717q-0.0441-0.77721-0.41892-1.2016-0.37483-0.42995-1.0142-0.42995zm3.3845 2.2049q0-1.3725 0.65044-2.2049 0.65043-0.83785 1.7033-0.83785 1.0473 0 1.6592 0.71658v-3.1089h1.0198v8.4667h-0.93707l-0.04961-0.63941q-0.61185 0.74965-1.7033 0.74965-1.0363 0-1.6922-0.84887-0.65044-0.84887-0.65044-2.2159zm1.0197 0.11576q0 1.0142 0.41892 1.5875 0.41892 0.57326 1.1576 0.57326 0.97014 0 1.4166-0.87092v-2.7395q-0.45751-0.84336-1.4056-0.84336-0.74965 0-1.1686 0.57878-0.41892 0.57878-0.41892 1.7143zm6.7028 2.9159h-1.0198v-5.9642h1.0198zm-1.1024-7.5461q0-0.24805 0.14883-0.41892 0.15434-0.17088 0.452-0.17088 0.29766 0 0.452 0.17088 0.15434 0.17088 0.15434 0.41892t-0.15434 0.41341q-0.15434 0.16536-0.452 0.16536-0.29766 0-0.452-0.16536-0.14883-0.16536-0.14883-0.41341zm5.1263 6.8241q0.5457 0 0.9536-0.33073 0.4079-0.33073 0.452-0.82682h0.96463q-0.02756 0.51263-0.35278 0.97565t-0.87092 0.73863q-0.54019 0.27561-1.1465 0.27561-1.2182 0-1.9403-0.81029-0.71658-0.8158-0.71658-2.2269v-0.17088q0-0.87092 0.31971-1.5489 0.3197-0.678 0.91502-1.0528 0.60082-0.37483 1.4166-0.37483 1.0032 0 1.6647 0.60083 0.66697 0.60082 0.71107 1.5599h-0.96463q-0.0441-0.57878-0.44097-0.94809-0.39136-0.37483-0.97014-0.37483-0.77722 0-1.2072 0.56224-0.42444 0.55673-0.42444 1.6151v0.19292q0 1.0308 0.42444 1.5875t1.2127 0.55673zm4.6247 0.72209h-1.0197v-5.9642h1.0197zm-1.1024-7.5461q0-0.24805 0.14883-0.41892 0.15434-0.17088 0.452-0.17088 0.29766 0 0.452 0.17088t0.15434 0.41892-0.15434 0.41341-0.452 0.16536q-0.29766 0-0.452-0.16536-0.14883-0.16536-0.14883-0.41341zm3.6987 1.582 0.03307 0.74965q0.68351-0.8599 1.7859-0.8599 1.8907 0 1.9072 2.1332v3.9412h-1.0197v-3.9467q-0.0055-0.64492-0.29766-0.9536-0.28663-0.30868-0.89848-0.30868-0.4961 0-0.87092 0.26458-0.37483 0.26458-0.58429 0.69453v4.2499h-1.0197v-5.9642zm7.7391 6.0744q-1.2127 0-1.9734-0.79375-0.76068-0.79926-0.76068-2.1332v-0.18741q0-0.88746 0.33624-1.582 0.34175-0.70004 0.94809-1.0914 0.61185-0.39688 1.3229-0.39688 1.1631 0 1.808 0.76619 0.64492 0.76619 0.64492 2.1938v0.42444h-4.0404q0.02205 0.88194 0.51263 1.4276 0.49609 0.54019 1.2568 0.54019 0.54019 0 0.91502-0.22049 0.37483-0.22049 0.65595-0.58429l0.62287 0.48507q-0.74965 1.152-2.249 1.152zm-0.12678-5.3468q-0.61736 0-1.0363 0.452-0.41892 0.44648-0.51814 1.2568h2.9876v-0.07717q-0.0441-0.77721-0.41892-1.2016-0.37483-0.42995-1.0142-0.42995zm9.9605 5.2366h-1.0638l-4.0404-6.1846v6.1846h-1.0638v-8.0257h1.0638l4.0514 6.2122v-6.2122h1.0528zm4.1948 0.11024q-1.2127 0-1.9734-0.79375-0.76068-0.79926-0.76068-2.1332v-0.18741q0-0.88746 0.33624-1.582 0.34175-0.70004 0.94809-1.0914 0.61185-0.39688 1.3229-0.39688 1.1631 0 1.808 0.76619 0.64492 0.76619 0.64492 2.1938v0.42444h-4.0404q0.02205 0.88194 0.51263 1.4276 0.4961 0.54019 1.2568 0.54019 0.54019 0 0.91502-0.22049 0.37483-0.22049 0.65595-0.58429l0.62287 0.48507q-0.74965 1.152-2.249 1.152zm-0.12678-5.3468q-0.61736 0-1.0363 0.452-0.41892 0.44648-0.51814 1.2568h2.9876v-0.07717q-0.0441-0.77721-0.41892-1.2016-0.37483-0.42995-1.0142-0.42995zm5.0161-2.1718v1.4442h1.1135v0.78824h-1.1135v3.6987q0 0.35829 0.14883 0.54019 0.14883 0.17639 0.50712 0.17639 0.17639 0 0.48507-0.06615v0.82682q-0.40239 0.11024-0.78273 0.11024-0.68351 0-1.0308-0.41341t-0.34727-1.1741v-3.6987h-1.0859v-0.78824h1.0859v-1.4442z" stroke-width=".26458" aria-label="RxList"/>
  </g>
</symbol>
</svg><svg hidden><symbol id="magnifying-glass-icon" width="30px" height="30px" viewBox="0 0 24 24" fill="none"><g stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"/><g><path d="M15 15L21 21" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/><path d="M17 10C17 13.866 13.866 17 10 17C6.13401 17 3 13.866 3 10C3 6.13401 6.13401 3 10 3C13.866 3 17 6.13401 17 10Z" stroke="currentColor" stroke-width="2"/></g></symbol></svg>
<svg hidden><symbol id="arrow-down-icon" viewBox="0 0 512 512" width="512px" height="512px"><polygon points="396.6,160 416,180.7 256,352 96,180.7 115.3,160 256,310.5 "/></symbol></svg>
<svg hidden><symbol id="arrow-up-icon" viewBox="0 0 512 512" width="512px" height="512px"><polygon points="396.6,352 416,331.3 256,160 96,331.3 115.3,352 256,201.5 "/></symbol></svg>
<svg hidden><symbol id="open-icon" viewBox="0 0 100 100" width="100" height="100"><rect width="100" height="10" y="20"></rect><rect width="100" height="10" y="50"></rect><rect width="100" height="10" y="80"></rect></symbol></svg>
<svg hidden><symbol id="close-icon" viewBox="0 0 100 100" width="100" height="100"><line style="stroke:currentColor;stroke-width:10;" x1="5" y1="5" x2="95" y2="95"></line><line style="stroke:currentColor;stroke-width:10;" x1="95" y1="5" x2="5" y2="95"></line></symbol></svg>
<div tw class="max-w-screen-xl mx-auto sticky w-full bg-white z-[10000] top-0 transition-[top] duration-500">
	<nav id="menu" class="w-full flex justify-between items-center box-border px-4 h-12 lg:h-16 border-b border-slate-400 group">
		<div class="hamburger-icon lg:hidden px-2.5 hover:text-sky-400 cursor-pointer">
			<svg class="open-icon fill-current self-center group-[.open-hamburger]:hidden" viewBox="0 0 100 100" width="20" height="20"><use xlink:href="#open-icon"/></svg>
			<svg class="close-icon fill-current self-center hidden group-[.open-hamburger]:inline-block" viewBox="0 0 100 100" width="20" height="20"><use xlink:href="#close-icon"/></svg>
		</div>
		<div class="bg-white z-10 h-full flex justify-between items-center lg:min-w-[200px] lg:max-w-[200px]">
			<a onclick="wmdTrack('tn-home');" itemprop="url" href="https://www.rxlist.com/">
        <img src="https://images.rxlist.com/images/mobile/rxlist/logo-rxl.png" alt="RxList Logo" title="RxList Logo">
    </a>
		</div>
		<div class="grow"></div>
		<div class="menu-center absolute flex flex-col-reverse justify-end lg:flex-row top-12 lg:top-auto lg:relative w-full h-[calc(100vh-128px)] lg:h-full overflow-y-scroll lg:overflow-initial -left-full lg:left-auto transition-all group-[.open-hamburger]:left-0 bg-black lg:bg-white bg-opacity-80 lg:bg-opacity-100">
		<ul class="menu-items flex lg:flex-col-auto flex-col lg:flex-row flex-nowrap w-full max-h-full h-auto lg:h-full overflow-y-scroll lg:overflow-initial p-0 list-none lg:group-[.open-search]:hidden bg-white">
      <li class="relative justify-around flex flex-col px-2 lg:px-0 whitespace-nowrap group/item border-b border-white lg:hover:border-sky-400 cursor-pointer">
        <div class="menu-item flex bg-white z-10 h-full peer group lg:px-3.5 lg:hover:text-sky-400">
					<div class="pointer-events-none lg:pointer-events-auto flex-grow lg:flex-grow-auto whitespace-nowrap self-center pl-3.5 py-2 group-[.show]:text-sky-400 lg:group-[.show]:text-black group-hover/item:text-sky-400 text-lg lg:text-base text-left hover:no-underline">
						<span>Drugs & Vitamins</span>
					</div>
					<div class="icon-button flex self-center">
						<svg class="icon-down self-center lg:group-hover/item:hidden group-[.show]:hidden" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-down-icon"/></svg>
						<svg class="icon-up self-center hidden lg:group-hover/item:inline-block lg:group-hover/item:fill-sky-400 group-[.show]:inline-block" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-up-icon"/></svg>
					</div>
				</div>
        <ul class="overflow-visible lg:absolute min-w-full hidden lg:flex lg:opacity-0 peer-[.show]:flex flex-col px-3.5 py-1 gap-y-1 top-16 lg:shadow-md lg:bg-neutral-100 group-focus:flex lg:-z-10 lg:transition lg:ease-in-out lg:-translate-y-[120%] lg:group-hover/item:opacity-100 lg:group-hover/item:-translate-y-0 lg:duration-300 border-t lg:border-t-0 border-sky-400">
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-drug');" href="https://www.rxlist.com/drugs/alpha_a.htm">Drugs A-Z</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-drug');" href="https://www.rxlist.com/script/main/alphaidx.asp?p=a_rx-mcon">Generic Drugs A-Z</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/drug_classification/article.htm">Drugs by Classification</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/drugs_comparison/article.htm">Drugs Comparison (Drug Vs. Drug)</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-vit');" href="https://www.rxlist.com/supplements/article.htm">Vitamins & Supplements</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-drugint');" href="https://www.rxlist.com/drug-interaction-checker.htm">Drug Interaction Checker</a></li>
	        <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-pillid');" href="https://www.rxlist.com/pill-identification-tool/article.htm">Pill Identifier</a></li>
        </ul>
      </li>
      <li  class="relative justify-around flex flex-col px-2 lg:px-0 whitespace-nowrap group/item border-b border-white lg:hover:border-sky-400 cursor-pointer">
        <div class="menu-item flex bg-white z-10 h-full peer group lg:px-3.5 lg:hover:text-sky-400">
					<div class="pointer-events-none lg:pointer-events-auto flex-grow lg:flex-grow-auto whitespace-nowrap self-center pl-3.5 py-2 group-[.show]:text-sky-400 lg:group-[.show]:text-black group-hover/item:text-sky-400 text-lg lg:text-base text-left hover:no-underline">
						<span>Tools & Resources</span>
					</div>
					<div class="icon-button flex self-center">
					<svg class="icon-down self-center lg:group-hover/item:hidden group-[.show]:hidden" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-down-icon"/></svg>
					<svg class="icon-up self-center hidden lg:group-hover/item:inline-block lg:group-hover/item:fill-sky-400 group-[.show]:inline-block" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-up-icon"/></svg>
					</div>
				</div>
        <ul class="overflow-visible lg:absolute min-w-full hidden lg:flex lg:opacity-0 peer-[.show]:flex flex-col px-3.5 py-1 gap-y-1 top-16 lg:shadow-md lg:bg-neutral-100 group-focus:flex lg:-z-10 lg:transition lg:ease-in-out lg:-translate-y-[120%] lg:group-hover/item:opacity-100 lg:group-hover/item:-translate-y-0 lg:duration-300 border-t lg:border-t-0 border-sky-400">
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-dict');" href="https://www.rxlist.com/drug-medical-dictionary/article.htm">Medical Dictionary</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-ss');" href="https://www.rxlist.com/drug-slideshows-all/article.htm">Slideshows</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-ic');" href="https://www.rxlist.com/image_gallery_collection/article.htm">Images</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-qz');" href="https://www.rxlist.com/quizzes_a-z_listing/article.htm">Quizzes</a></li>
					<!-- <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><privacy-button text="Privacy &amp; Other Trust Info"></privacy-button></li> -->
        </ul>
      </li>
			<li class="relative justify-around flex flex-col px-2 lg:px-0 whitespace-nowrap group/item border-b border-white lg:hover:border-sky-400 cursor-pointer">
					<div class="menu-item flex bg-white z-10 h-full peer group">
						<div class="pointer-events-none lg:pointer-events-auto flex-grow lg:flex-grow-auto whitespace-nowrap self-center pl-3.5 py-2 group-[.show]:text-sky-400 lg:group-[.show]:text-black group-hover/item:text-sky-400 text-lg lg:text-base text-left hover:no-underline">
							<span>Privacy & Other Trust Info</span>
						</div>	
						<div class="icon-button flex self-center">
							<svg class="icon-down self-center lg:group-hover/item:hidden group-[.show]:hidden" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-down-icon"/></svg>
							<svg class="icon-up self-center hidden lg:group-hover/item:inline-block lg:group-hover/item:fill-sky-400 group-[.show]:inline-block" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-up-icon"/></svg>
							</div>
					</div>
					<ul class="overflow-visible lg:absolute min-w-full hidden lg:flex lg:opacity-0 peer-[.show]:flex flex-col px-3.5 py-1 gap-y-1 top-16 lg:shadow-md lg:bg-neutral-100 group-focus:flex lg:-z-10 lg:transition lg:ease-in-out lg:-translate-y-[120%] lg:group-hover/item:opacity-100 lg:group-hover/item:-translate-y-0 lg:duration-300 border-t lg:border-t-0 border-sky-400">
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=64474" target="_blank">Privacy Policy</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=64467" target="_blank">About Us</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/contact_us/article.htm" target="_blank">Contact Us</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=64473" target="_blank">Terms of Use</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=77768" target="_blank">Advertising Policy</a></li>
					</ul>
			</li>
    </ul>
		<ce-search-box class="nav-search self-center block w-full h-auto lg:h-11 p-2 lg:p-0 lg:w-1/2 lg:absolute lg:right-0 lg:hidden lg:group-[.open-search]:block bg-white" 
			search-api="/rxl/api/search" 
			submit-api="/search/rxl" 
			show-search-button="True" 
			search-button-text="Search" 
			placeholder="Search RxList..." 
			wrapper-class="nav-search"></ce-search-box>
	</div>
		<div class="search-icon flex px-2 lg:p-2 relative box-content border-l lg:border-l-0 border-black hover:text-sky-400 cursor-pointer">
			<svg class="icon fill-current" viewBox="0 0 30 30" width="30" height="30"><use xlink:href="#magnifying-glass-icon"/></svg>
		</div>
	</div>
</nav>
</div>
    <div class="adTopWrapper">
        <!-- Start 728x90 Ad Tag -->
        <!-- Start 728x90 Ad Tag -->     
<div id="bannerAdContainer">
    <div id="bannerAd_ctr">
        <div id="bannerAd_rdr">
            <div id="bannerAd_fmt"> 
                <script>
var ooAdTarget={targets:{'pvid': window.s_pageview_id || '','tug': window.s_tug || '','pug': window.s_pug || '','art': '295205','pt': '4223','uri': '%2Fselarsdi-drug.htm','app': '8','cc': '9993','oohc': '61'},'blockCodes': '_l40_supplements_r529_o92_m07_j10_j069_i_h53_gen2_g473_fit_diet_cust4_cust115_cust050_age2_age123_age122_age121_age11_a15_57894060_'}
</script>
<div id="ads2-pos-101" class="ad_placeholder ad"
    data-is-mobile="false" 
    data-block-codes="_l40_supplements_r529_o92_m07_j10_j069_i_h53_gen2_g473_fit_diet_cust4_cust115_cust050_age2_age123_age122_age121_age11_a15_57894060_" 
    data-pos="101" 
    data-sizes="[[728,90],[970, 90]]">
</div>

            </div>
            <div style="clear:both"></div>
        </div>
    </div>
</div>			
<!-- End 728x90 Ad Tag -->

        <!-- End 728x90 Ad Tag -->
    </div>
    <section class="wrapper-hero">
        <div class="hero" itemscope itemtype="https://schema.org/CreativeWork">
            <h1>
                Selarsdi 
            </h1>
            <ul>
   <li itemprop="name">Generic Name: <span><a href="https://www.rxlist.com/ustekinumab/generic-drug.htm">ustekinumab-aekn injection</a></span></li>                   <li itemprop="name">Brand Name: <span>Selarsdi</span></li>
                    <li itemprop="name">Drug Class: <span><a href="https://www.rxlist.com/how_do_systemic_antipsoriatics_work/drug-class.htm">Antipsoriatics, Systemic</a>, <a href="https://www.rxlist.com/how_do_monoclonal_antibodies_work/drug-class.htm">Monoclonal Antibodies</a>, <a href="https://www.rxlist.com/how_do_interleukin_inhibitors_work/drug-class.htm">Interleukin Inhibitors</a></span></li>
            </ul>
        </div>
        <div class="monolastreviewed">
Medical Editor: 
    <!--START HREFPOPOUT-->
    <a onclick="wmdTrack('art-auth');" href="/script/main/art.asp?articlekey=81326" target="_blank">John P. Cunha, DO, FACOEP</a>
    <!--END HREFPOPOUT-->
    
            <i>Last updated on RxList: <span>4/30/2024</span></i>
        </div>
            <div id="breadcrumbs" itemscope itemtype="https://schema.org/WebPage">
                <p class="breadcrumbs" itemprop="breadcrumb">
                    <a href="https://www.rxlist.com">home</a>
                    <a href="https://www.rxlist.com/drugs/alpha_a.htm">drugs a-z list</a>
                    selarsdi (ustekinumab-aekn injection) drug
                </p>
            </div>
            <!--social icons inserted here from the JS after id=breadcrumb div via append-->
        <ul class="drugDropdown">
            <!-- RELATED CENTER -->
    <!-- RELATED DRUGS -->
    <li>
        <a class="drugSelect">Related Drugs</a>
        <div class="drugOption">
            <a onclick="wmdTrack('lr-reldrug_0');" href="https://www.rxlist.com/cimzia-drug.htm" title="Cimzia">Cimzia</a>
<a onclick="wmdTrack('lr-reldrug_1');" href="https://www.rxlist.com/cosentyx-drug.htm" title="Cosentyx">Cosentyx</a>
<a onclick="wmdTrack('lr-reldrug_2');" href="https://www.rxlist.com/enbrel-drug.htm" title="Enbrel">Enbrel</a>
<a onclick="wmdTrack('lr-reldrug_3');" href="https://www.rxlist.com/humira-drug.htm" title="Humira">Humira</a>
<a onclick="wmdTrack('lr-reldrug_4');" href="https://www.rxlist.com/otrexup-drug.htm" title="Otrexup">Otrexup</a>
<a onclick="wmdTrack('lr-reldrug_5');" href="https://www.rxlist.com/otrexup-pfs-drug.htm" title="Otrexup PFS">Otrexup PFS</a>
<a onclick="wmdTrack('lr-reldrug_6');" href="https://www.rxlist.com/plaquenil-drug.htm" title="Plaquenil">Plaquenil</a>
<a onclick="wmdTrack('lr-reldrug_7');" href="https://www.rxlist.com/rasuvo-drug.htm" title="Rasuvo">Rasuvo</a>
<a onclick="wmdTrack('lr-reldrug_8');" href="https://www.rxlist.com/remicade-drug.htm" title="Remicade">Remicade</a>
<a onclick="wmdTrack('lr-reldrug_9');" href="https://www.rxlist.com/skyrizi-drug.htm" title="Skyrizi">Skyrizi</a>
<a onclick="wmdTrack('lr-reldrug_10');" href="https://www.rxlist.com/sorilux-drug.htm" title="Sorilux">Sorilux</a>
<a onclick="wmdTrack('lr-reldrug_11');" href="https://www.rxlist.com/taltz-drug.htm" title="Taltz">Taltz</a>
<a onclick="wmdTrack('lr-reldrug_12');" href="https://www.rxlist.com/tremfya-drug.htm" title="Tremfya">Tremfya</a>

        </div>
    </li>
    <!-- END RELATED DRUGS -->
    
    
    
<!-- END RELATED CENTER -->
        </ul>
    </section>
    <main class="content">
        <section class="story">
	    <div id="apPage" class="apPage">
		 <div class="monograph_sum">
		 <div class="monograph_header">
                      <h2 class="monograph_source">Drug Summary</h2>
                 </div>
		 <div class="monograph_cont"><h4>What Is Selarsdi?</h4>

<p>Selarsdi (ustekinumab-aekn) is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy, and adult patients with active psoriatic arthritis (PsA). Selarsdi is also indicated for the treatment of pediatric patients 6 years and older with moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy and pediatric patients 6 years and older with active psoriatic arthritis (PsA).</p>

<p>Selarsdi is biosimilar to Stelara (ustekinumab).</p>

<h4>What Are Side Effects of Selarsdi?</h4>

<p>Side effects of Selarsdi include:</p>

<ul>
	<li>runny or stuffy nose,</li>
	<li>upper respiratory tract infection,</li>
	<li>headache, and</li>
	<li>fatigue</li>
</ul>

<p>Seek medical care or call 911 at once if you have the following serious side effects:</p>

<ul>
	<li>Serious eye symptoms such as sudden vision loss, blurred vision,tunnel vision,eye painor swelling, or seeing halos around lights;</li>
	<li>Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;</li>
	<li>Severe headache,confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.</li>
</ul>

<p>This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.</p>

<h4>Dosage for Selarsdi</h4>

<p>The recommended dosage of Selarsdi to treat psoriasis in adults weighing less than or equal to 100 kg is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks.</p>

<p>The recommended dosage of Selarsdi to treat psoriasis in adults weighing more than 100 kg is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks.</p>

<p>The recommended dosage of Selarsdi to treat psoriasis in pediatric patients (6 to 17 years old) weighing 60 kg to 100 kg is 45 mg. Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.</p>

<p>The recommended dosage of Selarsdi to treat psoriasis in pediatric patients (6 to 17 years old) weighing more than 100 kg is 90 mg. Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.</p>

<p>The recommended dosage of Selarsdi to treat psoriatic arthritis in adults&nbsp;is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. For adult patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks.</p>

<p>The recommended dosage of Selarsdi to treat psoriatic arthritis in pediatric patients (6 to 17 years old) weighing 60 kg or more is 45 mg. Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.</p>

<p>The recommended dosage of Selarsdi to treat psoriatic arthritis in pediatric patients (6 to 17 years old) weighing more than 100 kg with co- existent moderate-to-severe plaque psoriasis is 90 mg. Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.</p>

<h4>Selarsdi In Children</h4>

<p>The safety and effectiveness of Selarsdi have been established for the treatment of moderate to severe plaque psoriasis in pediatric patients 6 to 17 years of age who are candidates for phototherapy or systemic therapy.</p>

<p>The safety and effectiveness of Selarsdi have not been established in pediatric patients less than 6 years of age with plaque psoriasis.</p>

<p>The safety and effectiveness of Selarsdi have been established for treatment of psoriatic arthritis in pediatric patients 6 to 17 years old.</p>

<p>The safety and effectiveness of Selarsdi have not been established in pediatric patients less than 6 years old with psoriatic arthritis.</p>

<h4>What Drugs, Substances, or Supplements Interact with Selarsdi?</h4>

<p>Selarsdi may interact with other medicines.</p>

<p>Tell your doctor all medications and supplements you use.</p>

<h4>Selarsdi During Pregnancy and Breastfeeding</h4>

<p>Tell your doctor if you are pregnant or plan to become pregnant before using Selarsdi; it is unknown if it would affect a fetus. Selarsdi may pass into breast milk but its effects on nursing infants are unknown. Consult your doctor before breastfeeding.</p>

<h4>Additional Information</h4>

<p>Our Selarsdi (ustekinumab-aekn) Injection, for Subcutaneous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.</p>

<p>This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p></div>
            </div>
	    </div>	
            <nav class="submenu" visibility="hide">
            <span class="icon-menu"></span>
 
            <!--START PROFESSIONAL MENU-->
            <div class="toc link">
		<h2 class="drug_fda">FDA Drug Information</h2>
                <ul class="fda_toc">
                <li><a href="/selarsdi-drug.htm#description" id="mnuDESC">Drug Description</a></li>
                        <li><a href="/selarsdi-drug.htm#indications" id="mnuIDS1">Indications & Dosage</a></li>
                
                    <li><a href="/selarsdi-drug.htm#side_effects" id="mnuAD1">Side Effects</a></li>
                    <li><a href="/selarsdi-drug.htm#interactions" id="mnuAD2">Drug Interactions</a></li>

                        <li><a href="/selarsdi-drug.htm#warnings" id="mnuWCP1">Warnings & Precautions</a></li>    

                        <li><a href="/selarsdi-drug.htm#overdosage" id="mnuOD1">Overdose & Contraindications</a></li>
                    
                <li><a href="/selarsdi-drug.htm#clinpharm" id="mnuCP">Clinical Pharmacology</a></li>
                <li><a href="/selarsdi-drug.htm#medguide" id="mnuPI">Medication Guide</a></li>
                </ul>
            </div>
            <!--END PROFESSIONAL MENU-->
            </nav>

                <article class="pageContainer">	
                    <div>
                    	
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="description"></a>
            <div class="pgContent">
                

                /p>

<h2>Description for Selarsdi</h2>

<p>Ustekinumab-aekn, a human IgG1&kappa; <a href="https://www.rxlist.com/monoclonal_antibody/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">monoclonal antibody</a>, is a human interleukin-12 and -23 <a href="https://www.rxlist.com/antagonist/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">antagonist</a>. Using DNA <a href="https://www.rxlist.com/recombinant/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">recombinant</a> technology, ustekinumab-aekn is produced in a murine cell line (Sp2/0). The manufacturing process contains steps for the clearance of <a href="https://www.rxlist.com/viruses/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">viruses</a>. Ustekinumab-aekn is comprised of 1326 <a href="https://www.rxlist.com/amino_acids/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">amino acids</a> and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.</p>

<p>SELARSDI (ustekinumab-aekn) injection is a sterile, preservative-free, clear and colorless to slightly yellow solution free of visible particles with pH of 5.7 to 6.3.</p>

<p>Available as 45 mg of ustekinumab-aekn in 0.5 mL and 90 mg of ustekinumab-aekn in 1 mL, for subcutaneous use supplied as a sterile solution in a single-dose prefilled syringe with a 29 gauge fixed &frac12; inch needle. Not made with natural rubber latex.</p>

<p>Each 0.5 mL prefilled syringe delivers 45 mg ustekinumab-aekn, <a href="https://www.rxlist.com/supplements/histidine.htm" rel="vit" onclick="wmdTrack('embd-lnk');">histidine</a> (0.122 mg), L-histidine monohydrochloride monohydrate (0.507 mg), polysorbate 80 (0.02 mg), sucrose (38 mg) and water for injection (q.s).</p>

<p>Each 1 mL prefilled syringe delivers 90 mg ustekinumab-aekn, histidine (0.243 mg), L-histidine monohydrochloride monohydrate (1.013 mg), polysorbate 80 (0.04 mg), sucrose (76 mg) and water for injection (q.s).</p>

            </div>
            
<div id="667441035-1" class="medianet"><script type="text/javascript">try { window._mNHandle.queue.push(function () { window._mNDetails.loadTag("667441035-1", "510x175", "667441035"); }); } catch (error) { }</script></div>

        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="indications"></a>
            <div class="pgContent">
                

                <a name="I"></a>
<h2>Uses for Selarsdi</h2>

<h4>Plaque Psoriasis (PsO)</h4>

<p>SELARSDI&trade; is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe <a href="https://www.rxlist.com/plaque_psoriasis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">plaque psoriasis</a> who are candidates for <a href="https://www.rxlist.com/phototherapy/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">phototherapy</a> or systemic therapy.</p>

<h4>Psoriatic Arthritis (PsA)</h4>

<p>SELARSDI is indicated for the treatment of adults and pediatric patients 6 years of age and older with active <a href="https://www.rxlist.com/psoriatic_arthritis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">psoriatic arthritis</a>.</p>
<a name="D"></a>

<h2>Dosage for Selarsdi</h2>

<h4>Recommended Dosage In Plaque Psoriasis</h4>

<h5>Subcutaneous Adult Dosage Regimen</h5>

<ul>
	<li>For patients weighing 100 kg or less, the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.</li>
	<li>For patients weighing more than 100 kg, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.</li>
</ul>

<p>In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects [see <b>Clinical Studies</b>].</p>

<h5>Subcutaneous Pediatric Dosage Regimen</h5>

<p>Administer SELARSDI subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.</p>

<p>The recommended dose of SELARSDI for pediatric patients (6 to 17 years old) with plaque <a href="https://www.rxlist.com/psoriasis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">psoriasis</a> based on body weight is shown below (Table 1).</p>

<p align="center"><b>Table 1: Recommended Dose of SELARSDI for Subcutaneous Injection in Pediatric Patients (6 to 17 years old) with Plaque Psoriasis</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="450">
	<tbody>
		<tr>
			<td class="EmphTd" width="70%">Body Weight of Patient at the Time of Dosing</td>
			<td class="EmphTd" width="30%">Recommended Dose</td>
		</tr>
		<tr>
			<td>60 kg to 100 kg</td>
			<td align="center">45 mg</td>
		</tr>
		<tr>
			<td>more than 100 kg</td>
			<td align="center">90 mg</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>There is no dosage form for SELARSDI that allows weight-based dosing for pediatric patients below 60 kg.</p>

<h4>Recommended Dosage In Psoriatic Arthritis</h4>

<h5>Subcutaneous Adult Dosage Regimen</h5>

<ul>
	<li>The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.</li>
	<li>For patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.</li>
</ul>

<h5>Subcutaneous Pediatric Dosage Regimen</h5>

<p>Administer SELARSDI subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.</p>

<p>The recommended dose of SELARSDI for pediatric patients (6 to 17 years old) with psoriatic <a href="https://www.rxlist.com/arthritis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">arthritis</a>, based on body weight, is shown below (Table 2).</p>

<p align="center"><b>Table 2: Recommended Dose of SELARSDI for Subcutaneous Injection in Pediatric Patients (6 to 17 years old) with Psoriatic Arthritis</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="450">
	<tbody>
		<tr>
			<td class="EmphTd" width="70%">Body Weight of Patient at the Time of Dosing</td>
			<td class="EmphTd" width="30%">Recommended Dose</td>
		</tr>
		<tr>
			<td>60 kg or more</td>
			<td align="center">45 mg</td>
		</tr>
		<tr>
			<td>greater than 100 kg with co-existent moderate-to-severe plaque psoriasis</td>
			<td align="center">90 mg</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>There is no dosage form for SELARSDI that allows weight-based dosing for pediatric patients below 60 kg.</p>

<h4>General Considerations For Administration</h4>

<ul>
	<li>SELARSDI is intended for use under the guidance and supervision of a healthcare provider. SELARSDI should only be administered to patients who will be closely monitored and have regular follow-up visits with a healthcare provider. The appropriate dose should be determined by a healthcare provider using the patient&rsquo;s current weight at the time of dosing. In pediatric patients, it is recommended that SELARSDI be administered by a healthcare provider. If a healthcare provider determines that it is appropriate, a patient may self-inject or a caregiver may inject SELARSDI after proper training in subcutaneous injection technique. Instruct patients to follow the directions provided in the Medication Guide [see <b>PATIENT INFORMATION</b>].</li>
	<li>Not made with natural rubber latex.</li>
	<li>It is recommended that each injection be administered at a different anatomic location (such as upper arms, <a href="https://www.rxlist.com/gluteal/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">gluteal</a> regions, thighs, or any <a href="https://www.rxlist.com/quadrant/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">quadrant</a> of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated.</li>
	<li>Prior to administration, visually inspect SELARSDI for particulate matter and discoloration. SELARSDI is a clear and colorless to slightly yellow solution and free of visible particles. Do not use SELARSDI if it is discolored or cloudy, or if other particulate matter is present. SELARSDI does not contain preservatives; therefore, discard any unused product remaining in the syringe.</li>
</ul>

<h4>Instructions For Administration Of SELARSDI Prefilled Syringes Equipped With Passive Safety Device</h4>

<p>Refer to the diagram below for the provided instructions.</p>

<p></p>

<center>
<table cellspacing="0" class="blackpic" width="564">
	<tbody>
		<tr>
			<td><img alt="SELARSDI Prefilled Syringes Equipped With Passive Safety Device - Illustration" height="295" src="https://images.rxlist.com/images/selarsdi1.jpg" width="564" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<ul>
	<li>Hold the SYRINGE BODY and remove the NEEDLE COVER. <b>Do not hold the PLUNGER or PLUNGER HEAD while removing the NEEDLE COVER or the PLUNGER may move. Do not use the prefilled syringe if it is dropped without the NEEDLE COVER in place.</b></li>
	<li>Inject SELARSDI subcutaneously as recommended [see <b>Recommended Dosage In Plaque Psoriasis, Recommended Dosage In Psoriatic Arthritis, General Considerations For Administration</b>].</li>
	<li>Inject all of the medication by pushing in the PLUNGER HEAD all the way in until the plunger head is completely between the needle guard activation clips. <b>Injection of the entire prefilled syringe contents is necessary to activate the passive safety device guard.</b></li>
</ul>

<p></p>

<center>
<table cellspacing="0" class="blackpic" width="233">
	<tbody>
		<tr>
			<td><img alt="Inject all of the medication by pushing in the PLUNGER HEAD all the way in until the plunger head is completely between the needle guard activation clips - Illustration" height="296" src="https://images.rxlist.com/images/selarsdi2.jpg" width="233" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>After injection, maintain the pressure on the PLUNGER HEAD and remove the needle from the skin. Slowly take your thumb off the PLUNGER HEAD. The PLUNGER will move up with your thumb and retract the needle into the needle guard, as shown by the illustration below:</p>

<p></p>

<center>
<table cellspacing="0" class="blackpic" width="247">
	<tbody>
		<tr>
			<td><img alt="Slowly take your thumb off the PLUNGER HEAD - Illustration" height="254" src="https://images.rxlist.com/images/selarsdi3.jpg" width="247" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<ul>
	<li>Used syringes should be placed in a puncture-resistant container.</li>
</ul>
<a name="HS"></a>

<h2>HOW SUPPLIED</h2>

<h4>Dosage Forms And Strengths</h4>

<p><b>SELARSDI</b> (ustekinumab-aekn) injection is a clear and colorless to slightly yellow solution and free of visible particles.</p>

<ul>
	<li>Injection: 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe</li>
</ul>

<h4>Storage And Handling</h4>

<p><b>SELARSDI</b> (ustekinumab-aekn) injection, is a sterile, preservative-free, clear and colorless to slightly yellow solution and free of visible particles for subcutaneous use. It is supplied as individually packaged, single-dose prefilled syringes.</p>

<h5>Single-Dose Prefilled Syringes</h5>

<ul>
	<li>45 mg/0.5 mL <b>NDC</b> 51759-<b>505</b>-32</li>
	<li>90 mg/mL <b>NDC</b> 51759-<b>607</b>-32</li>
</ul>

<p>Each prefilled syringe is equipped with a 29 gauge fixed &frac12; inch needle equipped with a passive safety device and a needle cover. Not made with natural rubber latex.</p>

<h5>Storage And Stability</h5>

<p><b>SELARSDI</b> prefilled syringes must be refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake.</p>

<p>If needed, individual prefilled syringes may be stored at room temperature up to 30&deg;C (86&deg;F) for a maximum single period of up to 30 days in the original carton to protect from light. Record the date when the prefilled syringe is first removed from the refrigerator on the carton in the space provided. Once a syringe has been stored at room temperature, do not return to the refrigerator. Discard the syringe if not used within 30 days at room temperature storage. Do not use SELARSDI after the expiration date on the carton or on the prefilled syringe.</p>

<p class="credit"><b>REFERENCES</b></p>

<p class="credit">1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence -SEER 6.6.2 Regs Research Data, Nov 2009 Sub (1973-2007) -Linked To County Attributes -Total U.S., 1969-2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2010, based on the November 2009 submission.</p>

<p class="credit">Manufactured By: Alvotech USA Inc. Leesburg, VA 20175. Revised: Apr 2024.</p>

            </div>
            
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="side_effects"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_4-->
                <a name="AR"></a>
<h2>Side Effects for Selarsdi</h2>

<p>The following serious adverse reactions are discussed elsewhere in the label:</p>

<ul>
	<li>Infections [see <b>WARNINGS AND PRECAUTIONS</b>]</li>
	<li>Malignancies [see <b>WARNINGS AND PRECAUTIONS</b>]</li>
	<li>Hypersensitivity Reactions [see <b>WARNINGS AND PRECAUTIONS</b>]</li>
	<li>Posterior Reversible Encephalopathy Syndrome (PRES) [see <b>WARNINGS AND PRECAUTIONS</b>]</li>
	<li>Noninfectious Pneumonia [see <b>WARNINGS AND PRECAUTIONS</b>]</li>
</ul>

<h4>Clinical Trials Experience</h4>

<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>

<h5>Adult Subjects With Plaque Psoriasis</h5>

<p>The safety data reflect exposure to ustekinumab in 3117 adult subjects with plaque psoriasis, including 2414 exposed for at least 6 months, 1855 exposed for at least one year, 1653 exposed for at least two years, 1569 exposed for at least three years, 1482 exposed for at least four years and 838 exposed for at least five years.</p>

<p>Table 3 summarizes the adverse reactions that occurred at a rate of at least 1% with higher rates in the ustekinumab groups during the placebo-controlled period of Ps STUDY 1 and Ps STUDY 2 [see <b>Clinical Studies</b>].</p>

<p align="center"><b>Table 3: Adverse Reactions Reported by &ge;1% of Subjects with Plaque Psoriasis and at Higher Rates in the ustekinumab groups through Week 12 in Ps STUDY 1 and Ps STUDY 2</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="450">
	<tbody>
		<tr>
			<td class="EmphTd" width="40%"></td>
			<td class="EmphTd" width="20%">Placebo</td>
			<td class="EmphTd" width="20%">Ustekinumab<br />
			45 mg</td>
			<td class="EmphTd" width="20%">90 mg</td>
		</tr>
		<tr>
			<td><b>Subjects treated</b></td>
			<td align="center"><b>665</b></td>
			<td align="center"><b>664</b></td>
			<td align="center"><b>666</b></td>
		</tr>
		<tr>
			<td>Nasopharyngitis</td>
			<td align="center">51 (8%)</td>
			<td align="center">56 (8%)</td>
			<td align="center">49 (7%)</td>
		</tr>
		<tr>
			<td>Upper respiratory tract infection</td>
			<td align="center">30 (5%)</td>
			<td align="center">36 (5%)</td>
			<td align="center">28 (4%)</td>
		</tr>
		<tr>
			<td>Headache</td>
			<td align="center">23 (3%)</td>
			<td align="center">33 (5%)</td>
			<td align="center">32 (5%)</td>
		</tr>
		<tr>
			<td>Fatigue</td>
			<td align="center">14 (2%)</td>
			<td align="center">18 (3%)</td>
			<td align="center">17 (3%)</td>
		</tr>
		<tr>
			<td>Back pain</td>
			<td align="center">8 (1%)</td>
			<td align="center">9 (1%)</td>
			<td align="center">14 (2%)</td>
		</tr>
		<tr>
			<td>Dizziness</td>
			<td align="center">8 (1%)</td>
			<td align="center">8 (1%)</td>
			<td align="center">14 (2%)</td>
		</tr>
		<tr>
			<td>Pharyngolaryngeal pain</td>
			<td align="center">7 (1%)</td>
			<td align="center">9 (1%)</td>
			<td align="center">12 (2%)</td>
		</tr>
		<tr>
			<td>Pruritus</td>
			<td align="center">9 (1%)</td>
			<td align="center">10 (2%)</td>
			<td align="center">9 (1%)</td>
		</tr>
		<tr>
			<td>Injection site erythema</td>
			<td align="center">3 (&lt;1%)</td>
			<td align="center">6 (1%)</td>
			<td align="center">13 (2%)</td>
		</tr>
		<tr>
			<td>Myalgia</td>
			<td align="center">4 (1%)</td>
			<td align="center">7 (1%)</td>
			<td align="center">8 (1%)</td>
		</tr>
		<tr>
			<td>Depression</td>
			<td align="center">3 (&lt;1%)</td>
			<td align="center">8 (1%)</td>
			<td align="center">4 (1%)</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>Adverse reactions that occurred at rates less than 1% in the controlled period of Ps STUDIES 1 and 2 through week 12 included: cellulitis, herpes zoster, diverticulitis, and certain injection site reactions (pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation).</p>

<p>One case of PRES occurred during adult plaque psoriasis clinical trials [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<p><i>Infections</i></p>

<p>In the placebo-controlled period of clinical trials of subjects with plaque psoriasis (average follow-up of 12.6 weeks for placebo-treated subjects and 13.4 weeks for ustekinumab-treated subjects), 27% of ustekinumabtreated subjects reported infections (1.39 per subject-year of follow-up) compared with 24% of placebo-treated subjects (1.21 per subject-year of follow-up). Serious infections occurred in 0.3% of ustekinumab-treated subjects (0.01 per subject-year of follow-up) and in 0.4% of placebo-treated subjects (0.02 per subject-year of follow-up) [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<p>In the controlled and non-controlled portions of plaque psoriasis clinical trials (median follow-up of 3.2 years), representing 8998 subject-years of exposure, 72.3% of ustekinumab-treated subjects reported infections (0.87 per subject-years of follow-up). Serious infections were reported in 2.8% of subjects (0.01 per subject-years of follow-up).</p>

<p><i>Malignancies</i></p>

<p>In the controlled and non-controlled portions of plaque psoriasis clinical trials (median follow-up of 3.2 years, representing 8998 subject-years of exposure), 1.7% of ustekinumab-treated subjects reported malignancies excluding non-melanoma skin cancers (0.60 per hundred subject-years of follow-up). Non-melanoma skin cancer was reported in 1.5% of ustekinumab-treated subjects (0.52 per hundred subject-years of follow-up) [see <b>WARNINGS AND PRECAUTIONS</b>]. The most frequently observed malignancies other than non-melanoma skin cancer during the clinical trials were: prostate, melanoma, colorectal and breast. Malignancies other than non-melanoma skin cancer in ustekinumab-treated patients during the controlled and uncontrolled portions of trials were similar in type and number to what would be expected in the general U.S. population according to the SEER database (adjusted for age, gender and race).1</p>

<h5>Pediatric Subjects With Plaque Psoriasis</h5>

<p>The safety of ustekinumab was assessed in two trials of pediatric subjects with moderate to severe plaque psoriasis. Ps STUDY 3 evaluated safety for up to 60 weeks in 110 pediatric subjects 12 to 17 years old. Ps STUDY 4 evaluated safety for up to 56 weeks in 44 pediatric subjects 6 to 11 years old. The safety profile in pediatric subjects was similar to the safety profile from trials in adults with plaque psoriasis.</p>

<h5>Psoriatic Arthritis</h5>

<p>The safety of ustekinumab was assessed in 927 subjects in two randomized, double-blind, placebo-controlled trials in adults with active psoriatic arthritis (PsA). The overall safety profile of ustekinumab in subjects with PsA was consistent with the safety profile seen in adult psoriasis clinical trials. A higher incidence of arthralgia, nausea, and dental infections was observed in ustekinumab-treated subjects when compared with placebo-treated subjects (3% vs. 1% for arthralgia and 3% vs. 1% for nausea; 1% vs. 0.6% for dental infections) in the placebo-controlled portions of the PsA clinical trials.</p>

<h4>Immunogenicity</h4>

<p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ustekinumab or of other ustekinumab products.</p>

<p>Approximately 6 to 12.4% of subjects treated with ustekinumab in plaque psoriasis and psoriatic arthritis clinical trials developed antibodies to ustekinumab, which were generally low-titer. In plaque psoriasis clinical trials, antibodies to ustekinumab were associated with reduced or undetectable serum ustekinumab concentrations and reduced efficacy. In plaque psoriasis trials, the majority of subjects who were positive for antibodies to ustekinumab had neutralizing antibodies.</p>

<h4>Postmarketing Experience</h4>

<p>The following adverse reactions have been reported during post-approval of ustekinumab products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to ustekinumab products exposure.</p>

<p><i><b>Immune system disorders: </b></i>Serious hypersensitivity reactions (including anaphylaxis and angioedema), other hypersensitivity reactions (including rash and urticaria).</p>

<p><i><b>Infections and infestations: </b></i>Lower respiratory tract infection (including opportunistic fungal infections and tuberculosis).</p>

<p><i><b>Neurological disorders:</b></i> Posterior Reversible Encephalopathy Syndrome (PRES).</p>

<p><i><b>Respiratory, thoracic, and mediastinal disorders: </b></i>Interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia.</p>

<p><i><b>Skin reactions:</b></i> Pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis.</p>

            </div>
            <!--MOD_BOTTOMOFPAGE_4-->
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="interactions"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_5-->
                <a name="DI"></a>

<h2>Drug Interactions for Selarsdi</h2>

<h4>Concomitant Therapies</h4>

<p>In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab.</p>

<h4>CYP450 Substrates</h4>

<p>The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL10, TNF&alpha;, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Upon initiation of SELARSDI in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and adjust the individual dose of the drug as needed [see <b>CLINICAL PHARMACOLOGY</b>].</p>

<h4>Allergen Immunotherapy</h4>

<p>Ustekinumab products have not been evaluated in patients who have undergone allergy immunotherapy. Ustekinumab products may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.</p>

            </div>
            <!--MOD_BOTTOMOFPAGE_5-->
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="warnings"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_6-->
                <a name="W"></a>
<h2>Warnings for Selarsdi</h2>

<p>Included as part of the <b>&quot;PRECAUTIONS&quot;</b> Section</p>
<a name="P"></a>

<h2>Precautions for Selarsdi</h2>

<h4>Infections</h4>

<p>Ustekinumab products may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ustekinumab products [see <b>ADVERSE REACTIONS</b>].</p>

<p>Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following:</p>

<ul>
	<li><i><b>Plaque Psoriasis</b></i>: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.</li>
	<li><i><b>Psoriatic arthritis</b>:</i> cholecystitis.</li>
</ul>

<p>Avoid initiating treatment with SELARSDI in patients with any clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of SELARSDI in patients with a chronic infection or a history of recurrent infection.</p>

<p>Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with SELARSDI and discontinue SELARSDI for serious or clinically significant infections until the infection resolves or is adequately treated.</p>

<h4>Theoretical Risk For Vulnerability To Particular Infections</h4>

<p>Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including non typhi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients.</p>

<p>It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with ustekinumab products may be susceptible to these types of infections. Consider appropriate diagnostic testing, (e.g., tissue culture, stool culture, as dictated by clinical circumstances).</p>

<h4>Pre-treatment Evaluation For Tuberculosis</h4>

<p>Evaluate patients for tuberculosis infection prior to initiating treatment with SELARSDI.</p>

<p>Avoid administering SELARSDI to patients with active tuberculosis infection. Initiate treatment of latent tuberculosis prior to administering SELARSDI. Consider anti-tuberculosis therapy prior to initiation of SELARSDI in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving SELARSDI for signs and symptoms of active tuberculosis during and after treatment.</p>

<h4>Malignancies</h4>

<p>Ustekinumab products are immunosuppressants and may increase the risk of malignancy. Malignancies were reported among subjects who received ustekinumab in clinical trials [see <b>ADVERSE REACTIONS</b>]. In rodent models, inhibition of IL-12/IL-23p40 increased the risk of malignancy [see <b>Nonclinical Toxicology</b>].</p>

<p>The safety of ustekinumab products has not been evaluated in patients who have a history of malignancy or who have a known malignancy.</p>

<p>There have been post-marketing reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving ustekinumab products who had pre-existing risk factors for developing non-melanoma skin cancer. Monitor all patients receiving SELARSDI should be monitored for the appearance of non-melanoma skin cancer. Closely follow patients greater than 60 years of age, those with a medical history of prolonged immunosuppressant therapy and those with a history of PUVA treatment [see <b>ADVERSE REACTIONS</b>].</p>

<h4>Hypersensitivity Reactions</h4>

<p>Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with ustekinumab products [see <b>ADVERSE REACTIONS</b>]. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SELARSDI.</p>

<h4>Posterior Reversible Encephalopathy Syndrome (PRES)</h4>

<p>Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in postmarketing experience in patients with psoriasis and psoriatic arthritis. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after ustekinumab product initiation. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab products.</p>

<p>Monitor all patients treated with SELARSDI for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue SELARSDI.</p>

<h4>Immunizations</h4>

<p>Prior to initiating therapy with SELARSDI, patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with SELARSDI should avoid receiving live vaccines. Avoid administering BCG vaccines during treatment with SELARSDI or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving SELARSDI because of the potential risk for shedding from the household contact and transmission to patient.</p>

<p>Non-live vaccinations received during a course of SELARSDI may not elicit an immune response sufficient to prevent disease.</p>

<h4>Noninfectious Pneumonia</h4>

<p>Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab products. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. If diagnosis is confirmed, discontinue SELARSDI and institute appropriate treatment [see <b>Postmarketing Experience</b>].</p>

<h4>Patient Counseling Information</h4>

<p>Advise the patient and/or caregiver to read the FDA-approved patient labeling (<b>Medication Guide and Instructions for Use</b>).</p>

<h5>Infections</h5>

<p>Inform patients that SELARSDI may lower the ability of their immune system to fight infections and to contact their healthcare provider immediately if they develop any signs or symptoms of infection [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<h5>Malignancies</h5>

<p>Inform patients of the risk of developing malignancies while receiving SELARSDI [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<h5>Hypersensitivity Reactions</h5>

<p>Advise patients to seek immediate medical attention if they experience any signs or symptoms of serious hypersensitivity reactions and discontinue SELARSDI [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<h5>Posterior Reversible Encephalopathy Syndrome (PRES)</h5>

<p>Inform patients to immediately contact their healthcare provider if they experience signs and symptoms of PRES (which may include headache, seizures, confusion, or visual disturbances) [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<h5>Immunizations</h5>

<p>Inform patients that SELARSDI can interfere with the usual response to immunizations and that they should avoid live vaccines [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

<h5>Administration</h5>

<p>Instruct patients to follow sharps disposal recommendations, as described in the Instructions for Use.</p>

<p>Brands listed are the trademarks of their respective owners.</p>

<h4>Nonclinical Toxicology</h4>

<h4>Carcinogenesis, Mutagenesis, Impairment Of Fertility</h4>

<p>Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of ustekinumab products. Published literature showed that administration of murine IL-12 caused an anti-tumor effect in mice that contained transplanted tumors and IL-12/IL-23p40 knockout mice or mice treated with anti-IL-12/IL-23p40 antibody had decreased host defense to tumors. Mice genetically manipulated to be deficient in both IL-12 and IL-23 or IL-12 alone developed UV-induced skin cancers earlier and more frequently compared to wild-type mice. The relevance of these experimental findings in mouse models for malignancy risk in humans is unknown.</p>

<p>No effects on fertility were observed in male cynomolgus monkeys that were administered ustekinumab at subcutaneous doses up to 45 mg/kg twice weekly (45 times the MRHD on a mg/kg basis) prior to and during the mating period. However, fertility and pregnancy outcomes were not evaluated in mated females.</p>

<p>No effects on fertility were observed in female mice that were administered an analogous IL-12/IL-23p40 antibody by subcutaneous administration at doses up to 50 mg/kg, twice weekly, prior to and during early pregnancy.</p>
<a name="USP"></a>

<h4>Use In Specific Populations</h4>

<h4>Pregnancy</h4>

<h5>Risk Summary</h5>

<p>Limited data from observational studies, published case reports, and postmarketing surveillance on the use of ustekinumab products during pregnancy are insufficient to inform a drug associated risk of major birth defects, miscarriage, and other adverse maternal or fetal outcomes. Transport of human IgG antibody across the placenta increases as pregnancy progresses and peaks during the third trimester; therefore, SELARSDI may be transferred to the developing fetus (see <b>Clinical Considerations</b>). In animal reproductive and developmental toxicity studies, no adverse developmental effects were observed in offspring after administration of ustekinumab to pregnant monkeys at exposures greater than 100 times the maximum recommended human dose (MRHD).</p>

<p>The background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage of clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p>

<h5>Clinical Considerations</h5>

<p><i>Fetal/Neonatal Adverse Reactions</i></p>

<p>Because ustekinumab products may theoretically interfere with immune response to infections, consider risks and benefits prior to administering live vaccines to infants exposed to SELARSDI <i>in utero</i>. There are insufficient data regarding exposed infant serum levels of ustekinumab products at birth and the duration of persistence of ustekinumab products in infant serum after birth. Although a specific timeframe to delay administration of live attenuated vaccines in infants exposed <i>in utero</i> is unknown, consider the risks and benefits of delaying a minimum of 6 months after birth because of the clearance of the product.</p>

<h5>Data</h5>

<p><i>Animal Data</i></p>

<p>Ustekinumab was tested in two embryo-fetal development toxicity studies in cynomolgus monkeys. No teratogenic or other adverse developmental effects were observed in fetuses from pregnant monkeys that were 10 administered ustekinumab subcutaneously twice weekly or intravenously weekly during the period of organogenesis. Serum concentrations of ustekinumab in pregnant monkeys were greater than 100 times the serum concentration in patients treated subcutaneously with 90 mg of ustekinumab weekly for 4 weeks.</p>

<p>In a combined embryo-fetal development and pre-and post-natal development toxicity study, pregnant cynomolgus monkeys were administered subcutaneous doses of ustekinumab twice weekly at exposures greater than 100 times the MRHD from the beginning of organogenesis to Day 33 after delivery. Neonatal deaths occurred in the offspring of one monkey administered ustekinumab at 22.5 mg/kg and one monkey dosed at 45 mg/kg. No ustekinumab-related-effects on functional, morphological, or immunological development were observed in the neonates from birth through six months of age.</p>

<h4>Lactation</h4>

<h5>Risk Summary</h5>

<p>Limited data from published literature suggests that ustekinumab products are present in human breast milk. There are no available data on the effects of ustekinumab products on milk production. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to ustekinumab products are unknown. No adverse effects on the breastfed infant causally related to ustekinumab products have been identified in the published literature or postmarketing experience.</p>

<p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for SELARSDI and any potential adverse effects on the breastfed child from SELARSDI or from the underlying maternal condition.</p>

<h4>Pediatric Use</h4>

<h5>Plaque Psoriasis</h5>

<p>The safety and effectiveness of SELARSDI have been established for the treatment of moderate to severe plaque psoriasis in pediatric patients 6 to 17 years of age who are candidates for phototherapy or systemic therapy.</p>

<p>Use of SELARSDI in pediatric patients 12 to less than 17 years of age is supported by evidence from a multicenter, randomized, 60week trial (Ps STUDY 3) of ustekinumab that included a 12week, double-blind, placebo-controlled, parallel group portion, in 110 pediatric subjects 12 years of age and older [see <b>ADVERSE REACTIONS</b>, <b>Clinical Studies</b>].</p>

<p>Use of SELARSDI in pediatric patients 6 to 11 years of age is supported by evidence from an open-label, single-arm, efficacy, safety, and pharmacokinetics trial (Ps STUDY 4) of ustekinumab in 44 subjects [see <b>ADVERSE REACTIONS</b>, <b>Pharmacokinetics</b>].</p>

<p>The safety and effectiveness of SELARSDI have not been established in pediatric patients less than 6 years of age with plaque psoriasis.</p>

<h5>Psoriatic Arthritis</h5>

<p>The safety and effectiveness of SELARSDI have been established for treatment of psoriatic arthritis in pediatric patients 6 to 17 years old.</p>

<p>Use of SELARSDI in these age groups is supported by evidence from adequate and well controlled trials of ustekinumab in adults with psoriasis and PsA, pharmacokinetic data from adult patients with psoriasis, adult patients with PsA and pediatric patients with psoriasis, and safety data of ustekinumab from two clinical trials in 44 pediatric patients 6 to 11 years old with psoriasis and 110 pediatric patients 12 to 17 years old with psoriasis. The observed pre-dose (trough) concentrations are generally comparable between adult patients with psoriasis, adult patients with PsA and pediatric patients with psoriasis, and the PK exposure is expected to be comparable between adult and pediatric patients with PsA [see <b>ADVERSE REACTIONS</b>, <b>CLINICAL PHARMACOLOGY</b>, and <b>Clinical Studies</b>].</p>

<p>The safety and effectiveness of SELARSDI have not been established in pediatric patients less than 6 years old with psoriatic arthritis.</p>

<h4>Geriatric Use</h4>

<p>Of the 6709 patients exposed to ustekinumab, a total of 340 were 65 years of age or older (183 patients with plaque psoriasis, 65 patients with psoriatic arthritis, 58 patients with one indication, and 34 patients with another indication), and 40 patients were 75 years of age or older. Clinical trials of ustekinumab did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.</p>

            </div>
            <!--MOD_BOTTOMOFPAGE_6-->
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="overdosage"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_8-->
                <a name="OD"></a>
<h2>Overdose Information for Selarsdi</h2>

<p>Single doses up to 6 mg/kg intravenously have been administered in clinical trials without dose-limiting toxicity. In case of overdosage, monitor the patient for any signs or symptoms of adverse reactions or effects and institute appropriate symptomatic treatment immediately. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</p>
<a name="CI"></a>

<h2>Contraindications for Selarsdi</h2>

<p>SELARSDI is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in SELARSDI [see <b>WARNINGS AND PRECAUTIONS</b>].</p>

            </div>
            <!--MOD_BOTTOMOFPAGE_8-->
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="clinpharm"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_10-->
                <a name="CP"></a>
<h2>Clinical Pharmacology for Selarsdi</h2>

<h4>Mechanism Of Action</h4>

<p>Ustekinumab products are human IgG1&kappa; monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In <i>in vitro</i> models, ustekinumab products were shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12R&beta;1.</p>

<h4>Pharmacodynamics</h4>

<h5>Plaque Psoriasis</h5>

<p>In a small exploratory trial, a decrease was observed in the expression of mRNA of its molecular targets IL-12 and IL-23 in lesional skin biopsies measured at baseline and up to two weeks post-treatment in subjects with plaque psoriasis.</p>

<h4>Pharmacokinetics</h4>

<h5>Absorption</h5>

<p>In adult subjects with plaque psoriasis, the median time to reach the maximum serum concentration (Tmax) was 13.5 days and 7 days, respectively, after a single subcutaneous administration of 45 mg (N=22) and 90 mg (N=24) of ustekinumab. In healthy subjects (N=30), the median Tmax value (8.5 days) following a single subcutaneous administration of 90 mg of ustekinumab was comparable to that observed in subjects with plaque psoriasis.</p>

<p>Following multiple subcutaneous doses of ustekinumab in adult subjects with plaque psoriasis, steady-state serum concentrations of ustekinumab were achieved by Week 28. The mean (&plusmn;SD) steady-state trough serum ustekinumab concentrations were 0.69 &plusmn; 0.69 mcg/mL for patients less than or equal to 100 kg receiving a 45 mg dose and 0.74 &plusmn; 0.78 mcg/mL for patients greater than 100 kg receiving a 90 mg dose. There was no apparent accumulation in serum ustekinumab concentration over time when given subcutaneously every 12 weeks.</p>

<h5>Distribution</h5>

<p>Population pharmacokinetic analyses showed that the volume of distribution of ustekinumab in the central compartment was 2.7 L (95% CI: 2.69, 2.78) in patients with one indication and 3.0 L (95% CI: 2.96, 3.07) in patients with another indication. The total volume of distribution at steady-state was 4.6 L in patients with one indication and 4.4 L in patients with another indication.</p>

<h5>Elimination</h5>

<p>The mean (&plusmn;SD) half-life ranged from 14.9 &plusmn; 4.6 to 45.6 &plusmn; 80.2 days across all plaque psoriasis trials following subcutaneous administration.</p>

<h4>Metabolism</h4>

<p>The metabolic pathway of ustekinumab products have not been characterized. As a human IgG1&kappa; monoclonal antibody, ustekinumab products are expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p>

<h4>Specific Populations</h4>

<h5>Weight</h5>

<p>When given the same dose, subjects with plaque psoriasis or psoriatic arthritis weighing more than 100 kg had lower median serum ustekinumab concentrations compared with those subjects weighing 100 kg or less. The median trough serum concentrations of ustekinumab in subjects of higher weight (greater than 100 kg) in the 90 mg group were comparable to those in subjects of lower weight (100 kg or less) in the 45 mg group.</p>

<h5>Age</h5>

<p><i>Geriatric Population</i></p>

<p>A population pharmacokinetic analysis (N=106/1937 patients with plaque psoriasis greater than or equal to 65 years old) was performed to evaluate the effect of age on the pharmacokinetics of ustekinumab. There were no apparent changes in pharmacokinetic parameters (clearance and volume of distribution) in subjects older than 65 years old.</p>

<h5>Age</h5>

<p><i>Pediatric Population</i></p>

<p>Following multiple recommended doses of ustekinumab in pediatric subjects 6 to 17 years of age with plaque psoriasis, steady-state serum concentrations of ustekinumab were achieved by Week 28. At Week 28, the mean &plusmn;SD steady-state trough serum ustekinumab concentrations were 0.36 &plusmn; 0.26 mcg/mL and 0.54 &plusmn; 0.43 mcg/mL, respectively, in pediatric subjects 6 to 11 years of age and pediatric subjects 12 to 17 years of age.</p>

<p>Overall, the observed steady-state ustekinumab trough concentrations in pediatric patients with plaque psoriasis were within the range of those observed for adult patients with plaque psoriasis and adult patients with PsA after administration of ustekinumab.</p>

<h4>Drug Interaction Studies</h4>

<p>The effects of IL-12 or IL-23 on the regulation of CYP450 enzymes were evaluated in an <i>in vitro</i> study using human hepatocytes, which showed that IL-12 and/or IL-23 at levels of 10 ng/mL did not alter human CYP450 enzyme activities (CYP1A2, 2B6, 2C9, 2C19, 2D6, or 3A4). However, the clinical relevance of <i>in vitro</i> data has not been established [see <b>DRUG INTERACTIONS</b>].</p>

<p>No <i>in vivo</i> drug interaction studies have been conducted with ustekinumab products.</p>

<p>Population pharmacokinetic analyses indicated that the clearance of ustekinumab was not impacted by concomitant MTX, NSAIDs, and oral corticosteroids, or prior exposure to a TNF blocker in patients with psoriatic arthritis.</p>
<a name="AP"></a>

<h4>Animal Toxicology And/Or Pharmacology</h4>

<p>In a 26-week toxicology study, one out of 10 monkeys subcutaneously administered 45 mg/kg ustekinumab twice weekly for 26 weeks had a bacterial infection.</p>
<a name="CS"></a>

<h4>Clinical Studies</h4>

<h4>Adult Plaque Psoriasis</h4>

<p>Two multicenter, randomized, double-blind, placebo-controlled trials (Ps STUDY 1 and Ps STUDY 2) enrolled a total of 1996 subjects 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, and Psoriasis Area and Severity Index (PASI) score &ge;12, and who were candidates for phototherapy or systemic therapy. Subjects with guttate, erythrodermic, or pustular psoriasis were excluded from the trials.</p>

<p>Ps STUDY 1 enrolled 766 subjects and Ps STUDY 2 enrolled 1230 subjects. The trials had the same design through Week 28. In both trials, subjects were randomized in equal proportion to placebo, 45 mg or 90 mg of ustekinumab. Subjects randomized to ustekinumab received 45 mg or 90 mg doses, regardless of weight, at Weeks 0, 4, and 16. Subjects randomized to receive placebo at Weeks 0 and 4 crossed over to receive ustekinumab (either 45 mg or 90 mg) at Weeks 12 and 16.</p>

<p>In both trials, subjects in all treatment groups had a median baseline PASI score ranging from approximately 17 to 18. Baseline PGA score was marked or severe in 44% of subjects in Ps STUDY 1 and 40% of subjects in Ps STUDY 2. Approximately two-thirds of all subjects had received prior phototherapy, 69% had received either prior conventional systemic or biologic therapy for the treatment of psoriasis, with 56% receiving prior conventional systemic therapy and 43% receiving prior biologic therapy. A total of 28% of subjects had a history of psoriatic arthritis.</p>

<p>In both trials, the endpoints were the proportion of subjects who achieved at least a 75% reduction in PASI score (PASI 75) from baseline to Week 12 and treatment success (cleared or minimal) on the Physician&rsquo;s Global Assessment (PGA). The PGA is a 6-category scale ranging from 0 (cleared) to 5 (severe) that indicates the physician&rsquo;s overall assessment of psoriasis focusing on plaque thickness/induration, erythema, and scaling.</p>

<h5>Clinical Response</h5>

<p>The results of Ps STUDY 1 and Ps STUDY 2 are presented in Table 4 below.</p>

<p align="center"><b>Table 4: Clinical Outcomes at Week 12 in Adults with Plaque Psoriasis in Ps STUDY 1 and Ps STUDY 2</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="650">
	<tbody>
		<tr>
			<td class="EmphTd" rowspan="2" width="20%"></td>
			<td class="EmphTd" colspan="3">Ps STUDY 1</td>
			<td class="EmphTd" colspan="3">Ps STUDY 2</td>
		</tr>
		<tr>
			<td class="EmphTd" width="10%">Placebo</td>
			<td class="EmphTd" width="15%">45 mg</td>
			<td class="EmphTd" width="15%">90 mg</td>
			<td class="EmphTd" width="10%">Placebo</td>
			<td class="EmphTd" width="15%">45 mg</td>
			<td class="EmphTd" width="15%">90 mg</td>
		</tr>
		<tr>
			<td><b>Subjects randomized</b></td>
			<td align="center"><b>255</b></td>
			<td align="center"><b>255</b></td>
			<td align="center"><b>256</b></td>
			<td align="center"><b>410</b></td>
			<td align="center"><b>409</b></td>
			<td align="center"><b>411</b></td>
		</tr>
		<tr>
			<td>PASI 75 response</td>
			<td align="center">8 (3%)</td>
			<td align="center">171 (67%)</td>
			<td align="center">170 (66%)</td>
			<td align="center">15 (4%)</td>
			<td align="center">273 (67%)</td>
			<td align="center">311 (76%)</td>
		</tr>
		<tr>
			<td>PGA of Cleared or Minimal</td>
			<td align="center">10 (4%)</td>
			<td align="center">151 (59%)</td>
			<td align="center">156 (61%)</td>
			<td align="center">18 (4%)</td>
			<td align="center">277 (68%)</td>
			<td align="center">300 (73%)</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>Examination of age, gender, and race subgroups did not identify differences in response to ustekinumab among these subgroups.</p>

<p>In subjects who weighed 100 kg or less, response rates were comparable with both the 45 mg and 90 mg doses; however, in subjects who weighed greater than 100 kg, higher response rates were seen with 90 mg dosing compared with 45 mg dosing (Table 5 below).</p>

<p align="center"><b>Table 5: Clinical Outcomes by Weight Ps STUDY 1 and Ps STUDY 2</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="650">
	<tbody>
		<tr>
			<td class="EmphTd" rowspan="2" width="20%"></td>
			<td class="EmphTd" colspan="3">Ps STUDY 1<br />
			Ustekinumab</td>
			<td class="EmphTd" colspan="3">Ps STUDY 2<br />
			Ustekinumab</td>
		</tr>
		<tr>
			<td class="EmphTd" width="10%">Placebo</td>
			<td class="EmphTd" width="15%">45 mg</td>
			<td class="EmphTd" width="15%">90 mg</td>
			<td class="EmphTd" width="10%">Placebo</td>
			<td class="EmphTd" width="15%">45 mg</td>
			<td class="EmphTd" width="15%">90 mg</td>
		</tr>
		<tr>
			<td><b>Subjects randomized</b></td>
			<td align="center"><b>255</b></td>
			<td align="center"><b>255</b></td>
			<td align="center"><b>256</b></td>
			<td align="center"><b>410</b></td>
			<td align="center"><b>409</b></td>
			<td align="center"><b>411</b></td>
		</tr>
		<tr>
			<td colspan="7"><b>PASI 75 response*</b></td>
		</tr>
		<tr>
			<td rowspan="2">&le;100 kg</td>
			<td align="center">4%</td>
			<td align="center">74%</td>
			<td align="center">65%</td>
			<td align="center">4%</td>
			<td align="center">73%</td>
			<td align="center">78%</td>
		</tr>
		<tr>
			<td align="center">6/166</td>
			<td align="center">124/168</td>
			<td align="center">107/164</td>
			<td align="center">12/290</td>
			<td align="center">218/297</td>
			<td align="center">225/289</td>
		</tr>
		<tr>
			<td rowspan="2">&gt;100 kg</td>
			<td align="center">2%</td>
			<td align="center">54%</td>
			<td align="center">68%</td>
			<td align="center">3%</td>
			<td align="center">49%</td>
			<td align="center">71%</td>
		</tr>
		<tr>
			<td align="center">2/89</td>
			<td align="center">47/87</td>
			<td align="center">63/92</td>
			<td align="center">3/120</td>
			<td align="center">55/112</td>
			<td align="center">86/121</td>
		</tr>
		<tr>
			<td colspan="7"><b>PGA of Cleared or Minimal*</b></td>
		</tr>
		<tr>
			<td rowspan="2">&le;100 kg</td>
			<td align="center">4%</td>
			<td align="center">64%</td>
			<td align="center">63%</td>
			<td align="center">5%</td>
			<td align="center">74%</td>
			<td align="center">75%</td>
		</tr>
		<tr>
			<td align="center">7/166</td>
			<td align="center">108/168</td>
			<td align="center">103/164</td>
			<td align="center">14/290</td>
			<td align="center">220/297</td>
			<td align="center">216/289</td>
		</tr>
		<tr>
			<td rowspan="2">&gt;100 kg</td>
			<td align="center">3%</td>
			<td align="center">49%</td>
			<td align="center">58%</td>
			<td align="center">3%</td>
			<td align="center">51%</td>
			<td align="center">69%</td>
		</tr>
		<tr>
			<td align="center">3/89</td>
			<td align="center">43/87</td>
			<td align="center">53/92</td>
			<td align="center">4/120</td>
			<td align="center">57/112</td>
			<td align="center">84/121</td>
		</tr>
		<tr>
			<td class="credit" colspan="7">*Patients were dosed with trial medication at Weeks 0 and 4.</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>Subjects in Ps STUDY 1 who were PASI 75 responders at both Weeks 28 and 40 were re-randomized at Week 40 to either continued dosing of ustekinumab (ustekinumab at Week 40) or to withdrawal of therapy (placebo at Week 40). At Week 52, 89% (144/162) of subjects re-randomized to ustekinumab treatment were PASI 75 responders compared with 63% (100/159) of subjects re-randomized to placebo (treatment withdrawal after Week 28 dose). The median time to loss of PASI 75 response among the subjects randomized to treatment withdrawal was 16 weeks.</p>

<h4>Pediatric Plaque Psoriasis</h4>

<p>A multicenter, randomized, double blind, placebo-controlled trial (Ps STUDY 3) enrolled 110 pediatric subjects 12 to 17 years of age with a minimum <a href="https://www.rxlist.com/bsa/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">BSA</a> involvement of 10%, a PASI score greater than or equal to 12, and a PGA score greater than or equal to 3, who were candidates for phototherapy or systemic therapy and whose disease was inadequately controlled by topical therapy.</p>

<p>Subjects were randomized to receive placebo (n = 37), the recommended dose of ustekinumab (n = 36), or one-half the recommended dose of ustekinumab (n = 37) by subcutaneous injection at Weeks 0 and 4 followed by dosing every 12 weeks (q12w). The recommended dose of ustekinumab was 0.75 mg/kg for subjects weighing less than 60 kg, 45 mg for subjects weighing 60 kg to 100 kg, and 90 mg for subjects weighing greater than 100 kg. At Week 12, subjects who received placebo were crossed over to receive ustekinumab at the recommended dose or one-half the recommended dose.</p>

<p>Of the pediatric subjects, approximately 63% had prior exposure to phototherapy or conventional systemic therapy and approximately 11% had prior exposure to biologics.</p>

<p>The endpoints were the proportion of subjects who achieved a PGA score of cleared (0) or minimal (1), PASI 75, and PASI 90 at Week 12. Subjects were followed for up to 60 weeks following first administration of trial agent.</p>

<h5>Clinical Response</h5>

<p>The efficacy results at Week 12 for Ps STUDY 3 are presented in Table 6.</p>

<p align="center"><b>Table 6: Efficacy Results at Week 12 in the Pediatric Subjects 12 to 17 years with Plaque Psoriasis in Ps Study 3</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="450">
	<tbody>
		<tr>
			<td class="EmphTd" rowspan="2" width="40%"></td>
			<td class="EmphTd" colspan="2">Ps STUDY 3</td>
		</tr>
		<tr>
			<td class="EmphTd" width="30%">Placebo<br />
			n (%)</td>
			<td class="EmphTd" width="30%">Ustekinumab*<br />
			n (%)</td>
		</tr>
		<tr>
			<td><b>N</b></td>
			<td align="center"><b>37</b></td>
			<td align="center"><b>36</b></td>
		</tr>
		<tr>
			<td colspan="3"><b>PGA</b></td>
		</tr>
		<tr>
			<td>PGA of cleared (0) or minimal (1)</td>
			<td align="center">2 (5.4%)</td>
			<td align="center">25 (69.4%)</td>
		</tr>
		<tr>
			<td colspan="3"><b>PASI</b></td>
		</tr>
		<tr>
			<td>PASI 75 responders</td>
			<td align="center">4 (10.8%)</td>
			<td align="center">29 (80.6%)</td>
		</tr>
		<tr>
			<td>PASI 90 responders</td>
			<td align="center">2 (5.4%)</td>
			<td align="center">22 (61.1%)</td>
		</tr>
		<tr>
			<td class="credit" colspan="3">* Using the weight-based dosage regimen specified in Table 1.</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<h4>Psoriatic Arthritis</h4>

<p>The safety and efficacy of ustekinumab was assessed in 927 patients (PsA STUDY 1, n=615; PsA STUDY 2, n=312), in two randomized, double-blind, placebo-controlled trials in adult patients 18 years of age and older with active PsA (&ge;5 swollen joints and &ge;5 tender joints) despite non-steroidal anti-inflammatory (<a href="https://www.rxlist.com/nsaid/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">NSAID</a>) or disease modifying antirheumatic (DMARD) therapy. Patients in these trials had a diagnosis of PsA for at least 6 months. Patients with each subtype of PsA were enrolled, including polyarticular arthritis with the absence of rheumatoid nodules (39%), <a href="https://www.rxlist.com/spondylitis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">spondylitis</a> with peripheral arthritis (28%), asymmetric peripheral arthritis (21%), <a href="https://www.rxlist.com/distal/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">distal</a> interphalangeal involvement (12%) and arthritis mutilans (0.5%). Over 70% and 40% of the patients, respectively, had enthesitis and dactylitis at baseline.</p>

<p>Patients were randomized to receive treatment with ustekinumab 45 mg, 90 mg, or placebo subcutaneously at Weeks 0 and 4 followed by every 12 weeks (q12w) dosing. Approximately 50% of patients continued on stable doses of <a href="https://www.rxlist.com/mtx/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">MTX</a> (&le;25 mg/week). The primary endpoint was the percentage of patients achieving ACR 20 response at Week 24.</p>

<p>In PsA STUDY 1 and PsA STUDY 2, 80% and 86% of the patients, respectively, had been previously treated with DMARDs. In PsA STUDY 1, previous treatment with anti-<a href="https://www.rxlist.com/tumor_necrosis_factor/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">tumor necrosis factor</a> (TNF)-&alpha; agent was not allowed. In PsA STUDY 2, 58% (n=180) of the patients had been previously treated with TNF blocker, of whom over 70% had discontinued their TNF blocker treatment for lack of efficacy or intolerance at any time.</p>

<h5>Clinical Response</h5>

<p>In both trials, a greater proportion of patients achieved ACR 20, ACR 50 and PASI 75 response in the ustekinumab 45 mg and 90 mg groups compared to placebo at Week 24 (see Table 7). ACR 70 responses were also higher in the ustekinumab 45 mg and 90 mg groups, although the difference was only numerical (p=<a href="https://www.rxlist.com/ns/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">NS</a>) in STUDY 2. Responses were consistent in patients treated with ustekinumab alone or in combination with methotrexate. Responses were similar in patients regardless of prior TNF&alpha; exposure.</p>

<p align="center"><b>Table 7: ACR 20, ACR 50, ACR 70 and PASI 75 responses in PsA STUDY 1 and PsA STUDY 2 at Week 24</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="650">
	<tbody>
		<tr>
			<td class="EmphTd" rowspan="2" width="34%"></td>
			<td class="EmphTd" colspan="3">PsA STUDY 1<br />
			Ustekinumab</td>
			<td class="EmphTd" colspan="3">PsA STUDY 2<br />
			Ustekinumab</td>
		</tr>
		<tr>
			<td class="EmphTd" width="12%">Placebo</td>
			<td class="EmphTd" width="12%">45 mg</td>
			<td class="EmphTd" width="12%">90 mg</td>
			<td class="EmphTd" width="10%">Placebo</td>
			<td class="EmphTd" width="10%">45 mg</td>
			<td class="EmphTd" width="15%">90 mg</td>
		</tr>
		<tr>
			<td><b>Number of patients randomized</b></td>
			<td align="center"><b>206</b></td>
			<td align="center"><b>205</b></td>
			<td align="center"><b>204</b></td>
			<td align="center"><b>104</b></td>
			<td align="center"><b>103</b></td>
			<td align="center"><b>105</b></td>
		</tr>
		<tr>
			<td>ACR 20 response, N (%)</td>
			<td align="center">47 (23%)</td>
			<td align="center">87 (42%)</td>
			<td align="center">101 (50%)</td>
			<td align="center">21 (20%)</td>
			<td align="center">45 (44%)</td>
			<td align="center">46 (44%)</td>
		</tr>
		<tr>
			<td>ACR 50 response, N (%)</td>
			<td align="center">18 (9%)</td>
			<td align="center">51 (25%)</td>
			<td align="center">57 (28%)</td>
			<td align="center">7 (7%)</td>
			<td align="center">18 (17%)</td>
			<td align="center">24 (23%)</td>
		</tr>
		<tr>
			<td>ACR 70 response, N (%)</td>
			<td align="center">5 (2%)</td>
			<td align="center">25 (12%)</td>
			<td align="center">29 (14%)</td>
			<td align="center">3 (3%)</td>
			<td align="center">7 (7%)</td>
			<td align="center">9 (9%)</td>
		</tr>
		<tr>
			<td><b>Number of patients with &ge; 3% BSA<sup>a</sup></b></td>
			<td align="center"><b>146</b></td>
			<td align="center"><b>145</b></td>
			<td align="center"><b>149</b></td>
			<td align="center"><b>80</b></td>
			<td align="center"><b>80</b></td>
			<td align="center"><b>81</b></td>
		</tr>
		<tr>
			<td>PASI 75 response, N (%)</td>
			<td align="center">16 (11%)</td>
			<td align="center">83 (57%)</td>
			<td align="center">93 (62%)</td>
			<td align="center">4 (5%)</td>
			<td align="center">41 (51%)</td>
			<td align="center">45 (56%)</td>
		</tr>
		<tr>
			<td class="credit" colspan="7"><sup>a</sup> Number of patients with &ge; 3% BSA psoriasis skin involvement at baseline</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>The percent of patients achieving ACR 20 responses by visit is shown in Figure 1.</p>

<p align="center"><b>Figure 1: Percent of patients achieving ACR 20 response through Week 24</b></p>

<center>
<table cellspacing="0" class="blackpic" width="380">
	<tbody>
		<tr>
			<td><img alt="Percent of patients achieving ACR 20 response through Week 24 - Illustration" height="396" src="https://images.rxlist.com/images/selarsdi4.jpg" width="380" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>The results of the components of the ACR response criteria are shown in Table 8.</p>

<p align="center"><b>Table 8: Mean change from baseline in ACR components at Week 24</b></p>

<center>
<table cellspacing="0" class="blacktbl" width="450">
	<tbody>
		<tr>
			<td class="EmphTd" rowspan="2" width="40%"></td>
			<td class="EmphTd" colspan="3">PsA STUDY 1<br />
			Ustekinumab</td>
		</tr>
		<tr>
			<td class="EmphTd" width="20%">Placebo<br />
			(N = 206)</td>
			<td class="EmphTd" width="20%">45 mg<br />
			(N = 205)</td>
			<td class="EmphTd" width="20%">90 mg<br />
			(N = 204)</td>
		</tr>
		<tr>
			<td colspan="4"><b>Number of swollen joints<sup>a</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">15</td>
			<td align="center">12</td>
			<td align="center">13</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">-3</td>
			<td align="center">-5</td>
			<td align="center">-6</td>
		</tr>
		<tr>
			<td colspan="4"><b>Number of tender joints<sup>b</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">25</td>
			<td align="center">22</td>
			<td align="center">23</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">-4</td>
			<td align="center">-8</td>
			<td align="center">-9</td>
		</tr>
		<tr>
			<td colspan="4"><b>Patient&rsquo;s assessment of pain<sup>c</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">6.1</td>
			<td align="center">6.2</td>
			<td align="center">6.6</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">-0.5</td>
			<td align="center">-2.0</td>
			<td align="center">-2.6</td>
		</tr>
		<tr>
			<td colspan="4"><b>Patient global assessment<sup>c</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">6.1</td>
			<td align="center">6.3</td>
			<td align="center">6.4</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">-0.5</td>
			<td align="center">-2.0</td>
			<td align="center">-2.5</td>
		</tr>
		<tr>
			<td colspan="4"><b>Physician global assessment<sup>c</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">5.8</td>
			<td align="center">5.7</td>
			<td align="center">6.1</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">-1.4</td>
			<td align="center">-2.6</td>
			<td align="center">-3.1</td>
		</tr>
		<tr>
			<td colspan="4"><b>Disability index (HAQ)<sup>d</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">1.2</td>
			<td align="center">1.2</td>
			<td align="center">1.2</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">-0.1</td>
			<td align="center">-0.3</td>
			<td align="center">-0.4</td>
		</tr>
		<tr>
			<td colspan="4"><b>CRP (mg/dL)<sup>e</sup></b></td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Baseline</td>
			<td align="center">1.6</td>
			<td align="center">1.7</td>
			<td align="center">1.8</td>
		</tr>
		<tr>
			<td>&nbsp;&nbsp;Mean Change at Week 24</td>
			<td align="center">0.01</td>
			<td align="center">-0.5</td>
			<td align="center">-0.8</td>
		</tr>
		<tr>
			<td class="credit" colspan="4"><sup>a</sup> Number of swollen joints counted (0-66)<br />
			<sup>b</sup> Number of tender joints counted (0-68)<br />
			<sup>c</sup> Visual analogue scale; 0= best, 10=worst.<br />
			<sup>d</sup> Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the patient&rsquo;s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity.<br />
			<sup>e</sup> CRP: (Normal Range 0.0-1.0 mg/dL)</td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>An improvement in enthesitis and dactylitis scores was observed in each ustekinumab group compared with placebo at Week 24.</p>

<h5>Physical Function</h5>

<p>Ustekinumab-treated patients showed improvement in physical function compared to patients treated with placebo as assessed by HAQ-DI at Week 24. In both trials, the proportion of HAQ-DI responders (&ge;0.3 improvement in HAQ-DI score) was greater in the ustekinumab 45 mg and 90 mg groups compared to placebo at Week 24.</p>

            </div>
            <!--MOD_BOTTOMOFPAGE_10-->
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="medguide"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_11-->
                <a name="PI"></a>
<h2>Patient Information for Selarsdi</h2>

<p><b>SELARSDI&trade;</b><br />
(seh-LARS-dee)<br />
(ustekinumab-aekn) injection, for subcutaneous use</p>

<p><b>What is the most important information I should know about SELARSDI?</b></p>

<p>SELARSDI is a medicine that affects your immune system. SELARSDI can increase your risk of having serious side effects, including:</p>

<p><b>Serious infections.</b> SELARSDI may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have serious infections while taking ustekinumab products, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses. Some people have to be hospitalized for treatment of their infection.</p>

<ul>
	<li>Your doctor should check you for TB before starting SELARSDI.</li>
	<li>If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with SELARSDI and during treatment with SELARSDI.</li>
	<li>Your doctor should watch you closely for signs and symptoms of TB while you are being treated with SELARSDI.</li>
</ul>

<p>You should not start taking SELARSDI if you have any kind of infection unless your doctor says it is okay.</p>

<p><b>Before starting SELARSDI, tell your doctor if you: </b></p>

<ul>
	<li>think you have an infection or have symptoms of an infection such as:
	<ul>
		<li>fever, sweat, or chills</li>
		<li>warm, red, or painful skin or sores on your body</li>
		<li>muscle aches</li>
		<li>diarrhea or stomach pain</li>
		<li>cough</li>
		<li>burning when you urinate or urinate more often</li>
		<li>shortness of breath than normal</li>
		<li>blood in phlegm</li>
		<li>feel very tired</li>
		<li>weight loss</li>
	</ul>
	</li>
	<li>are being treated for an infection or have any open cuts.</li>
	<li>get a lot of infections or have infections that keep coming back.</li>
	<li>have TB, or have been in close contact with someone with TB.</li>
</ul>

<p><b>After starting SELARSDI,</b> call your doctor right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. SELARSDI can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL-12) and interleukin 23 (IL-23) are at a higher risk for certain serious infections. These infections can spread throughout the body and cause death. People who take SELARSDI may also be more likely to get these infections.</p>

<p><b>Cancers</b>. SELARSDI may decrease the activity of your immune system and increase your risk for certain types of cancers. Tell your doctor if you have ever had any type of cancer. Some people who are receiving ustekinumab products and have risk factors for skin cancer have developed certain types of skin cancers. During your treatment with SELARSDI, tell your doctor if you develop any new skin growths.</p>

<p><b>Posterior Reversible Encephalopathy Syndrome (PRES)</b>. PRES is a rare condition that affects the brain and can cause death. The cause of PRES is not known. If PRES is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including:</p>

<ul>
	<li>headache</li>
	<li>seizures</li>
	<li>confusion</li>
	<li>vision problems</li>
</ul>

<p><b>What is SELARSDI? </b></p>

<p>SELARSDI is a prescription medicine used to treat:</p>

<ul>
	<li>adults and children 6 years and older with moderate or severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).</li>
	<li>adults and children 6 years and older with active psoriatic arthritis.</li>
</ul>

<p>It is not known if SELARSDI is safe and effective in children less than 6 years of age.</p>

<p><b>Do not take SELARSDI if you are</b> allergic to ustekinumab products or any of the ingredients in SELARSDI. See the end of this Medication Guide for a complete list of ingredients in SELARSDI.</p>

<p><b>Before you receive SELARSDI, tell your doctor about all of your medical conditions, including if you:</b></p>

<ul>
	<li>have any of the conditions or symptoms listed in the section &ldquo;<b>What is the most important information I should know about SELARSDI?&rdquo; </b></li>
	<li>ever had an allergic reaction to ustekinumab products. Ask your doctor if you are not sure.</li>
	<li>have recently received or are scheduled to receive an immunization (vaccine). People who take SELARSDI should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems.<b> You should not receive the BCG vaccine during the one year before receiving SELARSDI or one year after you stop receiving SELARSDI. </b></li>
	<li>have any new or changing lesions within psoriasis areas or on normal skin.</li>
	<li>are receiving or have received allergy shots, especially for serious allergic reactions. Allergy shots may not work as well for you during treatment with SELARSDI. SELARSDI may also increase your risk of having an allergic reaction to an allergy shot.</li>
	<li>receive or have received phototherapy for your psoriasis.</li>
	<li>are pregnant or plan to become pregnant. It is not known if SELARSDI can harm your unborn baby. You and your doctor should decide if you will receive SELARSDI. See &ldquo;What should I avoid while using SELARSDI?&rdquo;</li>
	<li>received SELARSDI while you were pregnant. It is important that you tell your baby&rsquo;s healthcare provider before any vaccinations are given to your baby.</li>
	<li>are breastfeeding or plan to breastfeed. SELARSDI can pass into your breast milk.</li>
	<li>Talk to your doctor about the best way to feed your baby if you receive SELARSDI.</li>
</ul>

<p><b>Tell your doctor about all the medicines you take</b>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>

<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>

<p><b>How should I use SELARSDI? </b></p>

<ul>
	<li>Use SELARSDI exactly as your doctor tells you to.</li>
	<li>Adults with psoriasis or psoriatic arthritis, and children 6 years and older with psoriasis or psoriatic arthritis will receive SELARSDI as an injection under the skin (subcutaneous injection) as described below.</li>
	<li><b>Injecting SELARSDI under your skin</b>
	<ul>
		<li>SELARSDI is intended for use under the guidance and supervision of your doctor. In children 6 years and older, it is recommended that SELARSDI be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections of SELARSDI at home, you should receive training on the right way to prepare and inject SELARSDI. Your doctor will determine the right dose of SELARSDI for you, the amount for each injection, and how often you should receive it. Do not try to inject SELARSDI yourself until you or your caregiver have been shown how to inject SELARSDI by your doctor or nurse.</li>
		<li>Inject SELARSDI under the skin (subcutaneous injection) in your upper arms, buttocks, upper legs (thighs) or stomach area (abdomen).</li>
		<li>Do not give an injection in an area of the skin that is tender, bruised, red or hard. o Use a different injection site each time you use SELARSDI.</li>
		<li>If you inject more SELARSDI than prescribed, call your doctor right away.</li>
		<li>Be sure to keep all of your scheduled follow-up appointments.</li>
	</ul>
	</li>
</ul>

<p><b>Read the detailed Instructions for Use at the end of this Medication Guide for instructions about how to prepare and inject a dose of SELARSDI, and how to properly throw away (dispose of) used needles and prefilled syringes. The needle and prefilled syringe must never be re-used. SELARSDI can become contaminated by harmful bacteria which could cause an infection if re-used. Therefore, throw away any unused portion of SELARSDI.</b></p>

<p><b>What should I avoid while using SELARSDI?</b></p>

<p>You should not receive a live vaccine while taking SELARSDI. <b>See &ldquo;Before you receive SELARSDI, tell your doctor about all of your medical conditions, including if you:&rdquo;</b></p>

<p><b>What are the possible side effects of SELARSDI?</b></p>

<p><b>SELARSDI may cause serious side effects, including: </b></p>

<ul>
	<li>See <b>&ldquo;What is the most important information I should know about SELARSDI?&rdquo; </b></li>
	<li><b>Serious allergic reactions. </b>Serious allergic reactions can occur with SELARSDI. Stop using SELARSDI and get medical help right away if you have any of the following symptoms of a serious allergic reaction:
	<ul>
		<li>feeling faint</li>
		<li>chest tightness</li>
		<li>swelling of your face, eyelids, tongue, or throat</li>
		<li>skin rash</li>
	</ul>
	</li>
	<li><b>Lung inflammation.</b> Cases of lung inflammation have happened in some people who receive ustekinumab products and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn&rsquo;t go away during treatment with SELARSDI.</li>
</ul>

<p><b>Common side effects of SELARSDI include:</b></p>

<ul>
	<li>nasal congestion, sore throat, and runny nose</li>
	<li>headache</li>
	<li>upper respiratory infections</li>
	<li>tiredness</li>
</ul>

<p>These are not all of the possible side effects of SELARSDI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Teva Pharmaceuticals at 1-888-483-8279.</p>

<p><b>How should I store SELARSDI?</b></p>

<ul>
	<li>Store SELARSDI prefilled syringes in a refrigerator between 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C).</li>
	<li>Store SELARSDI in the original carton to protect it from light until time to use it.</li>
	<li>Do not freeze SELARSDI.</li>
	<li>Do not shake SELARSDI.</li>
</ul>

<p>If needed, individual SELARSDI prefilled syringes may also be stored at room temperature up to 30&deg;C (86&deg;F) for a maximum single period of up to 30 days in the original carton to protect from light. Record the date when the prefilled syringe is first removed from the refrigerator on the carton in the space provided. Once a syringe has been stored at room temperature, it should not be returned to the refrigerator. Discard the syringe if not used within 30 days at room temperature storage. Do not use SELARSDI after the expiration date on the carton or on the prefilled syringe.</p>

<p>Keep SELARSDI and all medicines out of the reach of children.</p>

<p><b>General information about the safe and effective use of SELARSDI. </b></p>

<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SELARSDI for a condition for which it was not prescribed. Do not give SELARSDI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your doctor or pharmacist for information about SELARSDI that was written for health professionals.</p>

<p><b>What are the ingredients in SELARSDI?</b></p>

<p><b>Active ingredient:</b> ustekinumab-aekn</p>

<p><b>Inactive ingredients:</b> histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose and water for injection.</p>

<p class="credit">This Medication Guide has been approved by the U.S. Food and Drug Administration Issued: 04/2024</p>

<p><b>INSTRUCTIONS FOR USE </b></p>

<p><b>SELARSDI&trade;</b><br />
[seh-LARS-dee]<br />
(ustekinumab-aekn) injection, for subcutaneous use</p>

<p><b>This Instructions for Use contains information on how to inject SELARSDI.</b></p>

<p><b>Read this Instructions for Use before you start using SELARSDI. Your doctor or nurse should show you how to prepare and give your injection of SELARSDI the right way.</b></p>

<p>If you cannot give yourself the injection:</p>

<ul>
	<li>ask your doctor or nurse to help you, or</li>
	<li>ask someone who has been trained by a doctor or nurse to give your injections.</li>
</ul>

<p>Do not try to inject SELARSDI yourself until you have been shown how to inject SELARSDI by your doctor, nurse or health professional.</p>

<p align="center"><b>Figure A</b></p>

<center>
<table cellspacing="0" class="blackpic" width="453">
	<tbody>
		<tr>
			<td><img alt="SELARSDI Prefilled Syringes Equipped With Passive Safety Device - Illustration" height="235" src="https://images.rxlist.com/images/selarsdi5.jpg" width="453" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>Important Information You Need to Know Before Injecting SELARSDI</b></p>

<ul>
	<li><b>For subcutaneous injection only (inject directly under the skin).</b></li>
	<li>Before you start, check the carton to make sure that it is the right dose. You will have either 45 mg or 90 mg as prescribed by your doctor.
	<ul>
		<li>If your dose is 45 mg, you will receive one 45 mg prefilled syringe.</li>
		<li>If your dose is 90 mg, you will receive either one 90 mg prefilled syringe or two 45 mg prefilled syringes.<b> If you receive two 45 mg prefilled syringes for a 90 mg dose, you will need to give yourself two injections, one right after the other.</b></li>
	</ul>
	</li>
	<li>Children 12 years of age and older with psoriasis who weigh 132 pounds or more may use a prefilled syringe.</li>
	<li>Check the expiration date on the prefilled syringe and carton. If the expiration date has passed or if the prefilled syringe has been kept at room temperature up to 30&deg;C (86&deg;F) for longer than a maximum single period of 30 days or if the prefilled syringe has been stored above 30&deg;C (86&deg;F), do not use it. If the expiration date has passed or if the prefilled syringe has been stored above 30&deg;C (86&deg;F), call your doctor or pharmacist, or call 1-888-483-8279 for help.</li>
	<li>Make sure the prefilled syringe is not damaged.</li>
	<li>Check your prefilled syringe for any particles or discoloration. Your prefilled syringe should look clear and colorless to slightly yellow solution and should not have any particles.</li>
	<li><b>Do not</b> use if it is frozen, discolored, cloudy, or has particles. Get a new prefilled syringe.</li>
	<li><b>Do not shake the prefilled syringe at any time.</b> Shaking your prefilled syringe may damage your SELARSDI medicine. If your prefilled syringe has been shaken, do not use it. Get a new prefilled syringe.</li>
	<li>To reduce the risk of accidental needle sticks, each prefilled syringe has a needle guard that is automatically activated to cover the needle after you have given your injection. Do not pull back on the plunger at any time.</li>
</ul>

<p><b>Storing SELARSDI</b></p>

<ul>
	<li>Store SELARSDI in a refrigerator between 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C).</li>
	<li>Store SELARSDI in the original carton to protect it from light until time to use it.</li>
	<li>Do not freeze SELARSDI.</li>
	<li>Do not shake SELARSDI.</li>
</ul>

<p>If needed, individual prefilled syringes may be stored at room temperature up to 30&deg;C (86&deg;F) for a maximum single period of up to 30 days in the original carton to protect from light. Record the date when the prefilled syringe is first removed from the refrigerator on the carton in the space provided. Once a syringe has been stored at room temperature, it should not be returned to the refrigerator. Discard the syringe if not used within 30 days at room temperature storage. Do not use SELARSDI after the expiration date on the carton or on the prefilled syringe. <b>Keep SELARSDI and all medicines out of the reach of children.</b></p>

<p><b>Preparing to inject SELARSDI</b></p>

<p><b>STEP 1: Gather Supplies</b></p>

<p><b>Gather the supplies you will need to prepare and to give your injection. (See Figure B)</b></p>

<ul>
	<li>You will need:
	<ul>
		<li><a href="https://www.rxlist.com/antiseptic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">antiseptic</a> wipes</li>
		<li><a href="https://www.rxlist.com/supplements/cotton.htm" rel="vit" onclick="wmdTrack('embd-lnk');">cotton</a> balls or gauze pads</li>
		<li>adhesive bandage</li>
		<li>your prescribed dose of SELARSDI (See <b>Figure A</b>)</li>
		<li>FDA-cleared sharps disposal container. <b>See &ldquo;STEP 9: Dispose of the used prefilled syringe.&rdquo;</b></li>
	</ul>
	</li>
</ul>

<p align="center"><b>Figure B</b></p>

<center>
<table cellspacing="0" class="blackpic" width="247">
	<tbody>
		<tr>
			<td><img alt="antiseptic wipes, cotton balls or gauze pads, adhesive bandage, SELARSDI and FDA-cleared sharps disposal container - Illustration" height="237" src="https://images.rxlist.com/images/selarsdi6.jpg" width="247" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>STEP 2: Prepare Your Injection Site</b></p>

<ul>
	<li>Choose a well-lit, clean, flat work surface.</li>
	<li>Wash your hands well with soap and warm water.</li>
	<li>Choose an injection site around your stomach area (abdomen), buttocks, or upper legs (thighs). If a caregiver is giving you the injection, the outer area of the upper arms may also be used. (<b>See Figure C</b>)</li>
	<li><b>Use a different injection site for each injection. Do not</b> give an injection in an area of the skin that is tender, bruised, red or hard.</li>
	<li>Clean the skin with an antiseptic wipe where you plan to give your injection.</li>
	<li><b>Do not</b> touch this area again before giving the injection. Let your skin dry before injecting.</li>
	<li><b>Do not </b>fan or blow on the clean area.</li>
	<li><b>Do not</b> inject through clothes.</li>
</ul>

<p align="center"><b>Figure C</b></p>

<center>
<table cellspacing="0" class="blackpic" width="296">
	<tbody>
		<tr>
			<td><img alt="Choose an injection site around your stomach area (abdomen), buttocks, or upper legs (thighs). If a caregiver is giving you the injection, the outer area of the upper arms may also be used - Illustration" height="179" src="https://images.rxlist.com/images/selarsdi7.jpg" width="296" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>Injecting SELARSDI</b></p>

<p><b>STEP 3: Remove Needle Cov</b>er</p>

<ul>
	<li>Remove the needle cover when you are ready to inject your SELARSDI.</li>
	<li><b>Do not </b>touch the plunger or plunger head while removing the needle cover.</li>
	<li>Hold the body of the prefilled syringe with one hand, and pull the needle cover straight off. (<b>See Figure D</b>)</li>
	<li>Put the needle cover in the trash. Do not recap.</li>
	<li>You may also see a drop of liquid at the end of the needle. This is normal.</li>
	<li><b>Do not</b> touch the needle or let it touch anything.</li>
	<li><b>Do not </b>use the prefilled syringe if it is dropped without the needle cover in place. Call your doctor, nurse or health professional for instructions.</li>
</ul>

<p align="center"><b>Figure D</b></p>

<center>
<table cellspacing="0" class="blackpic" width="195">
	<tbody>
		<tr>
			<td><img alt="Hold the body of the prefilled syringe with one hand, and pull the needle cover straight off - Illustration" height="234" src="https://images.rxlist.com/images/selarsdi8.jpg" width="195" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>STEP 4: Grasp the Syringe</b></p>

<ul>
	<li>Hold the body of the prefilled syringe in one hand between the thumb and index fingers. (See <b>Figure E</b>)</li>
	<li><b>Do not</b> pull back on the plunger at any time.</li>
</ul>

<p align="center"><b>Figure E</b></p>

<center>
<table cellspacing="0" class="blackpic" width="192">
	<tbody>
		<tr>
			<td><img alt="Hold the body of the prefilled syringe in one hand between the thumb and index fingers - Illustration" height="202" src="https://images.rxlist.com/images/selarsdi9.jpg" width="192" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>STEP 5: Pinch the Skin and Insert Needle</b></p>

<ul>
	<li>Use the other hand to gently pinch the cleaned area of skin. Hold firmly.</li>
	<li>Use a quick, dart-like motion to insert the needle into the pinched skin at about a 45-degree angle. (See <b>Figure F</b>)</li>
</ul>

<p align="center"><b>Figure F</b></p>

<center>
<table cellspacing="0" class="blackpic" width="196">
	<tbody>
		<tr>
			<td><img alt="Use a quick, dart-like motion to insert the needle into the pinched skin at about a 45-degree angle - Illustration" height="228" src="https://images.rxlist.com/images/selarsdi10.jpg" width="196" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>STEP 6: Inject the Drug</b></p>

<ul>
	<li>Inject all of the liquid by using your thumb to push in the plunger head all the way in until the plunger head is completely between the needle guard activation clips. (<b>See Figure G</b>)</li>
</ul>

<p align="center"><b>Figure G</b></p>

<center>
<table cellspacing="0" class="blackpic" width="208">
	<tbody>
		<tr>
			<td><img alt="Inject all of the liquid by using your thumb to push in the plunger head all the way in until the plunger head is completely between the needle guard activation clips - Illustration" height="251" src="https://images.rxlist.com/images/selarsdi11.jpg" width="208" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>STEP 7: Allow Needle to Retract</b></p>

<ul>
	<li>When the plunger is pushed as far as it will go, keep pressure on the plunger head. Take the needle out of the skin and let go of the skin.</li>
	<li>Slowly take your thumb off the plunger head. This will let the empty syringe move up until the entire needle is covered by the needle guard. (<b>See Figure H</b>)</li>
</ul>

<p align="center"><b>Figure H</b></p>

<center>
<table cellspacing="0" class="blackpic" width="201">
	<tbody>
		<tr>
			<td><img alt="Slowly take your thumb off the plunger head. This will let the empty syringe move up until the entire needle is covered by the needle guard - Illustration" height="234" src="https://images.rxlist.com/images/selarsdi12.jpg" width="201" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p><b>STEP 8: Treat Injection Site</b></p>

<ul>
	<li>When the needle is pulled out of your skin, there may be a little bleeding at the injection site. This is normal.</li>
	<li>You can press a cotton ball or gauze pad on the skin of the injection site, if needed (<b>See Figure I</b>). Do not rub the injection site.</li>
	<li>Cover the injection site with a small adhesive bandage, if necessary.</li>
</ul>

<p align="center"><b>Figure I</b></p>

<center>
<table cellspacing="0" class="blackpic" width="211">
	<tbody>
		<tr>
			<td><img alt="Press a cotton ball or gauze pad on the skin of the injection site, if needed - Illustration" height="200" src="https://images.rxlist.com/images/selarsdi13.jpg" width="211" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>If your dose is 90 mg, you will receive either one 90 mg prefilled syringe or two 45 mg prefilled syringes. If you receive two 45 mg prefilled syringes for a 90 mg dose, you will need to give yourself a second injection right after the first. Repeat Steps 1 to 8 for the second injection using a new syringe. <b>Choose a different site for the second injection.</b></p>

<p><b>Disposing of SELARSDI</b></p>

<p><b>STEP 9: Dispose of the used prefilled syringe</b></p>

<p align="center"><b>Figure J</b></p>

<center>
<table cellspacing="0" class="blackpic" width="189">
	<tbody>
		<tr>
			<td><img alt="Put the syringe in a FDA-cleared sharps disposal container right away after use - Illustration" height="206" src="https://images.rxlist.com/images/selarsdi14.jpg" width="189" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<ul>
	<li>Put the syringe in a FDA-cleared sharps disposal container right away after use (See <b>Figure J</b>)<b>. Do not throw away (dispose of) loose syringes in your household trash.</b></li>
	<li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
	<ul>
		<li>made of heavy-duty plastic,</li>
		<li>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li>
		<li>upright and stable during use,</li>
		<li>leak-resistant, and</li>
		<li>properly labeled to warn of hazardous waste inside the container.</li>
	</ul>
	</li>
	<li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local or state laws about how to throw away syringes and needles. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA&rsquo;s website at: http://www.fda.gov/safesharpsdisposal.</li>
	<li>Do not dispose of your sharps disposal container in your household trash unless your community guidelines permit this.</li>
	<li>Do not recycle your sharps disposal container.</li>
	<li>If you have any questions, talk to your doctor or pharmacist.</li>
</ul>

<p><b>Keep SELARSDI and all medicines out of the reach of children.</b></p>

<p class="credit">This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>

            </div>
            <!--MOD_BOTTOMOFPAGE_11-->
        </div>
    </div>
</section>
<!-- START US ONLY VISITOR RR2 --><div class="from_webmd">
    <h2>From <img class="logoTitle" src="https://images.medicinenet.com/images/promo/logo_webmd.gif" alt="WebMD Logo"></h2>
    <div class="content">
        <div class="wrapper">
    <h5>Healthy Resources</h5>
    <ul>
        <li><a onclick="wmdPageLink('rs-4223-4224_1');" href="https://www.webmd.com/skin-problems-and-treatments/psoriasis/features/psoriasis-questions-answers" target="_blank" rel="nofollow">Basic Psoriasis Questions Answered Here</a></li><li><a onclick="wmdPageLink('rs-4223-5180_2');" href="https://www.webmd.com/skin-problems-and-treatments/psoriasis/cm/qac/toc-qa-center-psoriasis" target="_blank" rel="nofollow">QA Center Psoriasis</a></li><li><a onclick="wmdPageLink('rs-4223-4564_3');" href="https://www.webmd.com/skin-problems-and-treatments/psoriasis/biologic-medications-psoriasis" target="_blank" rel="nofollow">Should You Take Biologic for Your Psoriasis?</a></li>
    </ul>
</div>
        <div class="wrapper">
    <h5>Featured Centers</h5>
    <ul>
        <li><a onclick="wmdPageLink('fc-3785-1');" href="https://www.webmd.com/skin-problems-and-treatments/psoriasis/psa-22/psa-make-treatment-work
" target="_blank" rel="nofollow">What Are the Best PsA Treatments for You?</a></li><li><a onclick="wmdPageLink('fc-3709-2');" href="https://www.webmd.com/rheumatoid-arthritis/video/ra-biologic-drugs" target="_blank" rel="nofollow">Understanding Biologics
</a></li><li><a onclick="wmdPageLink('fc-5056-3');" href="https://blogs.webmd.com/depression/20220131/what-i-wish-people-knew-about-depression
" target="_blank" rel="nofollow">10 Things People With Depression Wish You Knew
</a></li>
    </ul>
</div>
    </div>
</div>
<!-- END US ONLY VISITOR RR2 -->
<div id="fdaWrapper">
	<img src="https://images.medicinenet.com/images/logo_fda.png" border="0" alt="FDA Logo"/>	
	<h2>Report Problems to the Food and Drug Administration</h2>
	<p>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda" target="_blank" onclick="wmdPageLink('fda-prob');">FDA MedWatch</a> website or call 1-800-FDA-1088.</p>
</div>



                    </div>
                </article>
            </section>

                <aside class="stickyColRight">
                    <privacy-button></privacy-button>
                    <div class="sideBox promo">
                        <a onclick="wmdTrack('lr-pid');" href="https://www.rxlist.com/pill-identification-tool/article.htm">
                            <div class="rrpromo pid">
                                <span class="icon-arrow-right2"></span><span class="icon-pill-id"></span><p>Pill Identifier Tool <span>Quick, Easy, Pill Identification</span></p>
                            </div>
                        </a>
                        <a onclick="wmdTrack('lr-dic');" href="https://www.rxlist.com/drug-interaction-checker.htm">
                            <div class="rrpromo dic">
                                <span class="icon-arrow-right2"></span><span class="icon-drug-interaction "></span><p>Drug Interaction Tool <span>Check Potential Drug Interactions</span></p>
                            </div>
                        </a>
                        <a onclick="wmdTrack('lr-lrx');" href="https://www.rxlist.com/pharmacy/local_locations_pharmacies.htm">
                            <div class="rrpromo lrx">
                                <span class="icon-arrow-right2"></span><span class="icon-map"></span><p>Pharmacy Locator Tool <span>Including 24 Hour, Pharmacies</span></p>
                            </div>
                        </a>  
                    </div>
                    <sticky-polyfill top="120">
                        <!-- Start 300x250 Ad Tag -->
<div id="rightAd_rdr">
	<div class="rightAd_top_fmt"></div>
	<div id="rightAd_fmt" class="rightAd_BG_fmt">
        <div id="ads2-pos-121" class="ad_placeholder ad"
    data-is-mobile="false" 
    data-block-codes="_l40_supplements_r529_o92_m07_j10_j069_i_h53_gen2_g473_fit_diet_cust4_cust115_cust050_age2_age123_age122_age121_age11_a15_57894060_" 
    data-pos="121" 
    data-sizes="[[300,250],[300,600],[300,1050]]">
</div>

	</div>
	<div class="rightAd_bottom_fmt"></div>
</div>
<!-- End 300x250 Ad Tag -->

                        
                    </sticky-polyfill>

                </aside>	
        </main>
    
    <footer>
		<ul class="social-section">
        <li class="social fb">
            <offsite-button class="fb_share" theme="fb_share" url="https://www.facebook.com/rxlist" pagelink="soc-fb" icon="icon-facebook" title="Follow us on Facebook. Click Like, and we'll send authoritative health and medical information to your News Feed.">
            </offsite-button>
        </li>
        <li class="social tw">
            <offsite-button class="tw_share" theme="tw_share" url="https://www.twitter.com/rxlist" pagelink="soc-tw" icon="icon-twitter" title="Follow us on Twitter. Be the first to know the latest in health information.">
            </offsite-button>
        </li>
    </ul>
    <nav>
        <div class="col">
            <h4>Drug Categories</h4>
            <ul>
                <li><a href="/drugs/alpha_a.htm">Drugs &amp; Medications</a></li>
                <li><a href="/pill-identification-tool/article.htm">Pill Identification Tool</a></li>
                <li><a href="/supplements/article.htm">Vitamins, Herbs, &amp; Dietary Supplements</a></li>
                <li><a href="/drug-medical-dictionary/article.htm">Dictionary</a></li>
            </ul>
        </div>
        <div class="col">
            <h4>RxList</h4>
            <ul>
                <li><a href="/script/main/art.asp?articlekey=64467">About Us</a></li>
                <li><a href="javascript:void(0);" onclick="window.open('https://data.webmd.com/sdclive/SdcForm.aspx?FormId=rxlistContact','newWin','resizeable=yes,scrollbars=no,width=580,height=600');return false;">Consumer Contact RxList</a></li>
                <li><a href="/script/main/art.asp?articlekey=64473">Terms of Use</a></li>
                <li><a href="/script/main/art.asp?articlekey=64474">Privacy Policy</a></li>
                <li><a href="/script/main/art.asp?articlekey=77768">Sponsor Policy</a></li>                               
            </ul>
        </div>

    </nav>
    <div class="footerCopy">
        <div class="badge">
            <img class="rgb_tag" src="https://images.rxlist.com/images/footer/badges/rgb_tag_registered.png" width="60" height="60" />
            <a href="//privacy.truste.com/privacy-seal/validation?rid=07326333-3522-463d-81bf-f00fd7171fff" target="_blank"><img width="142" height="45" src="//privacy-policy.truste.com/privacy-seal/seal?rid=07326333-3522-463d-81bf-f00fd7171fff" alt="TRUSTe" /></a>
            <a onclick="TRUSTeWidget.Tab.link()"><img src="https://choices.truste.com/get?name=admarker2.png" width="77" height="16" border="0"></a>
        </div>            
        <div class="copyright">
            <a id="ot-sdk-btn1" class="ib-your-choices" onclick="OneTrust.ToggleInfoDisplay();" href="javascript:void(0);">Your Privacy Choices <img src="https://icons.internetbrands.com/ccpa/privacyoptions29x14.png"> </a>
            <p>Copyright &copy; 2024 by RxList Inc. An <a href="https://www.internetbrands.com" rel="nofollow">Internet Brands</a> company. RxList does not provide medical advice, diagnosis or treatment. <a href="https://www.rxlist.com/script/main/art.asp?articlekey=199773">See additional information</a>.</p>
        </div>
    </div>
		</footer>
	</div>
</div>
<scroll-page></scroll-page><!-- start ad 1x1 -->
<div id="ads2-pos-901" class="ad_placeholder ad"
    data-is-mobile="false" 
    data-block-codes="_l40_supplements_r529_o92_m07_j10_j069_i_h53_gen2_g473_fit_diet_cust4_cust115_cust050_age2_age123_age122_age121_age11_a15_57894060_" 
    data-pos="901" 
    data-sizes="[1,1]">
</div>
<script>
  (function(){      
    let adTags = document.querySelectorAll('.ad')
    if (window.ooAdTarget.targets) {
      let adTargets = JSON.stringify(window.ooAdTarget.targets).replaceAll(`"`,`'`)
      for (let adTag of adTags) {
        adTag.setAttribute('data-targets', adTargets)
      }
    }
  })()
</script>

<!-- end ad 1x1 -->


<script src="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_body.min.js"></script>
    <script language="javascript1.2" type="text/javascript" src="https://img.webmd.com/bi_common/bi_oocommon.js"></script>
<script type="text/javascript">    webmd.ads2.adTarget = ['consumer', 'rxlist']; var bIsDFPAdTag = true;</script>
<script>
if(!window.asyncBeacon && typeof _satellite != "undefined"){_satellite.pageBottom();}
if (!window.gdprMatch)
{
try {
    var _comscore = _comscore || [];
    _comscore.push({ c1: "2", c2: "6035829" });
    (function () {
        var s = document.createElement("script"),
            el = document.getElementsByTagName("script")[0];
        s.async = true;
        s.src = "https://sb.scorecardresearch.com/cs/6035829/beacon.js";
        el.parentNode.insertBefore(s, el);
 
        // Dynamic Pageview Tracking
        window.document.addEventListener("onAdobeOmniBeforePv", function () {
            if (self.COMSCORE) {
                COMSCORE.beacon({ c1: "2", c2: "6035829" });
            }
        });
    })();
} catch (err) {}
}
if (window.videoembed) {
    if (globalAsyncAdsCode) {
        webmd.ads.cmd.push(function(){
            webmd.ads.disableInitialLoad();
            webmd.ads.disableAdsInit = true;   
        });
    } else {
        webmd.ads.disableInitialLoad();
        webmd.ads.disableAdsInit = true;   
    }
}
if (!globalAsyncAdsCode){webmd.ads2Consumer.display();}
$(function() {if (window.s_sponsor_program && window.s_sponsor_program!='') $('.medianet').hide();});
function insertWebMDVideo(html) {
return;
    console.info('insertWebMDVideo called');
    if (s_articletype.indexOf("-ap")>0) {
        $(".wrapper .subtitleAP:first").parent().after(html);
    } else {
       $('#artPromoCunk').after(html);
       $('.article-promo').after(html);
    }
}
</script>
<script>if (!window.gdprMatch)
{document.write('<img src="https://bi.medscape.com/pi/global/rxlist-1x1.gif?' + new Date().getTime() + '" alt="" height="1" width="1" border="0" />');
}
</script>
<script src="https://images.rxlist.com/oocommon/js/20190620/legacy-light.js"></script>

</body>
</html> contentType 9 text/html url 44 https://www.rxlist.com:443/selarsdi-drug.htm responseCode 3 200 